1,5-anhydroglucitol levels |
1 |
-2.5 |
3-hydroxy-1-methylpropylmercapturic acid levels in smokers |
576 |
-3.9 |
3-hydroxypropylmercapturic acid levels in smokers |
744 |
-4.5 |
3-month functional outcome in ischaemic stroke (modified Rankin score) |
140 |
-3.3 |
3-month functional outcome in lacunar ischaemic stroke (modified Rankin score) |
10 |
-1.8 |
3-month functional outcome in non-lacunar ischaemic stroke (modified Rankin score) |
27 |
-3.9 |
6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction) |
238 |
-3.4 |
Abdominal aortic aneurysm |
24 |
-5.2 |
Ability to confide in someone |
39 |
-2.6 |
Abnormal white matter microstructure in first episode schizophrenia (multivariate analysis) |
3 |
-5.2 |
Accelerated cognitive decline after conversion of mild cognitive impairment to Alzheimer's disease (Alzhiemer's diagnosis trajectory interaction) |
33 |
-2.9 |
Accelerometer-based physical activity measurement (average acceleration) |
23 |
-4.2 |
|
1 |
-2.4 |
Achilles tendinopathy |
5 |
-3.5 |
Acne (severe) |
124 |
-7.0 |
Acoustic startle blink response |
43 |
-3.1 |
ACPA-positive rheumatoid arthritis (smoking interaction) |
5 |
-3.2 |
Activated partial thromboplastin time |
49 |
-2.9 |
Acute anterior uveitis (with or without ankylosing spondylitis) |
12 |
-4.8 |
Acute graft versus host disease in bone marrow transplantation (donor effect) |
72 |
-4.0 |
Acute graft versus host disease in bone marrow transplantation (recipient effect) |
59 |
-4.9 |
Acute insulin response |
66 |
-5.1 |
Acute kidney injury in coronary artery bypass surgery (creatinine rise) |
5 |
-2.9 |
Acute kidney injury in critical illness |
6 |
-3.2 |
Acute lymphoblastic leukemia (adolescents and young adults) |
2 |
-2.8 |
Acute lymphoblastic leukemia (B-cell precursor) |
48 |
-7.2 |
Acute lymphoblastic leukemia (childhood) |
223 |
-4.7 |
Acute lymphoblastic leukemia in childhood (B cell precursor) |
44 |
-5.3 |
Acute-on-chronic liver failure in hepatitis B |
1 |
-2.8 |
Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) |
51 |
-2.3 |
ADAMTS13 activity |
1 |
-2.4 |
Addiction |
12 |
-5.9 |
Adenocarcinoma |
17 |
-8.5 |
Adiponectin levels |
276 |
-3.9 |
Adiponectin levels (BMI-adjusted) |
14 |
-3.2 |
Adiponectin levels in pregnancy |
5 |
-2.5 |
Adiposity |
46 |
-6.3 |
Adolescent idiopathic scoliosis |
6967 |
-10.1 |
Adolescent idiopathic scoliosis (severe) |
1 |
0.0 |
Adult asthma |
65 |
-3.1 |
Advanced age-related macular degeneration |
131 |
-4.9 |
Advanced glycation end-product levels |
16 |
-4.9 |
Adventurousness |
988 |
-4.6 |
Adverse response to antithyroid drugs in Graves disease |
2 |
-2.2 |
Adverse response to aromatase inhibitors |
6 |
-4.2 |
Adverse response to chemotherapy in breast cancer (alopecia) |
2 |
-1.1 |
Adverse response to chemotherapy in breast cancer (alopecia) (anti-microtubule) |
54 |
-4.1 |
Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU) |
13 |
-2.8 |
Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+epirubicin+/-5FU) |
5 |
-2.4 |
Adverse response to chemotherapy in breast cancer (alopecia) (docetaxel) |
42 |
-4.3 |
Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel) |
41 |
-4.3 |
Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil) |
26 |
-2.6 |
Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) |
40 |
-4.4 |
Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs) |
6 |
-4.4 |
Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs) |
84 |
-3.8 |
Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) |
30 |
-6.4 |
Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors) |
18 |
-2.4 |
Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin) |
13 |
-4.3 |
Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin) |
21 |
-9.4 |
Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) |
86 |
-3.5 |
Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel) |
9 |
-4.1 |
Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin) |
20 |
-4.6 |
Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin) |
21 |
-6.2 |
Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide) |
9 |
-2.9 |
Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) |
29 |
-2.9 |
Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) |
14 |
-4.1 |
Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin) |
31 |
-3.9 |
Adverse response to lamotrigine and phenytoin |
97 |
-3.7 |
Adverse response to radiation therapy |
31 |
-4.3 |
Affective disorder and suicide attempts |
81 |
-4.0 |
Age at first birth |
22 |
-3.0 |
Age at first sexual intercourse |
89 |
-3.2 |
Age at loss of ambulation in Duchenne muscular dystrophy |
113 |
-2.8 |
Age at menopause |
176 |
-5.0 |
Age at smoking initiation in chronic obstructive pulmonary disease |
55 |
-2.8 |
Age at voice drop |
57 |
-4.7 |
Age of smoking initiation |
138 |
-2.8 |
Age of smoking initiation (MTAG) |
1014 |
-8.3 |
Age-related cataracts |
6 |
-2.6 |
Age-related disease endophenotypes |
92 |
-5.1 |
Age-related diseases and mortality |
78 |
-2.7 |
Age-related diseases, mortality and associated endophenotypes |
166 |
-3.7 |
Age-related hearing impairment |
164 |
-3.8 |
Age-related macular degeneration |
162 |
-5.9 |
Age-related macular degeneration (choroidal neovascularisation) |
1 |
-1.9 |
Age-related macular degeneration (geographic atrophy) |
3 |
-2.9 |
Age-related macular degeneration (smoking status interaction) |
10 |
-1.6 |
Age-related nuclear cataracts |
86 |
-3.3 |
Age spots |
10 |
-3.3 |
Aggressiveness in attention deficit hyperactivity disorder |
128 |
-3.3 |
Aggressive periodontitis |
1 |
0.0 |
Aggressive periodontitis (sex interaction) |
18 |
-3.9 |
Aging |
55 |
-4.1 |
Aging (facial) |
1 |
-1.6 |
Aging (time to death) |
15 |
-2.4 |
Aging (time to event) |
63 |
-4.2 |
Aging traits |
77 |
-3.4 |
AIDS |
20 |
-2.4 |
AIDS progression |
13 |
-4.4 |
Airflow obstruction |
106 |
-3.1 |
Airway imaging phenotypes |
97 |
-3.1 |
Airway responsiveness in chronic obstructive pulmonary disease |
55 |
-5.5 |
Airway wall thickness |
41 |
-3.2 |
Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL) |
147 |
-2.6 |
Alanine aminotransferase levels |
32 |
-2.6 |
Alanine aminotransferase levels in excessive alcohol consumption |
59 |
-5.7 |
Alanine aminotransferase levels in low alcohol consumption |
107 |
-3.7 |
Alanine transaminase levels |
79 |
-4.7 |
Albumin-globulin ratio |
93 |
-4.6 |
Alcohol and nicotine co-dependence |
23 |
-4.4 |
Alcohol consumption |
246 |
-3.0 |
Alcohol consumption (drinkers vs non-drinkers) |
1 |
-1.9 |
Alcohol consumption (drinks per week) |
679 |
-4.4 |
Alcohol consumption (drinks per week) (MTAG) |
855 |
-4.8 |
Alcohol consumption in current drinkers |
3 |
-1.7 |
Alcohol consumption (max-drinks) |
33 |
-5.5 |
Alcohol consumption over the past year |
7 |
-1.9 |
Alcohol consumption (transferrin glycosylation) |
1 |
-3.3 |
Alcohol dependence |
224 |
-7.8 |
Alcohol dependence (age at onset) |
169 |
-3.6 |
Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis |
5 |
-1.9 |
Alcohol dependence symptom count |
129 |
-3.4 |
Alcoholic chronic pancreatitis |
184 |
-10.2 |
Alcoholism (12-month weekly alcohol consumption) |
38 |
-5.3 |
Alcoholism (alcohol dependence factor score) |
15 |
-5.5 |
Alcoholism (alcohol use disorder factor score) |
5 |
-2.5 |
Alcoholism (heaviness of drinking) |
38 |
-3.3 |
Alcohol misuse (trauma interaction) |
7 |
-3.8 |
Alcohol use disorder (consumption score) |
145 |
-7.2 |
Alcohol use disorder (dependence and problematic use scores) |
1 |
0.0 |
Alcohol use disorder (total score) |
36 |
-7.1 |
Allergic dermatitis (nickel) |
11 |
-3.1 |
Allergic disease (asthma, hay fever or eczema) |
609 |
-15.9 |
Allergic rhinitis |
262 |
-4.4 |
Allergic rhinitis in asthma |
3 |
-3.0 |
Allergic rhinitis in non-asthmatics |
40 |
-2.9 |
Allergic sensitization |
101 |
-7.3 |
Allergy |
63 |
-4.6 |
Alloimmunization response to pregnancy (HLA class I) |
1 |
-2.6 |
Alloimmunization response to red blood cell transfusion in sickle cell anemia |
2 |
-4.1 |
Alopecia areata |
143 |
-7.1 |
Alzheimer disease and age of onset |
591 |
-2.9 |
Alzheimer's disease |
227 |
-6.8 |
Alzheimer's disease (age of onset) |
39 |
-3.4 |
Alzheimer's disease (APOE e4 interaction) |
8 |
-3.2 |
Alzheimer's disease biomarkers |
34 |
-4.1 |
Alzheimer's disease (cognitive decline) |
72 |
-3.4 |
Alzheimer's disease in APOE e4+ carriers |
48 |
-2.4 |
Alzheimer's disease in APOE e4- carriers |
103 |
-5.3 |
Alzheimer's disease (late onset) |
373 |
-6.3 |
Alzheimer's disease or family history of Alzheimer's disease |
382 |
-13.8 |
Alzheimer's disease progression score |
39 |
-2.6 |
Alzheimer's disease (survival time) |
19 |
-4.8 |
Alzheimer's disease with language domain impairment |
30 |
-3.7 |
Alzheimer's disease with memory domain impairment |
3 |
-3.0 |
Alzheimer's disease with multiple cognitive domain impairments |
11 |
-4.6 |
Alzheimer's disease with no specific cognitive domain impairment |
15 |
-4.8 |
Alzheimer's disease with visuospatial domain impairment |
123 |
-5.2 |
Amino acid levels |
29 |
-3.5 |
Amyotrophic lateral sclerosis |
302 |
-6.9 |
Amyotrophic lateral sclerosis (age of onset) |
48 |
-4.1 |
Amyotrophic lateral sclerosis (C9orf72 mutation interaction) |
8 |
-4.4 |
Amyotrophic lateral sclerosis in C9orf72 mutation negative individuals |
20 |
-4.1 |
Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals |
37 |
-2.1 |
Amyotrophic lateral sclerosis (sporadic) |
498 |
-5.3 |
Androgen levels |
4 |
-2.0 |
Anger |
65 |
-4.4 |
Angiotensin-converting enzyme activity |
4 |
-3.1 |
Angiotensin-converting enzyme inhibitor intolerance |
86 |
-5.4 |
Ankle-brachial index |
3 |
-2.3 |
Ankle injury |
166 |
-7.6 |
Ankylosing spondylitis |
227 |
-7.0 |
Anorexia nervosa |
126 |
-4.6 |
Anorexia nervosa (excluding migration to or from binge-eating disorder or bulimia nervosa) |
11 |
-3.2 |
Anorexia nervosa or obsessive-compulsive disorder |
32 |
-6.5 |
Anterior cruciate ligament rupture |
37 |
-3.5 |
Anthropometric traits |
78 |
-3.3 |
Anthropometric traits (multi-trait analysis) |
56 |
-2.7 |
Antibody level in response to infection |
44 |
-2.3 |
Antibody status in Tripanosoma cruzi seropositivity |
46 |
-3.6 |
Anticoagulant levels |
36 |
-3.3 |
|
10 |
-3.0 |
Antidepressant treatment resistance (number of drugs prescribed) |
25 |
-3.1 |
Anti-Epstein-Barr virus nuclear antigen (EBNA) IgG levels |
1 |
0.0 |
Anti-Mullerian hormone levels in pre-menopausal women of late reproductive age |
21 |
-3.5 |
Antineutrophil cytoplasmic antibody-associated vasculitis |
47 |
-3.5 |
antipsychotic drug dosage in schizophrenia or schizoaffective disorder |
98 |
-4.6 |
Antipsychotic drug-induced QTc interval change in schizophrenia |
76 |
-2.0 |
Antipsychotic drug-induced QTc interval prolongation |
32 |
-5.2 |
Antipsychotic drug-induced weight gain |
1 |
0.0 |
Anti-saccade error rate in psychotic disorders |
2 |
-2.7 |
Anti-saccade response |
261 |
-4.9 |
Anti-thyroid drug induced agranulocytosis |
2 |
-4.3 |
Antitragus size |
3 |
-3.0 |
Anxiety and major depressive disorder |
31 |
-6.5 |
Anxiety disorder |
44 |
-4.6 |
Anxiety in major depressive disorder |
29 |
-2.8 |
Anxiety/tension (special factor of neuroticism) |
75 |
-3.9 |
Aortic root size |
85 |
-4.5 |
Aortic stiffness |
21 |
-2.6 |
Aortic valve stenosis |
33 |
-4.1 |
Apolipoprotein A1 levels |
12 |
-6.2 |
Appendicitis |
7 |
-2.6 |
Appendicular lean mass |
41 |
-2.9 |
Area under the curve of insulin levels |
2 |
-5.4 |
Arterial stiffness |
8 |
-2.6 |
Arthritis (juvenile idiopathic) |
45 |
-4.0 |
Asparaginase hypersensitivity in acute lymphoblastic leukemia |
6 |
-3.9 |
Asparaginase-induced acute pancreatitis in acute lymphoblastic leukemia (onset time) |
1 |
-2.3 |
Aspartate aminotransferase levels |
105 |
-5.4 |
Aspartate aminotransferase levels in excessive alcohol consumption |
46 |
-2.9 |
Aspartate aminotransferase levels in low alcohol consumption |
73 |
-3.3 |
Asperger disorder |
43 |
-3.0 |
Asthma |
1128 |
-11.8 |
Asthma and hay fever |
139 |
-5.3 |
Asthma (bronchodilator response) |
11 |
-3.2 |
Asthma (childhood onset) |
704 |
-11.2 |
Asthma-chronic obstructive pulmonary disease overlap syndrome |
10 |
-1.7 |
Asthma (corticosteroid response) |
16 |
-3.0 |
Asthma exacerbations in inhaled corticosteroid treatment |
52 |
-4.5 |
Asthma (moderate or severe) |
134 |
-6.0 |
Asthma or allergic disease (pleiotropy) |
155 |
-5.4 |
Asthma or chronic obstructive pulmonary disease |
13 |
-4.7 |
Asthma (sex interaction) |
9 |
-2.8 |
Asthma (toluene diisocyanate-induced) |
32 |
-2.9 |
Asymmetrical dimethylarginine levels |
40 |
-2.8 |
Atazanavir levels |
6 |
-4.6 |
Atopic dermatitis |
200 |
-8.7 |
Atopic march |
81 |
-6.9 |
Atopy |
16 |
-4.1 |
Atrial fibrillation |
1042 |
-5.2 |
Atrial fibrillation/atrial flutter |
37 |
-3.3 |
Atrioventricular conduction |
15 |
-2.8 |
Atrioventricular septal defects in Down syndrome |
1 |
-2.7 |
Attention deficit hyperactivity disorder |
605 |
-4.9 |
Attention deficit hyperactivity disorder and conduct disorder |
105 |
-4.4 |
Attention deficit hyperactivity disorder (combined symptoms) |
30 |
-3.6 |
Attention deficit hyperactivity disorder (hyperactivity-impulsivity symptoms) |
57 |
-3.5 |
Attention deficit hyperactivity disorder (inattention symptoms) |
45 |
-3.3 |
Attention deficit hyperactivity disorder motor coordination |
2 |
-1.3 |
Attention deficit hyperactivity disorder or amygdala volume (pleiotropy) |
7 |
-2.1 |
Attention deficit hyperactivity disorder or cannabis use |
179 |
-4.8 |
Attention deficit hyperactivity disorder or caudate nucleus volume (pleiotropy) |
1 |
-3.6 |
Attention deficit hyperactivity disorder or intracranial volume (pleiotropy) |
8 |
-1.9 |
Attention deficit hyperactivity disorder symptom score |
23 |
-3.1 |
Attention deficit hyperactivity disorder symptoms (maternal expressed emotions interaction) |
28 |
-2.5 |
Attention deficit hyperactivity disorder (time to onset) |
34 |
-4.2 |
Attention function in attention deficit hyperactive disorder |
187 |
-4.2 |
Autism |
24 |
-4.0 |
Autism and educational attainment (MTAG) |
14 |
-5.2 |
Autism and major depressive disorder (MTAG) |
11 |
-3.9 |
Autism spectrum disorder |
162 |
-5.3 |
Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined) |
454 |
-3.9 |
Autism spectrum disorder or schizophrenia |
556 |
-6.3 |
Autism spectrum disorder-related traits |
20 |
-3.7 |
Autoimmune hepatitis type-1 |
7 |
-5.1 |
Autoimmune thyroid diseases (Graves disease or Hashimoto's thyroiditis) |
23 |
-2.5 |
Autoimmune traits |
314 |
-7.4 |
Automobile speeding propensity |
204 |
-4.9 |
Axial length |
61 |
-4.7 |
Axial length or spherical error (univariate decomposition analysis) |
23 |
-4.2 |
B6 vitamer levels (multivariate analysis) |
7 |
-5.0 |
Bacteremia |
42 |
-4.1 |
Bacterial meningitis |
111 |
-2.7 |
Balding |
5 |
-2.7 |
Balding type 1 |
2068 |
-11.1 |
Barrett's esophagus |
33 |
-3.3 |
Barrett's esophagus or Esophageal adenocarcinoma |
29 |
-5.7 |
Barrett's esophagus x pack-years of smoking exposure interaction |
11 |
-4.9 |
Basal cell carcinoma |
87 |
-4.3 |
Basal ganglia growth |
4 |
-1.7 |
Basal metabolic rate |
11 |
-3.0 |
Baseline cortisol levels in response to low dose short synacthen test in corticosteroid treated asthma |
1 |
0.0 |
Basophil percentage of granulocytes |
126 |
-15.6 |
Basophil percentage of white cells |
148 |
-9.5 |
B cell acute lymphoblastic leukaemia (abnormal cytogenetics) |
2 |
-2.8 |
B cell acute lymphoblastic leukaemia (hyperdiploid negative) |
2 |
-2.8 |
B cell acute lymphoblastic leukaemia in adulthood |
2 |
-2.8 |
B cell acute lymphoblastic leukaemia in young adulthood |
2 |
-2.8 |
B cell acute lymphoblastic leukaemia (normal cytogenetics) |
2 |
-2.8 |
B cell acute lymphoblastic leukaemia (Philadelphia chromosome negative) |
2 |
-2.8 |
B-cell malignancies (chronic lymphocytic leukemia, Hodgkin lymphoma or multiple myeloma) (pleiotropy) |
16 |
-3.8 |
B cell non-Hodgkin lymphoma |
10 |
-4.1 |
Beard thickness |
53 |
-3.9 |
Behavioral disturbance or psychiatric symptoms and prion disease |
18 |
-3.1 |
Behavioral disturbance or psychiatric symptoms in prion disease |
8 |
-4.3 |
Behavioural changes in frontotemporal lobe dementia |
6 |
-2.7 |
Behavioural disinhibition (generation interaction) |
84 |
-2.7 |
Behcet's disease |
38 |
-5.2 |
Benign prostatic hyperplasia and lower urinary tract symptoms |
119 |
-5.2 |
Benign prostatic hyperplasia and lower urinary tract symptoms (prostate cancer excluded) |
112 |
-5.3 |
Benign prostatic hyperplasia and/or lower urinary tract symptoms |
3 |
-2.0 |
β2-Glycoprotein I (β2-GPI) plasma levels |
35 |
-2.9 |
beta-nerve growth factor levels |
57 |
-3.0 |
Beta thalassemia/hemoglobin E disease |
18 |
-5.1 |
Biliary atresia |
32 |
-4.7 |
Bilirubin levels |
90 |
-3.7 |
Binge eating behaviour and bipolar disorder |
45 |
-2.2 |
Binge eating behaviour in bipolar disorder |
5 |
-2.2 |
Biochemical measures |
157 |
-3.3 |
Biomedical quantitative traits |
92 |
-6.3 |
Bipolar disorder |
1218 |
-4.2 |
Bipolar disorder (age of onset <21) or attention deficit hyperactivity disorder |
7 |
-4.6 |
Bipolar disorder (age of onset and psychotic symptoms) |
2 |
-2.3 |
Bipolar disorder and eating disorder |
14 |
-4.3 |
Bipolar disorder and schizophrenia |
703 |
-5.0 |
Bipolar disorder (body mass index interaction) |
283 |
-7.0 |
Bipolar disorder (early onset) |
5 |
-3.5 |
Bipolar disorder (inflammation and infection response interaction) |
31 |
-3.4 |
Bipolar disorder lithium response (categorical) or schizophrenia |
22 |
-3.4 |
Bipolar disorder lithium response (continuous) or schizophrenia |
2 |
-2.4 |
Bipolar disorder or attention deficit hyperactivity disorder |
41 |
-6.2 |
Bipolar disorder or major depressive disorder |
103 |
-3.9 |
Bipolar disorder with mood-incongruent psychosis |
69 |
-3.8 |
Bipolar I disorder |
249 |
-4.7 |
Birth weight |
828 |
-5.8 |
Bitter taste perception |
1 |
-2.2 |
Bitter taste perception (multivariate analysis) |
5 |
-5.3 |
Black vs. blond hair color |
1 |
0.0 |
Black vs. red hair color |
1 |
0.0 |
Bladder cancer |
117 |
-34.5 |
Bladder cancer (smoking interaction) |
18 |
-3.7 |
Blond vs. brown/black hair color |
886 |
-9.4 |
Blond vs. brown hair color |
54 |
-6.1 |
Blond vs non-blond hair color |
60 |
-6.0 |
Blood and toenail selenium levels |
7 |
-2.9 |
Blood metabolite levels |
183 |
-10.2 |
Blood metabolite ratios |
59 |
-3.9 |
Blood osmolality (transformed sodium) |
121 |
-4.1 |
Blood pressure |
503 |
-3.0 |
Blood pressure (age interaction) |
8 |
-2.8 |
Blood pressure (anthropometric measures interaction) |
24 |
-3.5 |
Blood pressure measurement (cold pressor test) |
11 |
-3.0 |
Blood pressure measurement (high sodium and potassium intervention) |
55 |
-3.5 |
Blood pressure measurement (high sodium intervention) |
26 |
-3.3 |
Blood pressure measurement (low sodium intervention) |
33 |
-4.1 |
Blood pressure (smoking interaction) |
133 |
-3.4 |
Blood pressure traits (multi-trait analysis) |
39 |
-3.8 |
Blood protein levels |
3220 |
-13.6 |
Blood sugar levels |
75 |
-4.9 |
Blood trace element (Cu levels) |
21 |
-2.5 |
Blood trace element (Se levels) |
48 |
-5.3 |
Blood trace element (Zn levels) |
37 |
-2.6 |
Blood urea nitrogen levels |
681 |
-9.1 |
BMI (adjusted for smoking behaviour) |
422 |
-5.3 |
BMI in non-smokers |
297 |
-3.4 |
BMI in smokers |
183 |
-5.9 |
BMI (smoking interaction) |
61 |
-8.8 |
Body fat distribution (arm fat ratio) |
165 |
-4.7 |
Body fat distribution (leg fat ratio) |
230 |
-4.2 |
Body fat distribution (trunk fat ratio) |
215 |
-4.3 |
Body fat mass |
180 |
-4.6 |
Body fat percentage |
459 |
-3.8 |
Body mass in chronic obstructive pulmonary disease |
30 |
-7.9 |
Body mass index |
7863 |
-9.0 |
Body mass index (adult) |
179 |
-3.5 |
Body mass index (age <50) |
119 |
-8.0 |
|
132 |
-4.1 |
Body mass index (age interaction) |
38 |
-5.9 |
Body mass index (alcohol intake interaction) |
6 |
-3.7 |
Body mass index and cholesterol (psychopharmacological treatment) |
25 |
-3.2 |
Body mass index and waist-hip ratio (pleiotropy) |
34 |
-6.1 |
Body mass index (change over time) |
35 |
-2.9 |
Body mass index (change over time) in cancer or chronic obstructive pulmonary disease |
19 |
-4.3 |
Body mass index (change over time) in chronic obstructive pulmonary disease |
29 |
-4.4 |
Body mass index (change over time) in gastrointestinal cancer or chronic obstructive pulmonary disease |
8 |
-4.1 |
Body mass index (change over time) in lung cancer |
12 |
-2.6 |
Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease |
12 |
-3.6 |
Body mass index (dietary energy interaction) |
4 |
-1.7 |
Body mass index (education interaction) |
53 |
-3.3 |
Body mass index (ever vs never smoking interaction) |
17 |
-2.2 |
Body mass index in asthmatics |
27 |
-5.3 |
Body mass index in non-asthmatics |
38 |
-4.3 |
Body mass index in physically active individuals |
383 |
-4.2 |
Body mass index in physically inactive individuals |
231 |
-7.7 |
Body mass index (joint analysis main effects and physical activity interaction) |
434 |
-5.8 |
Body mass index (joint analysis main effects and smoking interaction) |
483 |
-6.1 |
Body mass index (physical activity interaction) |
10 |
-3.1 |
Body mass index (recreational physical activity interaction) |
24 |
-7.7 |
Body mass index (smoking years interaction) |
43 |
-2.4 |
Body mass index (SNP x SNP interaction) |
72 |
-5.0 |
Body mass index x age interaction |
60 |
-4.2 |
Body mass index x sex x age interaction (4df test) |
159 |
-7.3 |
Bone erosion in rheumatoid arthritis |
1 |
-4.4 |
Bone fracture in osteoporosis |
23 |
-3.7 |
Bone mineral accretion in asthma (oral corticosteroid dose interaction) |
30 |
-1.9 |
Bone mineral density |
237 |
-3.9 |
Bone mineral density change response to combined chemotherapy in acute lymphoblastic leukemia |
4 |
-2.0 |
Bone mineral density (femoral neck) |
3 |
-4.4 |
Bone mineral density (femoral neck) in inflammatory bowel disease |
11 |
-5.0 |
Bone mineral density (hip) |
273 |
-4.3 |
Bone mineral density (hip) and age at menarche |
36 |
-5.3 |
Bone mineral density (lumbar spine) in inflammatory bowel disease |
36 |
-11.0 |
Bone mineral density (paediatric, lower limb) |
1 |
-2.8 |
Bone mineral density (paediatric, skull) |
32 |
-3.8 |
Bone mineral density (paediatric, total body less head) |
66 |
-3.8 |
Bone mineral density (paediatric, upper limb) |
82 |
-4.3 |
Bone mineral density (spine) |
122 |
-5.0 |
Bone mineral density (spine) and age at menarche |
20 |
-5.8 |
Bone mineral density (total hip) |
123 |
-4.7 |
Bone mineral density (Ward's triangle area) |
88 |
-2.7 |
Bone mineral density (wrist) |
29 |
-2.8 |
Bone mineral density x blood lead interaction in current smokers (1df test) |
1 |
-2.4 |
Bone mineral density x blood lead interaction in current smokers (2df test) |
4 |
-4.3 |
Bone properties (heel) |
67 |
-3.7 |
Bone ultrasound measurement (broadband ultrasound attenuation) |
76 |
-5.7 |
Bone ultrasound measurement (velocity of sound) |
61 |
-3.8 |
Borderline personality disorder |
34 |
-3.5 |
Bortezomib-induced peripheral neuropathy in multiple myeloma |
23 |
-1.9 |
Brain connectivity |
69 |
-3.2 |
Brain cytoarchitecture |
10 |
-2.6 |
Brain glucose metabolism (fluorodeoxyglucose uptake) |
15 |
-3.4 |
Brain imaging |
40 |
-6.9 |
Brain imaging in schizophrenia (dorsolateral prefrontal cortex interaction) |
64 |
-3.7 |
Brain imaging measurements |
3 |
-3.0 |
Brain lesion load |
14 |
-3.4 |
Brain structure |
67 |
-2.6 |
Brain structure (hippocampal volume) |
21 |
-3.9 |
Brain structure (temporal lobe volume) |
42 |
-3.1 |
Brain volume in infants (cerebrospinal fluid) |
14 |
-3.2 |
Brain volume in infants (grey matter) |
49 |
-3.3 |
Brain volume in infants (intracranial brain volume) |
3 |
-3.1 |
Brain volume in infants (white matter) |
7 |
-2.2 |
Branched-chain amino acid levels (Isoleucine) |
30 |
-4.9 |
BRCA1/2-negative high-risk breast cancer |
52 |
-2.9 |
Breast cancer |
2692 |
-16.7 |
Breast cancer and/or colorectal cancer |
16 |
-5.0 |
Breast cancer (early onset) |
47 |
-4.6 |
Breast cancer (estrogen-receptor negative) |
250 |
-9.4 |
Breast cancer (estrogen-receptor negative, progesterone-receptor negative, and human epidermal growth factor-receptor negative) |
17 |
-7.7 |
Breast cancer (estrogen-receptor positive) |
21 |
-4.4 |
Breast cancer-free interval (treatment with aromatase inhibitor) |
4 |
-4.1 |
Breast Cancer in BRCA1 mutation carriers |
47 |
-7.2 |
Breast cancer in BRCA2 mutation carriers |
5 |
-2.8 |
Breast cancer in childhood cancer survivors |
6 |
-2.5 |
Breast cancer in childhood cancer survivors treated with less than 10 gray radiotherapy |
30 |
-4.1 |
Breast cancer in childhood cancer survivors treated with more than 10 gray radiotherapy |
4 |
-2.7 |
Breast cancer (male) |
56 |
-16.7 |
Breast cancer (menopausal hormone therapy interaction) |
5 |
-3.3 |
Breast cancer (progesterone-receptor positive) |
7 |
-6.4 |
Breast cancer (prognosis) |
18 |
-5.4 |
Breast cancer specific mortality in breast cancer |
49 |
-2.9 |
Breast cancer specific mortality in estrogen receptor negative breast cancer |
53 |
-4.7 |
Breast cancer specific mortality in estrogen receptor positive breast cancer |
62 |
-4.7 |
Breast cancer (survival) |
19 |
-4.0 |
Breastfeeding duration |
10 |
-2.9 |
Breast milk fatty acid composition (infant genotype effect) |
32 |
-2.5 |
Breast milk fatty acid composition (maternal genotype effect) |
35 |
-2.3 |
Breast size |
232 |
-5.6 |
Broad depression or bipolar disorder |
1 |
-3.1 |
Broad depression or major depressive disorder (self-reported) |
25 |
-2.1 |
Broad depression or schizophrenia |
65 |
-2.9 |
Bronchial neuroendocrine tumor |
1 |
0.0 |
Bronchodilator response in asthma |
5 |
-2.6 |
Bronchodilator response in asthma (inhaled corticosteroid treatment interaction) |
4 |
-2.3 |
Bronchopulmonary dysplasia |
69 |
-2.9 |
Bronchopulmonary dysplasia in preterm infants |
44 |
-3.4 |
Brooding (response to stress) |
13 |
-4.2 |
Brown vs. black hair color |
168 |
-6.5 |
Brown vs. non-brown hair color |
60 |
-6.0 |
Bulimia nervosa |
129 |
-3.8 |
Caffeine consumption |
25 |
-3.3 |
Caffeine metabolism (plasma 1,3,7-trimethylxanthine (caffeine) level) |
16 |
-4.2 |
Caffeine metabolism (plasma 1,3-dimethylxanthine (theophylline) level) |
3 |
-3.1 |
Caffeine metabolism (plasma 1,7-dimethylxanthine (paraxanthine) level) |
1 |
-1.8 |
Caffeine metabolism (plasma 1,7-dimethylxanthine (paraxanthine) to 1,3,7-trimethylxanthine (caffeine) ratio) |
32 |
-4.9 |
Calcific aortic valve stenosis |
15 |
-5.5 |
Calcium levels |
253 |
-4.2 |
Callous-unemotional behaviour |
11 |
-2.8 |
Cancer |
37 |
-2.8 |
Cancer (pleiotropy) |
68 |
-3.4 |
Cannabis dependence |
113 |
-2.9 |
Cannabis dependence symptom count |
175 |
-3.8 |
Cannabis use |
49 |
-3.4 |
Cannabis use (age at onset) |
43 |
-1.5 |
Cannabis use (initiation) |
103 |
-4.7 |
Capecitabine sensitivity |
68 |
-3.6 |
Carboplatin disposition in epthelial ovarian cancer |
157 |
-2.5 |
Cardiac hypertrophy |
129 |
-3.3 |
Cardiac muscle measurement |
70 |
-5.0 |
Cardiac repolarization |
25 |
-5.2 |
Cardiac structure and function |
26 |
-3.3 |
Cardiac Troponin-T levels |
168 |
-3.4 |
Cardiometabolic and hematological traits |
72 |
-2.4 |
Cardiovascular disease |
1326 |
-4.3 |
Cardiovascular disease in hypertension (calcium channel blocker interaction) |
6 |
-4.8 |
Cardiovascular disease risk factors |
22 |
-4.8 |
Cardiovascular event in rheumatoid arthritis |
6 |
-4.2 |
Cardiovascular heart disease in diabetics |
7 |
-3.1 |
Cardiovascular risk factors |
4 |
-2.2 |
Cardiovascular risk factors (age interaction) |
7 |
-2.4 |
Carotenoid and tocopherol levels |
12 |
-4.4 |
Carotenoid levels (alpha-carotene) |
4 |
-2.0 |
Carotid artery intima media thickness (sex interaction) |
68 |
-3.8 |
Carotid atherosclerosis in HIV infection |
8 |
-4.3 |
Carotid intima media thickness |
54 |
-4.5 |
Carotid intima media thickness in rheumatoid arthritis |
3 |
-1.7 |
Carotid plaque burden |
77 |
-4.5 |
Carotid plaque burden (smoking interaction) |
12 |
-3.6 |
Carotid plaques in rheumatoid arthritis |
17 |
-5.1 |
Carotid plaque |
19 |
-4.2 |
Carpal tunnel syndrome |
102 |
-3.5 |
Caudate activity during reward |
184 |
-5.6 |
Caudate volume in trauma-exposed individuals |
39 |
-4.7 |
Celiac disease |
396 |
-23.8 |
Celiac disease or Rheumatoid arthritis |
137 |
-7.6 |
Cellular adhesion molecule (red blood cell fatty acid level interaction) |
3 |
-2.0 |
Cellular nuclear factor (erythroid-derived 2)-like 2 levels |
25 |
-4.1 |
Central corneal thickness |
294 |
-5.1 |
Cephalic index |
72 |
-5.7 |
Cerebellum growth |
2 |
-2.2 |
Cerebral amyloid angiopathy |
20 |
-2.3 |
Cerebral amyloid deposition in APOEe4 non-carriers (PET imaging) |
122 |
-5.2 |
Cerebral amyloid deposition (PET imaging) |
104 |
-3.2 |
Cerebral cortical growth |
25 |
-6.0 |
Cerebrospinal AB1-42 levels in Alzheimer's disease dementia |
20 |
-2.9 |
Cerebrospinal AB1-42 levels in mild cognitive impairment |
3 |
-3.6 |
Cerebrospinal AB1-42 levels in normal cognition |
74 |
-7.6 |
Cerebrospinal fluid AB1-42 levels |
145 |
-5.5 |
Cerebrospinal fluid beta-site APP cleaving enzyme levels |
68 |
-2.9 |
Cerebrospinal fluid biomarker levels |
60 |
-3.7 |
Cerebrospinal fluid clusterin levels |
65 |
-3.2 |
Cerebrospinal fluid clusterin levels in APOEe4+ carriers |
11 |
-4.2 |
Cerebrospinal fluid p-Tau181p:AB1-42 ratio |
19 |
-5.2 |
Cerebrospinal fluid p-tau levels |
6 |
-2.2 |
Cerebrospinal fluid p-tau levels in Alzheimer's disease dementia |
5 |
-4.3 |
Cerebrospinal fluid p-tau levels in mild cognitive impairment |
9 |
-3.7 |
Cerebrospinal fluid p-tau levels in normal cognition |
11 |
-1.8 |
Cerebrospinal fluid pyridoxal phosphate levels |
1 |
-2.3 |
Cerebrospinal fluid pyridoxal phosphate to pyridoxal ratio |
1 |
-2.3 |
Cerebrospinal fluid ?-synuclein levels |
41 |
-4.8 |
Cerebrospinal fluid t-tau:AB1-42 ratio |
193 |
-5.0 |
Cerebrospinal fluid t-tau levels |
81 |
-3.4 |
Cerebrospinal fluid t-tau levels in Alzheimer's disease dementia |
3 |
-3.0 |
Cerebrospinal fluid t-tau levels in mild cognitive impairment |
4 |
-2.7 |
Cerebrospinal fluid t-tau levels in normal cognition |
8 |
-4.0 |
Cerebrospinal P-tau181p levels |
75 |
-4.0 |
Cerebrospinal T-tau levels |
104 |
-4.6 |
Cervical artery dissection |
17 |
-2.9 |
Cervical cancer |
55 |
-3.7 |
Chagas cardiomyopathy in Tripanosoma cruzi seropositivity |
67 |
-5.9 |
Change in glucose in response to thiazide diuretic treatment in hypertension |
19 |
-4.4 |
Change in intraocular pressure in response to steroid treatment (triamcinolone acetonide) |
3 |
-2.5 |
Change in LVEF in response to paclitaxel and trastuzumab in HER2+ breast cancer |
28 |
-3.8 |
Cheek morphology (partial least square model) |
1 |
-4.3 |
Chemerin levels |
50 |
-3.9 |
Chickenpox |
94 |
-3.8 |
Childhood absence epilepsy |
43 |
-3.5 |
Childhood and early adolescence aggressive behavior |
14 |
-2.3 |
Childhood body mass index |
235 |
-3.0 |
Childhood dental caries in permanent teeth |
1 |
-3.1 |
Childhood ear infection |
448 |
-10.1 |
Childhood onset systemic lupus erythematosus |
3 |
-4.3 |
Childhood steroid-sensitive nephrotic syndrome |
53 |
-6.4 |
Chin dimples |
410 |
-4.1 |
Chlamydia trachomatis seropositivity |
26 |
-8.6 |
Chloride levels |
94 |
-3.7 |
Cholangiocarcinoma in primary sclerosing cholangitis (time to event) |
10 |
-4.4 |
Cholesterol efflux capacity |
5 |
-2.1 |
Cholesterol efflux capacity (ABCA-1 dependent assay) |
6 |
-3.6 |
Cholesterol efflux capacity (BHK stimulated assay) |
4 |
-4.0 |
Cholesterol efflux capacity (cAMP stimulated assay) |
4 |
-2.2 |
Cholesterol ester levels in large LDL |
4 |
-3.0 |
Cholesterol ester levels in medium LDL |
5 |
-2.9 |
Cholesterol ester levels in very large HDL |
1 |
-2.9 |
Cholesterol, total |
214 |
-8.3 |
Cholesteryl ester transfer protein levels |
5 |
-2.1 |
Chronic back pain |
6 |
-9.1 |
Chronic bronchitis and chronic obstructive pulmonary disease |
43 |
-3.4 |
Chronic central serous retinopathy |
5 |
-4.4 |
Chronic hepatitis B infection |
12 |
-5.3 |
Chronic hepatitis C infection |
6 |
-2.7 |
Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) |
997 |
-29.4 |
Chronic kidney disease |
316 |
-5.4 |
Chronic kidney disease and serum creatinine levels |
56 |
-9.0 |
Chronic kidney disease (chronic kidney disease vs normal or mildly reduced eGFR) in type 1 diabetes |
14 |
-4.3 |
Chronic kidney disease in diabetes |
6 |
-2.4 |
Chronic kidney disease in type 2 diabetes |
22 |
-4.7 |
Chronic kidney disease (severe chronic kidney disease vs normal kidney function) in type 1 diabetes |
2 |
0.0 |
Chronic lymphocytic leukemia |
160 |
-12.9 |
Chronic mucus hypersecretion |
6 |
-2.9 |
Chronic obstructive pulmonary disease |
616 |
-5.2 |
Chronic obstructive pulmonary disease (moderate to severe) |
63 |
-3.1 |
Chronic obstructive pulmonary disease or coronary artery disease (pleiotropy) |
25 |
-3.3 |
Chronic obstructive pulmonary disease or high blood pressure (pleiotropy) |
81 |
-3.3 |
Chronic obstructive pulmonary disease or resting heart rate (pleiotropy) |
122 |
-7.5 |
Chronic obstructive pulmonary disease-related biomarkers |
60 |
-4.8 |
Chronic obstructive pulmonary disease (severe) |
39 |
-3.7 |
Chronic periodontitis |
8 |
-4.0 |
Chronic periodontitis (mean interproximal clinical attachment level) |
36 |
-4.7 |
Chronic rhinosinusitis |
29 |
-2.3 |
Chronic rhinosinusitis with nasal polyps |
2 |
-3.3 |
Chronic sinus infection |
72 |
-2.5 |
Chronic venous disease |
2 |
-2.5 |
Chronotype |
2504 |
-6.7 |
Cigarettes smoked per day (MTAG) |
356 |
-3.1 |
Cingulate cortical amyloid beta load |
8 |
-4.5 |
Circulating chemerin levels |
15 |
-4.3 |
Circulating chromogranin peptide levels |
29 |
-7.8 |
Circulating fibroblast growth factor 23 levels |
104 |
-4.3 |
circulating leptin levels |
46 |
-6.6 |
circulating leptin levels adjusted for BMI |
16 |
-8.6 |
Circulating myeloperoxidase levels (plasma) |
1 |
-2.7 |
Circulating myeloperoxidase levels (serum) |
15 |
-4.0 |
Circulating odd-numbered chain saturated fatty acid levels (C15:0) |
26 |
-3.2 |
Circulating odd-numbered chain saturated fatty acid levels (C15:0+C17:0) |
18 |
-2.8 |
Circulating odd-numbered chain saturated fatty acid levels (C17:0) |
27 |
-3.2 |
Circulating odd-numbered chain saturated fatty acid levels (C19:0) |
66 |
-5.4 |
Circulating odd-numbered chain saturated fatty acid levels (C23:0) |
35 |
-4.8 |
Circulating phylloquinone levels |
6 |
-4.0 |
Cisplatin-induced ototoxicity |
53 |
-3.2 |
Classic bladder exstrophy |
119 |
-2.6 |
Cleft lip |
10 |
-1.7 |
Cleft lip with or without cleft palate |
73 |
-5.5 |
Cleft lip with or without cleft palate (maternal periconceptional alcohol intake interaction) |
2 |
-7.1 |
Cleft lip with or without cleft palate (maternal periconceptional cigarette smoking interaction) |
6 |
-3.1 |
Cleft lip with or without cleft palate (maternal periconceptional vitamin use interaction) |
35 |
-4.0 |
Cleft palate |
75 |
-2.2 |
Clinical laboratory measurements |
38 |
-2.5 |
Clopidogrel active metabolite levels |
50 |
-6.1 |
Clostridium difficile infection in multiple myeloma |
102 |
-3.7 |
Clozapine-induced agranulocytosis |
154 |
-4.3 |
Clozapine-induced agranulocytosis/granulocytopenia in treatment-resistant schizophrenia |
23 |
-3.6 |
Clozapine-induced cytotoxicity |
50 |
-4.6 |
Cluster headache |
6 |
-4.7 |
Cocaine dependence |
93 |
-4.1 |
Coenzyme Q10 levels |
51 |
-3.1 |
Coffee consumption |
377 |
-4.2 |
Coffee consumption (cups per day) |
22 |
-3.9 |
Cognitive ability |
337 |
-9.8 |
Cognitive ability (MTAG) |
483 |
-8.3 |
Cognitive decline (age-related) |
102 |
-5.0 |
Cognitive decline rate in late mild cognitive impairment |
181 |
-3.3 |
Cognitive empathy |
375 |
-3.2 |
Cognitive flexibility |
7 |
-2.9 |
Cognitive function |
387 |
-6.4 |
Cognitive impairment test score |
63 |
-7.4 |
Cognitive performance |
1486 |
-4.6 |
Cognitive performance (MTAG) |
2662 |
-5.5 |
Cognitive test performance |
144 |
-5.6 |
Cold medicine-related Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) with severe mucosal involvement |
15 |
-5.6 |
Cold medicine-related Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) with severe ocular complications |
2 |
-1.7 |
Cold sores |
125 |
-16.9 |
Colonoscopy-negative controls vs population controls |
576 |
-3.6 |
Colorectal adenoma (advanced) |
57 |
-3.1 |
Colorectal cancer |
1135 |
-6.9 |
Colorectal cancer (alcohol consumption interaction) |
2 |
-2.9 |
Colorectal cancer (aspirin and/or NSAID use interaction) |
18 |
-5.5 |
Colorectal cancer (calcium intake interaction) |
12 |
-2.9 |
Colorectal cancer (diet interaction) |
66 |
-5.9 |
Colorectal cancer (oestrogen-progestogen hormone therapy interaction) |
3 |
-6.7 |
Colorectal or endometrial cancer |
160 |
-2.9 |
Common carotid intima-media thickness |
52 |
-1.6 |
Common carotid intima-media thickness in HIV infection |
44 |
-5.1 |
Common carotid intima-media thickness in HIV negative individuals |
28 |
-3.2 |
Common traits (Other) |
46 |
-6.7 |
Complete remission in asthma |
2 |
-2.3 |
Conduct disorder |
126 |
-3.7 |
Conduct disorder (maternal expressed emotions interaction) |
56 |
-2.5 |
Conduct disorder (symptom count) |
158 |
-3.3 |
Congenital heart disease (inherited effect) |
58 |
-3.0 |
Congenital heart disease (maternal effect) |
55 |
-2.5 |
Congenital heart malformation |
20 |
-3.0 |
Congenital left-sided heart lesions |
3 |
-2.4 |
Congenital left-sided heart lesions (maternal effect) |
9 |
-2.5 |
Conotruncal heart defects |
45 |
-4.4 |
Conotruncal heart defects (inherited effects) |
45 |
-2.9 |
Conotruncal heart defects (maternal effects) |
65 |
-2.5 |
Contrast sensitivity |
4 |
-1.9 |
Corneal astigmatism |
219 |
-2.7 |
Corneal curvature |
70 |
-2.2 |
Corneal structure |
186 |
-5.4 |
Coronary artery aneurysm in Kawasaki disease |
67 |
-8.5 |
Coronary artery calcification |
250 |
-4.7 |
Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes |
416 |
-3.2 |
Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes |
338 |
-3.5 |
Coronary artery calcified atherosclerotic plaque score in type 2 diabetes |
137 |
-3.2 |
Coronary artery disease |
1714 |
-7.7 |
Coronary artery disease and triglyceride levels (multivariate analysis) |
4 |
-2.7 |
Coronary artery disease in type 1 diabetes |
38 |
-2.0 |
Coronary artery disease (myocardial infarction, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease) |
158 |
-7.0 |
Coronary artery disease or ischemic stroke |
31 |
-3.9 |
Coronary artery disease or large artery stroke |
30 |
-4.0 |
Coronary atherosclerosis (increased number of diseased vessels) (traffic exposure interaction) |
75 |
-3.6 |
Coronary heart disease |
289 |
-4.3 |
Coronary restenosis |
2 |
-3.6 |
Corrected insulin response adjusted for insulin sensitivity index |
17 |
-3.8 |
Corrected insulin response |
17 |
-3.8 |
Cortical amyloid beta load |
97 |
-3.1 |
Cortical brain region measurements (area, volume and thickness) |
12 |
-2.6 |
Cortical thickness |
1 |
0.0 |
Corticobasal degeneration |
7 |
-4.7 |
Corticosteroid-induced adrenal suppression (peak cortisol < 350 nmol/L) |
7 |
-5.1 |
Corticosteroid-induced adrenal suppression (peak cortisol < 500 nmol/L) |
7 |
-5.1 |
Cortisol levels (saliva) |
40 |
-4.5 |
Cotinine glucuronidation |
30 |
-2.7 |
Cough in response to angiotensin-converting enzyme inhibitor drugs |
62 |
-3.9 |
C-peptide levels in type I diabetes |
5 |
-2.8 |
Cranial base width |
5 |
-4.8 |
Craniofacial microsomia |
28 |
-3.2 |
C-reactive protein |
61 |
-3.4 |
C-reactive protein and white blood cell count |
34 |
-2.6 |
C-reactive protein levels |
516 |
-5.7 |
C-reactive protein levels in ischemic stroke |
15 |
-1.4 |
C-reactive protein levels or HDL-cholesterol levels (pleiotropy) |
73 |
-5.0 |
C-reactive protein levels or LDL-cholesterol levels (pleiotropy) |
66 |
-5.2 |
C-reactive protein levels or total cholesterol levels (pleiotropy) |
69 |
-4.6 |
C-reactive protein levels or triglyceride levels (pleiotropy) |
79 |
-3.7 |
Creatine kinase levels |
110 |
-5.6 |
Creatinine levels |
323 |
-3.6 |
Creatinine levels in ischemic stroke |
19 |
-4.4 |
Creutzfeldt-Jakob disease |
14 |
-2.9 |
Creutzfeldt-Jakob disease (sporadic) |
4 |
-3.0 |
Creutzfeldt-Jakob disease (variant) |
19 |
-3.4 |
Crohn's disease |
1263 |
-28.8 |
Crohn's disease and celiac disease |
13 |
-3.0 |
Crohn's disease and sarcoidosis (combined) |
9 |
-5.0 |
Crohn's disease (indolent vs progressive) |
69 |
-3.7 |
Crohn's disease (need for surgery) |
28 |
-2.5 |
Crohn's disease-related phenotypes |
31 |
-3.0 |
Crohn's disease (time to first abdominal surgery) |
37 |
-6.0 |
Crohn's disease (time to progression) |
75 |
-6.0 |
Crohn's disease (time to surgery) |
7 |
-2.8 |
CSF tryptophan concentration in tuberculous meningitis |
40 |
-4.9 |
CTACK levels |
144 |
-4.5 |
Current cigarettes per day in chronic obstructive pulmonary disease |
27 |
-2.7 |
Cutaneous malignant melanoma |
80 |
-4.1 |
Cutaneous nevi |
4 |
-2.5 |
Cutaneous squamous cell carcinoma |
7 |
-3.2 |
Cystic fibrosis severity |
51 |
-5.3 |
Cytomegalovirus antibody response |
19 |
-5.7 |
Daytime nap |
17 |
-3.9 |
Daytime sleepiness |
4 |
-3.1 |
Daytime sleep phenotypes |
394 |
-3.4 |
D-dimer levels |
48 |
-2.4 |
DDT metabolite (p,p'-DDE levels) |
5 |
-5.4 |
Decline in glucose metabolism in posterior cingulate cortex |
5 |
-3.1 |
Deep ovarian and/or rectovaginal disease with dense adhesions |
68 |
-6.8 |
Dehydroepiandrosterone sulphate levels |
37 |
-5.2 |
Delayed reward discounting |
72 |
-3.3 |
Deliberate self-harm |
60 |
-8.7 |
Delta-5 desaturase activity |
24 |
-2.8 |
Delta-5 desaturase activity response to n3-polyunsaturated fat supplement |
12 |
-3.7 |
Delta-6 desaturase activity |
14 |
-6.5 |
Dementia and core Alzheimer's disease neuropathologic changes |
74 |
-2.7 |
Dementia with Lewy bodies |
1 |
-2.1 |
Dengue shock syndrome |
14 |
-3.0 |
Dental caries |
383 |
-5.5 |
Dentate gyrus granule cell layer volume |
14 |
-4.1 |
Dentate gyrus granule cell layer volume (corrected for total hippocampal volume) |
1 |
-3.1 |
Dentate gyrus molecular layer volume |
18 |
-3.7 |
Depressed affect |
641 |
-3.5 |
Depression |
1084 |
-4.0 |
Depression and alcohol dependence |
3 |
-2.6 |
Depression (broad) |
646 |
-5.4 |
Depression in response to interferon-based therapy in chronic hepatitis C |
15 |
-2.9 |
Depression in smokers |
105 |
-4.5 |
Depression (quantitative trait) |
99 |
-4.6 |
Depressive and manic episodes in bipolar disorder |
55 |
-2.4 |
Depressive episodes in bipolar disorder |
70 |
-3.4 |
Depressive symptom improvement |
28 |
-6.1 |
Depressive symptom measurement or major depressive disorder |
9 |
-2.0 |
Depressive symptoms |
1566 |
-6.7 |
Depressive symptoms (MTAG) |
447 |
-4.0 |
Depressive symptoms (SSRI exposure interaction) |
29 |
-3.0 |
Depressive symptoms (stressful life events interaction) |
9 |
-2.2 |
Depressive symptoms x dependent stressful life events interaction (1df test) |
53 |
-5.4 |
Depressive symptoms x dependent stressful life events interaction (2df test) |
52 |
-3.1 |
Depressive symptoms x independent stressful life events interaction (1df test) |
30 |
-4.1 |
Depressive symptoms x independent stressful life events interaction (2df test) |
24 |
-3.7 |
Dermatomyositis or juvenile dermatomyositis |
2 |
-3.4 |
Developmental dysplasia of the hip |
9 |
-2.2 |
Developmental language disorder |
4 |
-3.5 |
Developmental language disorder (linguistic errors) |
6 |
-4.5 |
Diabetes (gestational) |
75 |
-5.3 |
Diabetes (incident) |
28 |
-2.4 |
Diabetes in response to antihypertensive drug treatment (treatment strategy interaction) |
1 |
-3.4 |
Diabetes mellitus |
13 |
-2.1 |
Diabetes related insulin traits |
5 |
-2.8 |
Diabetic kidney disease |
235 |
-2.9 |
Diabetic kidney disease in diabetes (ESRD vs. no ESRD) |
1 |
-3.1 |
Diabetic kidney disease in type 2 diabetes |
13 |
-5.1 |
Diabetic kidney disease in type 2 diabetes (ESRD vs. no ESRD) |
18 |
-2.8 |
Diabetic macular edema in type 2 diabetes |
2 |
0.0 |
Diabetic nephropathy in type 1 diabetes |
8 |
-5.4 |
Diabetic retinopathy |
126 |
-4.4 |
Diabetic retinopathy (all NPDR and PDR) |
71 |
-3.8 |
Diabetic retinopathy (moderate NPDR and PDR) |
35 |
-4.9 |
Dialysis-related mortality |
80 |
-3.4 |
Diarrhoea-associated Entamoeba histolytica infection |
1 |
-1.9 |
Diarrhoea in darapladib-treated cardiovascular disease (time to event) |
4 |
-3.3 |
diarrhoeal disease at age 1 with doctor diagnosis |
1 |
-2.4 |
diarrhoeal disease at age 2 |
2 |
-2.9 |
Diastolic blood pressure |
2944 |
-17.0 |
Diastolic blood pressure (alcohol consumption interaction) |
1 |
-1.7 |
Diastolic blood pressure (cigarette smoking interaction) |
213 |
-2.4 |
Diastolic blood pressure in combination therapy (beta blocker and thiazide diuretic) |
1 |
0.0 |
Diastolic blood pressure night-to-day ratio in hypertension |
20 |
-3.8 |
Diastolic blood pressure response to hydrochlorothiazide in hypertension |
26 |
-3.2 |
Diastolic blood pressure x alcohol consumption interaction (2df test) |
405 |
-6.4 |
Diastolic blood pressure x alcohol consumption (light vs heavy) interaction (2df test) |
173 |
-7.8 |
Diastolic blood pressure x smoking status (current vs non-current) interaction (1df test) |
83 |
-3.1 |
Diastolic blood pressure x smoking status (current vs non-current) interaction (2df test) |
267 |
-3.7 |
Diastolic blood pressure x smoking status (ever vs never) interaction (1df test) |
2 |
-2.1 |
Diastolic blood pressure x smoking status (ever vs never) interaction (2df test) |
184 |
-4.1 |
Diastolic blood pressure x sodium interaction (1df test) |
13 |
-3.5 |
Diastolic blood pressure x sodium interaction (2df test) |
4 |
-4.6 |
Dietary macronutrient intake |
47 |
-5.4 |
Differentiated thyroid cancer |
70 |
-3.6 |
Diffuse cutaneous systemic sclerosis |
8 |
-3.2 |
Diffuse large B cell lymphoma |
12 |
-3.2 |
Diffusing capacity of carbon monoxide |
245 |
-4.6 |
Diffusing capacity of the lung for carbon monoxide traits |
11 |
-3.1 |
Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined) |
55 |
-4.9 |
Digit length ratio |
51 |
-8.6 |
Digit length ratio (left hand) |
51 |
-8.6 |
Digit length ratio (right hand) |
43 |
-8.8 |
Diisocyanate-induced asthma |
553 |
-2.7 |
Disc degeneration (lumbar) |
85 |
-3.8 |
Discordance in emotional problems in monozygotic twins |
27 |
-3.9 |
Disease-free survival in breast cancer |
13 |
-5.1 |
Disease progression in age-related macular degeneration |
142 |
-3.4 |
Disease progression to choroidal neovascularization form in age-related macular degeneration |
2 |
0.0 |
Disrupted circadian rhythm (low relative amplitude of rest-activity cycles) |
8 |
-2.6 |
Disturbances of the gamma-frequency band of electroencephalography measures in schizophrenia |
21 |
-3.6 |
Diverticular disease |
546 |
-3.0 |
DNA methylation (parent-of-origin) |
52 |
-3.3 |
DNA methylation (variation) |
43 |
-2.8 |
DNA methylation variation (age effect) |
1772 |
-4.4 |
Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer |
37 |
-2.6 |
Double-edged eyelids |
25 |
-2.0 |
Drinking behavior |
2 |
-3.1 |
Drug experimentation measurement |
7 |
-3.3 |
Drug-induced cholestatic/mixed liver injury |
5 |
-2.1 |
Drug-induced liver injury |
8 |
-1.9 |
Drug-induced liver injury (anti-tuberculosis drugs) |
22 |
-3.4 |
Drug-induced liver injury (diclofenac) |
50 |
-1.7 |
Drug-induced liver injury (flucloxacillin) |
19 |
-4.3 |
Drug-induced liver injury (fluoroquinolones) |
11 |
-2.7 |
Drug-induced liver injury (nitrofurantoin) |
41 |
-2.2 |
Drug-induced liver injury (nonsteroidal anti-inflammatory drugs) |
4 |
-2.9 |
Drug-induced liver injury (statins) |
26 |
-3.3 |
Drug-induced Stevens-Johnson syndrome or toxic epidermal necrolysis (SJS/TEN) |
23 |
-5.3 |
Duloxetine response in major depressive disorder ( change in symptom score) |
11 |
-2.7 |
Duodenal ulcer |
3 |
-3.3 |
Dupuytren's disease |
171 |
-3.2 |
Dysmenorrheic pain |
1 |
-2.2 |
Dysmenorrheic pain severity |
27 |
-4.2 |
Dysphagia |
39 |
-1.9 |
Early age at menarche |
3 |
-2.1 |
Early childhood aggressive behavior |
7 |
-2.7 |
Early diabetic kidney disease in diabetes |
11 |
-5.4 |
Early onset atrial fibrillation |
65 |
-5.7 |
Ear morphology |
16 |
-5.3 |
Ease of getting up in the morning |
323 |
-3.2 |
Eating disorder in bipolar disorder |
6 |
-2.4 |
Eating disorders |
71 |
-3.7 |
Eating disorders (purging via substances) |
69 |
-3.8 |
Echocardiographic traits |
25 |
-2.3 |
Economic and political preferences |
100 |
-4.1 |
Economic and political preferences (environmentalism) |
72 |
-3.0 |
Economic and political preferences (fairness) |
54 |
-2.7 |
Economic and political preferences (feminism/equality) |
86 |
-2.9 |
Economic and political preferences (immigration/crime) |
15 |
-3.2 |
Economic and political preferences (time) |
20 |
-4.8 |
Eczema |
700 |
-16.5 |
Educational attainment |
444 |
-5.1 |
Educational attainment (college completion) |
99 |
-4.9 |
Educational attainment (MTAG) |
6475 |
-10.4 |
Educational attainment (years of education) |
8308 |
-12.5 |
EGFR mutation-positive lung adenocarcinoma |
11 |
-3.3 |
Egg allergy |
6 |
-3.0 |
Egg allergy (maternal genetic effects) |
42 |
-4.3 |
Egg allergy (parent-of-origin effect) |
6 |
-2.1 |
Ejection fraction |
13 |
-5.6 |
Ejection fraction in Tripanosoma cruzi seropositivity |
133 |
-3.9 |
Electrocardiographic conduction measures |
30 |
-2.6 |
Electrocardiographic traits |
135 |
-5.3 |
Electrodermal activity |
118 |
-6.0 |
Electroencephalogram traits |
169 |
-7.6 |
Electroencephalographic traits in alcoholism |
25 |
-3.2 |
Elevated fasting plasma glucose |
8 |
-3.5 |
Elevated serum carcinoembryonic antigen levels |
4 |
-2.6 |
Emotional dysregulation |
4 |
-2.2 |
Empathy quotient |
33 |
-2.3 |
Emphysema distribution in smoking |
32 |
-3.8 |
Emphysema imaging phenotypes |
130 |
-3.2 |
Emphysema-related traits |
24 |
-2.3 |
Endometrial cancer |
105 |
-4.2 |
Endometrial cancer (endometrioid histology) |
80 |
-4.8 |
Endometrial cancer (Non-endometrioid histology) |
9 |
-1.2 |
Endometrial endometrioid carcinoma |
6 |
-2.8 |
Endometrioid ovarian cancer |
1 |
-2.8 |
Endometriosis |
327 |
-7.8 |
Endometriosis or endometrial cancer (pleiotropy) |
9 |
-3.3 |
End-stage coagulation |
40 |
-4.3 |
End-stage renal disease |
49 |
-3.5 |
End stage renal disease in APOL1 risk genotype-negative individuals |
44 |
-6.2 |
End-stage renal disease in Type 1 diabetics |
6 |
-3.5 |
End-stage renal disease in type 2 diabetes |
4 |
-3.7 |
End stage renal disease x APOL1 genotype interaction |
15 |
-2.4 |
Energy expenditure (24h) |
16 |
-2.9 |
Energy expenditure |
32 |
-2.5 |
Energy intake |
6 |
-4.2 |
Enteric fever |
2 |
-2.2 |
Entorhinal cortical thickness |
43 |
-3.6 |
Entorhinal cortical thickness (Alzheimer's disease interaction) |
1 |
-3.1 |
Entorhinal cortical volume |
3 |
-2.5 |
Eosinophil counts |
2527 |
-44.5 |
Eosinophilic esophagitis |
43 |
-3.6 |
Eosinophilic esophagitis (pediatric) |
55 |
-3.6 |
Eosinophil percentage of granulocytes |
440 |
-17.3 |
Eosinophil percentage of white cells |
421 |
-20.4 |
Eotaxin levels |
121 |
-3.4 |
Epilepsy |
76 |
-4.4 |
Epilepsy and lamotrigine-induced maculopapular eruptions |
205 |
-5.4 |
Epilepsy (remission after treatment) |
23 |
-5.5 |
Epirubicin-induced leukopenia |
6 |
-3.6 |
Epithelial ovarian cancer |
367 |
-7.0 |
Epstein-Barr virus copy number in lymphoblastoid cell lines |
159 |
-2.4 |
Epstein-Barr virus immune response (EBNA-1) |
12 |
-6.0 |
Epstein Barr virus nuclear antigen 1 IgG levels |
2 |
-3.2 |
Epstein Barr virus nuclear antigen 1 IgG levels or multiple sclerosis |
10 |
-3.3 |
Erectile dysfunction |
109 |
-4.7 |
Erectile dysfunction and prostate cancer treatment |
73 |
-5.9 |
Erectile dysfunction in type 1 diabetes |
5 |
-2.1 |
Erosive tooth wear (severe vs none or mild) |
102 |
-7.3 |
Erosive tooth wear (severe vs non-severe) |
352 |
-6.3 |
Erythema nodosum in inflammatory bowel disease |
22 |
-4.5 |
Erythrocyte cadmium concentration |
43 |
-3.5 |
Erythrocyte cadmium concentration in never smokers |
4 |
-2.8 |
E-selectin levels |
4 |
-3.1 |
Esophageal adenocarcinoma |
21 |
-3.9 |
Esophageal adenocarcinoma x gastroesophageal reflux disease interaction |
28 |
-3.4 |
Esophageal adenocarcinoma x pack-years of smoking exposure interaction |
1 |
-2.0 |
Esophageal adenocarcinoma x smoking interaction |
60 |
-7.1 |
Esophageal cancer |
44 |
-3.1 |
Esophageal cancer (alcohol interaction) |
19 |
-3.8 |
Esophageal squamous cell carcinoma |
16 |
-4.5 |
Essential tremor |
59 |
-4.5 |
Esterified cholesterol levels |
1 |
-3.6 |
Estimated glomerular filtration rate |
1760 |
-7.7 |
Estimated glomerular filtration rate after 1 year in renal transplantation (donor effect) |
19 |
-2.7 |
Estimated glomerular filtration rate after 1 year in renal transplantation (recipient effect) |
10 |
-2.5 |
Estimated glomerular filtration rate after 5 years in renal transplantation (donor effect) |
35 |
-3.5 |
Estimated glomerular filtration rate after 5 years in renal transplantation (recipient effect) |
53 |
-3.2 |
Estimated glomerular filtration rate change in renal transplantation (donor effect) |
3 |
-2.1 |
Estimated glomerular filtration rate change in renal transplantation (recipient effect) |
48 |
-3.9 |
Estimated glomerular filtration rate in coronary artery disease and impaired kidney function |
3 |
-2.5 |
Estradiol levels |
74 |
-4.0 |
Estradiol plasma levels (breast cancer) |
73 |
-2.2 |
Estrogen receptor status in HER2 negative breast cancer |
4 |
-3.7 |
Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer |
44 |
-4.6 |
Estrone levels |
3 |
-5.0 |
Eudaimonic well-being |
50 |
-3.9 |
Event free survival in diffuse large B-cell lymphoma treated with immunochemotherapy |
4 |
-3.3 |
Ewing sarcoma |
16 |
-5.0 |
Excessive daytime sleepiness |
25 |
-3.6 |
Excessive hairiness |
19 |
-6.6 |
Excessive sweating |
9 |
-3.0 |
Executive function in ADHD |
17 |
-10.1 |
Executive inhibition (Stroop WIT and CIT) in attention deficit hyperactivity disorder |
8 |
-5.5 |
Exercise treadmill test traits |
5 |
-2.8 |
Exhaled carbon monoxide levels in smokers with chronic obstructive pulmonary disease |
14 |
-3.2 |
Exhaled nitric oxide levels |
43 |
-4.1 |
Exhaled nitric oxide output |
35 |
-4.1 |
Experiencing mood swings |
269 |
-3.3 |
Exploratory eye movement dysfunction in schizophrenia (cognitive search score) |
32 |
-3.7 |
Exploratory eye movement dysfunction in schizophrenia (mean eye scanning length) |
1 |
0.0 |
Exploratory eye movement dysfunction in schizophrenia (number of eye fixations) |
83 |
-3.3 |
Exploratory eye movement dysfunction in schizophrenia (responsive search score) |
41 |
-4.6 |
Exploratory eye movement dysfunction in schizophrenia (total eye scanning length) |
84 |
-2.9 |
Expressive vocabulary in infants |
76 |
-2.6 |
Extraversion |
28 |
-4.0 |
Extremely high intelligence |
175 |
-3.3 |
Exudative age-related macular degeneration |
4 |
-2.2 |
Eyebrow thickness |
43 |
-4.6 |
Eye color |
35 |
-3.4 |
Eye color (brightness) |
8 |
-4.7 |
Eye color (saturation) |
19 |
-3.9 |
Eye length |
13 |
-7.2 |
Eye morphology |
78 |
-5.3 |
Eye movement (horizontal position gain) |
19 |
-3.5 |
Eye movement in schizophrenia (horizontal position gain) |
52 |
-3.8 |
Facial depth |
6 |
-3.2 |
Facial emotion recognition |
18 |
-4.9 |
Facial emotion recognition (angry faces) |
40 |
-2.8 |
Facial emotion recognition (fearful faces) |
5 |
-5.0 |
Facial emotion recognition (happy faces) |
1 |
-2.8 |
Facial emotion recognition (sad faces) |
2 |
-2.8 |
Facial morphology |
32 |
-4.2 |
Facial morphology (factor 10, width of nasal floor) |
41 |
-4.7 |
Facial morphology (factor 11, projection of the nose) |
82 |
-5.4 |
Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface) |
33 |
-2.8 |
Facial morphology (factor 13, vertical position of alar curvature relative to upper lip) |
35 |
-6.9 |
Facial morphology (factor 14, intercanthal width) |
56 |
-3.6 |
Facial morphology (factor 15, philtrum width) |
36 |
-3.9 |
Facial morphology (factor 16) |
38 |
-3.4 |
Facial morphology (factor 17, height of vermillion upper lip) |
47 |
-3.3 |
Facial morphology (factor 18) |
49 |
-4.1 |
Facial morphology (factor 19) |
143 |
-2.8 |
Facial morphology (factor 1, breadth of lateral portion of upper face) |
53 |
-3.8 |
Facial morphology (factor 20) |
67 |
-5.0 |
Facial morphology (factor 21, depth of nasal alae) |
42 |
-3.8 |
Facial morphology (factor 22) |
62 |
-2.6 |
Facial morphology (factor 23) |
33 |
-3.9 |
Facial morphology (factor 2, vertical position of orbits relative to midface) |
36 |
-3.0 |
Facial morphology (factor 3, length of philtrum) |
15 |
-2.3 |
Facial morphology (factor 4, facial height related to vertical position of gnathion) |
22 |
-8.5 |
Facial morphology (factor 5, width of mouth relative to central midface) |
59 |
-4.7 |
Facial morphology (factor 6, height of vermillion lower lip) |
41 |
-2.6 |
Facial morphology (factor 7, width of cartilaginous portion of nose) |
47 |
-3.5 |
Facial morphology (factor 8, orbital inclination due to vertical and horizontal position of exocanthion) |
48 |
-3.3 |
Facial morphology (factor 9, facial height related to vertical position of nasion) |
40 |
-3.0 |
facial morphology traits (multivariate analysis) |
19 |
-3.8 |
Facial pigmentation |
1 |
-2.5 |
Facial wrinkles |
24 |
-4.1 |
Factor VII |
15 |
-3.4 |
Factor VII activity |
32 |
-2.2 |
Factor VIII levels |
39 |
-6.9 |
Familial hepatitis B virus-related hepatocellular carcinoma |
31 |
-2.8 |
Familial lung adenocarcinoma |
72 |
-5.2 |
Familial lung cancer |
12 |
-2.3 |
Familial squamous cell lung carcinoma |
202 |
-5.9 |
Family history of Alzheimer's disease |
112 |
-15.0 |
Fast beta electroencephalogram |
29 |
-5.0 |
Fasting blood glucose |
220 |
-3.7 |
Fasting blood glucose adjusted for BMI |
10 |
-4.2 |
Fasting blood glucose (BMI interaction) |
155 |
-4.0 |
Fasting blood insulin |
104 |
-3.7 |
Fasting blood insulin (BMI interaction) |
124 |
-3.2 |
Fasting glucose in pregnancy (gestational week 14-16) |
2 |
-2.8 |
Fasting insulin (dietary factor interaction) |
97 |
-4.2 |
Fasting plasma glucose |
149 |
-5.0 |
Fasting plasma glucose (childhood) |
3 |
-3.9 |
Fat body mass |
15 |
-2.6 |
Fat distribution (HIV) |
26 |
-3.7 |
Fat-free mass |
787 |
-8.4 |
Fatty acid desaturase activity (adipose tissue) |
1 |
-3.6 |
Fatty acid desaturase activity (serum) |
2 |
-5.0 |
F-cell distribution |
23 |
-6.6 |
F-cell distribution in sickle cell anaemia |
54 |
-2.1 |
Fear of medical pain (dental) |
3 |
-3.0 |
Fear of minor pain |
15 |
-2.6 |
Fear of pain |
3 |
-2.6 |
Fear of severe pain |
12 |
-3.4 |
Febrile seizures (MMR vaccine-related) |
11 |
-2.5 |
Feeling fed-up |
239 |
-12.0 |
Feeling guilty |
141 |
-42.9 |
Feeling hurt |
248 |
-3.8 |
Feeling lonely |
43 |
-4.6 |
Feeling miserable |
275 |
-3.3 |
Feeling nervous |
156 |
-3.0 |
Feeling tense |
154 |
-4.9 |
Feeling worry |
308 |
-3.6 |
Femoral neck bone geometry |
1 |
0.0 |
Femoral neck bone geometry and menarche (age at onset) |
21 |
-4.7 |
Femoral neck bone mineral density |
433 |
-3.9 |
Femoral neck length |
19 |
-3.9 |
Fetal hemoglobin levels |
26 |
-3.8 |
Fetal hemoglobin levels in sickle cell anemia |
6 |
-3.8 |
FEV1 |
1176 |
-8.5 |
Fibrinogen |
16 |
-4.8 |
Fibrinogen levels |
112 |
-6.6 |
Fibroblast growth factor basic levels |
65 |
-2.6 |
Focal epilepsy (with hippocampal sclerosis) |
15 |
-3.5 |
Folate pathway vitamin levels |
23 |
-1.9 |
Folding of antihelix |
28 |
-4.1 |
Follicular lymphoma |
46 |
-8.5 |
Follicule stimulating hormone |
10 |
-5.6 |
Follicule stimulating hormone levels in polycystic ovary syndrome |
73 |
-4.8 |
Food addiction |
84 |
-6.2 |
Food allergy |
26 |
-4.1 |
Food allergy (maternal genetic effects) |
69 |
-3.3 |
Food allergy (parent-of-origin effect) |
3 |
-6.0 |
Food antigen IgG levels |
19 |
-2.5 |
Foot ulcer and neuropathy in diabetes |
87 |
-3.9 |
Forced expiratory volume in 1 second (occupational environmental exposures interaction) |
75 |
-3.2 |
Forearm bone mineral density |
3 |
-5.2 |
Forehead morphology |
9 |
-1.9 |
Formal thought disorder in schizophrenia |
37 |
-3.9 |
Fractional excretion of metabolites in chronic kidney disease |
4 |
-2.2 |
Fractional excretion of uric acid |
3 |
-4.1 |
Fractional exhaled nitric oxide (childhood) |
82 |
-3.9 |
Fractional exhaled nitric oxide levels |
47 |
-4.5 |
Fractional shortening |
16 |
-5.3 |
Fractures |
148 |
-4.8 |
Fractures (vertebral) |
8 |
-4.2 |
Freckles |
17 |
-4.2 |
Free cholesterol levels |
1 |
-3.6 |
Free cholesterol levels in large LDL |
2 |
-3.3 |
Free cholesterol levels in medium HDL |
1 |
-2.9 |
Free thyroxine concentration |
110 |
-3.3 |
Frontotemporal dementia |
33 |
-4.6 |
Frontotemporal dementia (age at onset) |
8 |
-4.8 |
Frontotemporal dementia with GRN mutation |
62 |
-2.6 |
Frontotemporal dementia with GRN mutation (age at onset) |
11 |
-4.1 |
Fructosamine levels |
22 |
-4.2 |
Fuchs's corneal dystrophy |
13 |
-4.7 |
Full scale intelligence quotient (cesarean section interaction) |
8 |
-2.9 |
Fulminant type 1 diabetes |
4 |
-2.4 |
Functional impairment in major depressive disorder, bipolar disorder and schizophrenia |
27 |
-2.5 |
Gait rhythm |
19 |
-7.3 |
Gait speed in old age |
158 |
-3.9 |
Gait variability |
1 |
-2.3 |
Gallbladder cancer |
66 |
-2.5 |
Gallstone disease |
55 |
-3.8 |
Gambling |
8 |
-3.7 |
Gamma glutamyl transferase levels |
180 |
-11.9 |
Gamma glutamyl transferase levels in excessive alcohol consumption |
31 |
-4.6 |
Gamma glutamyl transferase levels in low alcohol consumption |
56 |
-4.7 |
Gamma glutamyl transpeptidase |
5 |
-4.5 |
Gastric cancer |
35 |
-3.0 |
Gastric parietal cell autoantibody levels in type 1 diabetes |
2 |
-4.3 |
Gastritis |
53 |
-5.3 |
Gastroesophageal reflux disease |
15 |
-2.2 |
Gaucher disease severity |
8 |
-3.6 |
Gemcitabine-induced early high-grade neutropenia in pancreatic cancer |
61 |
-4.4 |
Gene methylation in lung tissue |
1 |
-1.9 |
General cognitive ability |
4743 |
-12.8 |
General factor of neuroticism |
852 |
-5.1 |
General glucose level in pregnancy (gestational week 30-32) |
1 |
0.0 |
Generalized epilepsy |
162 |
-3.3 |
General risk tolerance (MTAG) |
1771 |
-5.9 |
Gestational age at birth (child effect) |
33 |
-4.9 |
Gestational age at birth in labor-initiated deliveries (child effect) |
53 |
-3.0 |
Gestational age at birth in labor-initiated deliveries (maternal effect) |
9 |
-2.9 |
Gestational age at birth in premature rupture of membrane-initiated deliveries (child effect) |
19 |
-4.2 |
Gestational age at birth in premature rupture of membrane-initiated deliveries (maternal effect) |
38 |
-4.8 |
Gestational age at birth (maternal effect) |
44 |
-3.2 |
Giant cell arteritis |
19 |
-7.2 |
GIP levels in response to oral glucose tolerance test (120 minutes) |
10 |
-6.2 |
Glaucoma |
185 |
-7.9 |
Glaucoma (high intraocular pressure) |
9 |
-3.3 |
Glaucoma (low intraocular pressure) |
13 |
-2.5 |
Glaucoma (primary angle closure) |
33 |
-4.7 |
Glaucoma (primary open-angle) |
341 |
-4.4 |
Glioblastoma |
35 |
-4.9 |
Glioblastoma (age-stratified) |
25 |
-5.1 |
Glioma |
105 |
-6.0 |
Glioma (high-grade) |
1 |
-1.7 |
Global electrical heterogeneity phenotypes |
63 |
-5.8 |
Glomerular filtration rate |
321 |
-3.5 |
Glomerular filtration rate change in heart transplantation |
13 |
-2.9 |
Glomerular filtration rate (creatinine) |
378 |
-3.3 |
Glomerular filtration rate in chronic kidney disease |
90 |
-3.7 |
Glomerular filtration rate in diabetes |
14 |
-5.5 |
Glomerular filtration rate in non diabetics (creatinine) |
144 |
-4.1 |
Glomerular filtration rate in type 2 diabetes |
29 |
-2.3 |
GLP-1 levels in response to oral glucose tolerance test (fasting) |
2 |
-7.3 |
Glucocorticoid-induced osteonecrosis |
42 |
-3.7 |
Glucocorticoid-induced osteonecrosis (age 10 years and older) |
24 |
-2.8 |
Glucocorticoid-induced osteonecrosis (time dependent analysis) |
7 |
-2.5 |
Glucose homeostasis traits |
245 |
-3.9 |
Glycated hemoglobin levels |
386 |
-5.3 |
Glycated hemoglobin levels in type 1 diabetes |
10 |
-2.1 |
Glycemic traits |
10 |
-4.6 |
Glycemic traits (multi-trait analysis) |
2 |
-1.8 |
Glycemic traits (pregnancy) |
12 |
-5.2 |
Glycerophospholipid levels |
43 |
-5.5 |
Glycine levels |
116 |
-4.2 |
Gout |
162 |
-5.5 |
Gout in chronic kidney disease |
1 |
0.0 |
Gout vs. Hyperuricemia |
37 |
-2.3 |
Granulocyte-colony stimulating factor levels |
53 |
-3.5 |
Granulocyte count |
387 |
-13.1 |
Granulocyte percentage of myeloid white cells |
522 |
-35.2 |
Graves' disease |
87 |
-5.3 |
Gray matter volume (schizophrenia interaction) |
4 |
-2.7 |
Growth-regulated protein alpha levels |
130 |
-7.0 |
Gut microbiome composition (summer) |
256 |
-2.5 |
Gut microbiome composition (summer and winter) |
95 |
-2.5 |
Gut microbiome composition (winter) |
166 |
-2.6 |
Gut microbiota (bacterial taxa) |
336 |
-3.4 |
Gut microbiota (beta diversity) |
65 |
-9.5 |
Gut microbiota (functional units) |
192 |
-2.4 |
Hair color |
2038 |
-7.4 |
Hair greying |
22 |
-3.3 |
Hair morphology |
22 |
-4.8 |
Hair morphology traits |
2 |
-2.0 |
Hair shape |
21 |
-3.4 |
Handedness |
15 |
-2.1 |
Handedness (Left-handed vs. non-left-handed) |
1 |
-2.2 |
Hand grip strength |
536 |
-4.9 |
Hashimoto thyroiditis |
1 |
-1.6 |
Hashimoto thyroiditis versus Graves' disease |
9 |
-1.6 |
HATA volume |
7 |
-3.1 |
HbA2 levels |
18 |
-5.4 |
HDL cholesterol |
791 |
-9.7 |
HDL cholesterol and triglyceride levels |
68 |
-4.7 |
HDL cholesterol and triglyceride levels (pleiotropy) |
11 |
-2.2 |
HDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes |
61 |
-3.6 |
HDL Cholesterol in HIV-infection |
4 |
-2.2 |
HDL cholesterol levels |
485 |
-7.1 |
HDL Cholesterol - Triglycerides (HDLC-TG) |
32 |
-5.2 |
HDL cholesterol x physical activity interaction (2df test) |
98 |
-5.1 |
Headache |
112 |
-4.2 |
Head circumference (infant) |
11 |
-2.4 |
Healthspan |
35 |
-2.6 |
Hearing function |
8 |
-2.9 |
Hearing impairment |
1 |
-3.4 |
Heart failure |
147 |
-5.7 |
Heart rate |
283 |
-8.6 |
Heart rate increase in response to exercise |
30 |
-6.0 |
Heart rate response to beta blockers |
2 |
-2.9 |
Heart rate response to beta blockers (atenolol add-on therapy) |
106 |
-3.3 |
Heart rate response to beta blockers (atenolol monotherapy) |
141 |
-3.8 |
Heart rate response to exercise |
91 |
-4.6 |
Heart rate response to recovery post exercise (10 sec) |
24 |
-6.3 |
Heart rate response to recovery post exercise (20 sec) |
42 |
-5.6 |
Heart rate response to recovery post exercise (30 sec) |
46 |
-5.5 |
Heart rate response to recovery post exercise (40 sec) |
30 |
-6.0 |
Heart rate response to recovery post exercise (50 sec) |
52 |
-5.3 |
Heart rate response to recovery post exercise |
197 |
-30.7 |
Heart rate variability traits |
75 |
-4.1 |
Heart rate variability traits (pvRSA/HF) |
47 |
-5.4 |
Heart rate variability traits (RMSSD) |
42 |
-5.6 |
Heart rate variability traits (SDNN) |
63 |
-5.1 |
Heavy vaginal discharge |
9 |
-5.9 |
Hedonic well-being |
14 |
-1.9 |
Heel bone mineral density |
8416 |
-21.0 |
Height |
10558 |
-14.4 |
Height adjusted BMI |
23 |
-7.2 |
Helix rolling |
8 |
-3.5 |
Helping behaviour (self reported) |
11 |
-3.9 |
Hematocrit |
408 |
-7.7 |
Hematological and biochemical traits |
49 |
-2.7 |
Hematological parameters |
12 |
-6.9 |
Hematology traits |
23 |
-6.0 |
Hematoma volume in lobar spontaneous intracerebral hemorrhage |
2 |
-2.4 |
Hemoglobin |
60 |
-5.4 |
Hemoglobin A1c levels |
168 |
-6.5 |
Hemoglobin A2 levels in sickle cell anemia |
11 |
-3.0 |
Hemoglobin concentration |
322 |
-6.6 |
Hemoglobin levels |
52 |
-6.8 |
Hemostatic factors and hematological phenotypes |
161 |
-4.8 |
Hen's egg allergy |
1 |
-1.6 |
Hepatic lipid content in extreme obesity |
2 |
-2.8 |
Hepatitis |
26 |
-3.4 |
Hepatitis A |
67 |
-6.1 |
Hepatitis B |
152 |
-3.4 |
Hepatitis B surface antigen seroclearance in chronic hepatitis B infection |
6 |
-5.2 |
Hepatitis B vaccine response |
12 |
-6.0 |
Hepatitis C induced liver cirrhosis |
3 |
-3.2 |
Hepatitis C induced liver fibrosis |
6 |
-3.1 |
Hepatitis C (spontaneous viral clearance) |
10 |
-5.5 |
Hepatocellular carcinoma |
25 |
-2.2 |
Hepatocellular carcinoma in hepatitis B infection |
18 |
-5.0 |
Hepatocellular carcinoma in hepatitis C infection |
10 |
-5.5 |
Hepatocyte growth factor levels |
75 |
-3.9 |
Hepcidin/ferritin ratio |
310 |
-4.9 |
Hepcidin levels |
71 |
-3.4 |
Hepcidin/transferrin saturation ratio |
11 |
-3.4 |
HER2 status in breast cancer |
11 |
-2.9 |
Heroin dependence |
109 |
-4.9 |
Heschl's gyrus morphology |
191 |
-4.2 |
High altitude adaptation |
14 |
-5.0 |
High density lipoprotein cholesterol levels |
934 |
-9.8 |
Highest math class taken |
1817 |
-4.2 |
Highest math class taken (MTAG) |
5523 |
-14.6 |
High fetal hemoglobin in sickle cell disease |
10 |
-3.1 |
High-grade serous ovarian cancer |
17 |
-3.3 |
High IL-1beta levels in gingival crevicular fluid |
130 |
-11.6 |
High light scatter reticulocyte count |
554 |
-10.5 |
High light scatter reticulocyte percentage of red cells |
489 |
-13.3 |
Hip bone size |
63 |
-4.8 |
Hip circumference |
531 |
-5.0 |
Hip circumference adjusted for BMI |
526 |
-4.8 |
Hip circumference (psychosocial stress interaction) |
14 |
-2.1 |
Hip geometry |
147 |
-3.1 |
Hip minimal joint space width |
62 |
-5.2 |
Hippocampal atrophy |
164 |
-4.1 |
Hippocampal sclerosis |
32 |
-4.3 |
Hippocampal subfield CA1 volume |
13 |
-2.9 |
Hippocampal subfield CA1 volume (corrected for total hippocampal volume) |
1 |
-3.1 |
Hippocampal subfield CA3 volume |
13 |
-2.9 |
Hippocampal subfield CA4 volume |
14 |
-4.1 |
Hippocampal tail volume |
52 |
-2.3 |
Hippocampal tail volume (corrected for total hippocampal volume) |
39 |
-3.4 |
Hippocampal volume |
143 |
-2.1 |
Hippocampal volume in Alzheimer's disease dementia |
22 |
-2.2 |
Hippocampal volume in mild cognitive impairment |
23 |
-3.8 |
Hippocampal volume in normal cognition |
2 |
-2.1 |
Hip shape (DXA scan) |
154 |
-4.4 |
Hirschsprung disease |
55 |
-3.3 |
HIV-1 control |
138 |
-3.9 |
HIV-1 progression |
12 |
-2.0 |
HIV-1 susceptibility |
27 |
-3.0 |
HIV-1 viral setpoint |
186 |
-3.1 |
HIV-associated dementia |
34 |
-2.6 |
HIV-associated neurocognitive disorder |
2 |
-1.9 |
HIV-associated neurocognitive disorder (asymptomatic neurocogntive impairment) |
10 |
-4.5 |
HIV-associated neurocognitive disorder (mild neurocognitive disorder) |
47 |
-4.5 |
HIV-associated neurocognitive disorder (mild neurocognitive disorder or asymptomatic neurocognitive impairment) |
16 |
-2.8 |
Hoarding |
30 |
-2.7 |
Hodgkin's lymphoma |
141 |
-12.1 |
Homeostasis model assessment of beta-cell function |
8 |
-2.5 |
Homeostasis model assessment of beta-cell function (dietary factor interaction) |
26 |
-2.9 |
Homeostasis model assessment of insulin resistance |
4 |
-3.4 |
Homeostasis model assessment of insulin resistance (dietary factor interaction) |
97 |
-4.2 |
Hormone measurements |
18 |
-5.2 |
Household income |
5 |
-3.6 |
HPV seropositivity |
15 |
-5.1 |
Huntington's disease progression |
32 |
-2.3 |
Hyperactive-impulsive symptoms |
42 |
-2.6 |
Hyperemesis gravidarum |
1 |
0.0 |
Hyperopia |
21 |
-4.4 |
Hypersomnia during a major depressive episode in bipolar disorder |
1 |
-3.6 |
Hypersomnia (HLA-DQB1*06:02 negative) |
14 |
-2.4 |
Hypertension |
681 |
-5.1 |
Hypertension risk in short sleep duration |
5 |
-3.3 |
Hyperthyroidism |
55 |
-4.4 |
Hypertriglyceridemia |
21 |
-4.0 |
Hypospadias |
106 |
-5.3 |
Hypothyroidism |
594 |
-10.9 |
Idiopathic dilated cardiomyopathy |
363 |
-26.4 |
Idiopathic inflammatory myopathy |
2 |
-2.7 |
Idiopathic intracranial hypertension |
62 |
-3.5 |
Idiopathic membranous nephropathy |
3 |
-4.0 |
Idiopathic osteonecrosis of the femoral head |
47 |
-4.0 |
Idiopathic pulmonary fibrosis |
19 |
-6.7 |
IgA levels |
14 |
-2.8 |
IgA nephropathy |
39 |
-8.2 |
IgE grass sensitization |
63 |
-4.0 |
IgE levels |
3 |
-4.6 |
IgE levels in asthmatics |
16 |
-3.2 |
IgE levels in asthmatics (D.f. specific) |
22 |
-3.5 |
IgE levels in asthmatics (D.p. specific) |
33 |
-4.4 |
IgG1 response to Plasmodium falciparum antigen (GLURP) |
7 |
-3.1 |
IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis) |
3 |
-3.2 |
IgG digalactosylation phenotypes (multivariate analysis) |
17 |
-3.4 |
IgG disialylation phenotypes (multivariate analysis) |
3 |
-3.2 |
IgG fucosylation phenotypes (multivariate analysis) |
17 |
-3.4 |
IgG galactosylation phenotypes (multivariate analysis) |
19 |
-3.3 |
IgG glycosylation |
1516 |
-3.3 |
IgG glycosylation patterns |
99 |
-7.2 |
IgG levels |
20 |
-3.8 |
IgG monogalactosylation phenotypes (multivariate analysis) |
17 |
-3.4 |
IgG monosialylation phenotypes (multivariate analysis) |
17 |
-3.4 |
IgG N-glycosylation phenotypes (multivariate analysis) |
19 |
-3.3 |
IgG sialylation phenotypes (multivariate analysis) |
17 |
-3.4 |
IgM levels |
26 |
-5.7 |
Ileal carcinoids |
51 |
-4.8 |
Illicit drug use |
31 |
-7.7 |
Immature fraction of reticulocytes |
400 |
-13.4 |
Immune reponse to smallpox (secreted IFN-alpha) |
74 |
-2.9 |
Immune reponse to smallpox (secreted IL-10) |
68 |
-3.1 |
Immune reponse to smallpox (secreted IL-12p40) |
64 |
-4.3 |
Immune reponse to smallpox (secreted IL-1beta) |
21 |
-5.0 |
Immune reponse to smallpox (secreted IL-2) |
75 |
-3.9 |
Immune reponse to smallpox (secreted TNF-alpha) |
29 |
-3.0 |
Immune response to anthrax vaccine |
16 |
-2.5 |
Immune response to measles-mumps-rubella vaccine |
83 |
-2.2 |
Immune response to smallpox vaccine (IL-6) |
315 |
-3.3 |
Immunoglobulin A |
34 |
-4.6 |
Immunoglobulin A vasculitis |
108 |
-3.7 |
Immunoglobulin G index levels in multiple sclerosis |
8 |
-4.7 |
Immunoglobulin light chain (AL) amyloidosis |
1 |
0.0 |
Immunoglobulin light chain (AL) amyloidosis (heart and kidney involvement) |
1 |
0.0 |
Immunoglobulin light chain (AL) amyloidosis (liver involvement) |
9 |
-1.9 |
Immunoglobulin measurement (zinc sulfate turbidity test) |
1 |
-1.7 |
Impulsivity |
3 |
-2.1 |
Impulsivity (attentional) |
7 |
-2.2 |
Impulsivity (motor) |
9 |
-3.9 |
Impulsivity (non-planning) |
7 |
-2.0 |
Inattentive symptoms |
83 |
-2.8 |
Incident atrial fibrillation |
62 |
-5.7 |
Incident coronary heart disease |
1 |
0.0 |
Incident myocardial infarction |
16 |
-1.7 |
Incremental insulin |
2 |
-1.8 |
Infant, child and juvenile death in continuous marriage (proportion of children died <15 years) |
22 |
-2.3 |
Infant, child and juvenile death (proportion of children died <15 years) |
4 |
-2.3 |
Infantile hypertrophic pyloric stenosis |
23 |
-3.1 |
Infant length |
63 |
-5.8 |
Inflammatory biomarkers |
77 |
-2.8 |
Inflammatory bowel disease |
1075 |
-26.2 |
Inflammatory bowel disease (early onset) |
6 |
-10.5 |
Inflammatory skin disease |
284 |
-4.2 |
Influenza A (H1N1) infection |
16 |
-2.5 |
Influenza A (H1N1) severity |
41 |
-3.9 |
Information processing speed |
146 |
-4.1 |
Inguinal hernia |
55 |
-8.8 |
Inhibitory control |
33 |
-4.7 |
Initial alcohol sensitivity |
158 |
-3.3 |
Initial pursuit acceleration |
160 |
-2.9 |
Initial pursuit acceleration in psychotic disorders |
78 |
-2.7 |
Insomnia |
2187 |
-6.5 |
Insomnia (caffeine-induced) |
40 |
-2.7 |
Insomnia complaints |
5 |
-3.9 |
Insomnia complaints (continuous) |
3 |
-4.9 |
Insomnia complaints (dichotomous) |
3 |
-4.9 |
Insomnia symptoms (never/rarely vs. sometimes/usually) |
239 |
-3.3 |
Insomnia symptoms (never/rarely vs. usually) |
273 |
-2.9 |
Insulin disposition index |
16 |
-3.9 |
Insulin levels adjusted for BMI |
2 |
-1.8 |
Insulin levels in response to oral glucose tolerance test (fasting) |
10 |
-2.5 |
Insulin levels |
2 |
-1.8 |
Insulin-like growth factors |
13 |
-4.0 |
Insulin resistance/response |
15 |
-4.8 |
Insulin secretion rate |
31 |
-4.4 |
Insulin sensitivity index |
8 |
-4.0 |
Intelligence |
2558 |
-7.4 |
Intelligence (childhood) |
12 |
-3.5 |
Intelligence (MTAG) |
2216 |
-9.1 |
Interferon alpha levels in systemic lupus erythematosus |
41 |
-3.5 |
Interferon gamma-induced protein 10 levels |
133 |
-4.3 |
Interferon gamma levels |
54 |
-5.6 |
Interleukin-10 levels |
101 |
-3.8 |
Interleukin-12p70 levels |
93 |
-4.6 |
Interleukin-13 levels |
48 |
-4.9 |
Interleukin-16 levels |
47 |
-5.4 |
Interleukin-17 levels |
82 |
-3.4 |
Interleukin-18 levels |
142 |
-2.4 |
Interleukin-1-beta levels |
19 |
-2.6 |
Interleukin-1-receptor antagonist levels |
32 |
-3.7 |
Interleukin-2 levels |
89 |
-3.2 |
Interleukin-2 receptor antagonist levels |
96 |
-4.3 |
Interleukin-4 levels |
69 |
-4.6 |
Interleukin-5 levels |
28 |
-2.7 |
Interleukin-6 levels |
146 |
-15.9 |
Interleukin-6 (red blood cell fatty acid level interaction) |
48 |
-4.1 |
Interleukin-7 levels |
106 |
-22.4 |
Interleukin-8 levels |
33 |
-3.8 |
Interleukin-9 levels |
42 |
-3.6 |
Interstitial lung disease |
18 |
-2.4 |
Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy) |
38 |
-4.4 |
Intracranial aneurysm |
268 |
-6.2 |
Intracranial volume |
84 |
-5.2 |
Intra-individual response time variability (selective attention) |
17 |
-7.1 |
Intraocular pressure |
1728 |
-5.7 |
Invasive epithelial ovarian cancer |
19 |
-3.2 |
Iris characteristics |
12 |
-3.7 |
Iris color (a* coordinate) |
199 |
-3.8 |
Iris color (b* coordinate) |
156 |
-4.8 |
Iris color (L* coordinate) |
158 |
-5.0 |
Iris heterochromicity |
168 |
-4.0 |
Iron deficiency |
5 |
-4.5 |
Iron status biomarkers |
83 |
-5.7 |
Iron status biomarkers (ferritin levels) |
22 |
-6.9 |
Iron status biomarkers (iron levels) |
41 |
-3.5 |
Iron status biomarkers (total iron binding capacity) |
23 |
-4.2 |
Iron status biomarkers (transferrin levels) |
19 |
-8.8 |
Iron status biomarkers (transferrin saturation) |
29 |
-6.3 |
Irritable bowel syndrome |
94 |
-3.4 |
Irritable mood |
338 |
-3.2 |
Ischemic stroke |
167 |
-4.5 |
Ischemic stroke (cardioembolic) |
105 |
-6.0 |
Ischemic stroke (large artery atherosclerosis) |
32 |
-6.4 |
Ischemic stroke (small-vessel) |
26 |
-4.2 |
Ischemic stroke (undetermined subtype) |
2 |
-5.0 |
Isovolumetric relaxation time |
54 |
-2.0 |
Itch intensity from mosquito bite |
603 |
-5.4 |
Itch intensity from mosquito bite adjusted by bite size |
868 |
-4.8 |
Job-related exhaustion |
4 |
-2.9 |
Job-related exhaustion in shift workers |
1 |
-2.0 |
Joint damage progression in ACPA-negative rheumatoid arthritis |
2 |
-1.9 |
Joint mobility (Beighton score) |
62 |
-7.4 |
JT interval (sulfonylurea treatment interaction) |
156 |
-4.1 |
Juvenile idiopathic arthritis (oligoarticular or rheumatoid factor-negative polyarticular) |
73 |
-4.4 |
Juvenile osteochondritis dissecans |
24 |
-2.3 |
Kashin-Beck disease |
13 |
-2.8 |
Kawasaki disease |
110 |
-11.6 |
Keloid |
11 |
-3.5 |
Kidney disease (early stage) in type 1 diabetes |
9 |
-2.7 |
Kidney disease (end stage renal disease vs non-end stage renal disease) in type 1 diabetes |
7 |
-2.2 |
Kidney disease (end stage renal disease vs normoalbuminuria) in type 1 diabetes |
2 |
-1.6 |
Kidney disease (late stage) in type 1 diabetes |
3 |
-3.9 |
Kidney function decline traits |
3 |
-2.1 |
Kidney stones |
12 |
-2.7 |
Knee osteoarthritis |
53 |
-3.4 |
Lachrymal/Salivary gland lesion in type 1 autoimmune pancreatitis |
3 |
-3.7 |
Lack of perseverance |
6 |
-2.1 |
Lack of premeditation |
12 |
-2.9 |
Lactate dehydrogenase levels |
20 |
-5.3 |
Language impairment in frontotemporal lobe dementia |
8 |
-2.5 |
Language performance in older adults (adjusted for episodic memory) |
4 |
-3.5 |
Lapatinib-induced hepatotoxicity |
21 |
-5.4 |
Large artery stroke |
46 |
-3.2 |
Large B-cell lymphoma |
8 |
-5.8 |
Large HDL particle concentration |
14 |
-5.8 |
Large LDL particle concentration |
4 |
-3.0 |
Laryngeal squamous cell carcinoma |
8 |
-4.8 |
Late diabetic kidney disease in type 2 diabetes |
13 |
-3.6 |
Latent autoimmune diabetes |
3 |
-2.7 |
Late-onset Alzheimer's disease |
260 |
-3.1 |
Late-onset myasthenia gravis |
20 |
-2.9 |
Laterality in neovascular age-related macular degeneration |
28 |
-3.3 |
Lateral ventricular volume in normal aging |
24 |
-3.2 |
LDL cholesterol |
349 |
-7.6 |
LDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes |
6 |
-2.6 |
LDL cholesterol levels |
194 |
-10.1 |
LDL cholesterol x physical activity interaction (1df test) |
1 |
-2.3 |
LDL cholesterol x physical activity interaction (2df test) |
65 |
-9.5 |
LDL peak particle diameter (total fat intake interaction) |
133 |
-2.9 |
Lead levels in blood |
77 |
-4.2 |
Lean body mass |
143 |
-4.0 |
Left atrial antero-posterior diameter |
48 |
-3.0 |
Left inferior lateral ventricle volume (Cerebrospinal fluid biomarker status interaction) |
3 |
-2.4 |
Left superior temporal gyrus thickness (schizophrenia interaction) |
34 |
-3.0 |
Left ventricle diastolic internal dimension |
15 |
-5.4 |
Left ventricle systolic dysfunction |
43 |
-5.9 |
Left ventricle wall thickness |
94 |
-6.4 |
Left ventricular function change in anthracycline treatment |
12 |
-3.2 |
Left ventricular internal dimension in diastole |
20 |
-5.0 |
Left ventricular internal dimension in systole |
20 |
-5.0 |
Left ventricular mass |
24 |
-3.8 |
Left ventricular obstructive tract defect (inherited effect) |
76 |
-4.1 |
Left ventricular obstructive tract defect (maternal effect) |
42 |
-2.8 |
Leishmaniasis (visceral) |
2 |
-3.3 |
Leisure-time exercise behaviour |
8 |
-2.7 |
Leisure-time exercise behaviour (age-stratified) |
1 |
0.0 |
Length of menstrual cycle |
4 |
-4.1 |
Lentiform nucleus volume |
23 |
-3.5 |
Leprosy |
156 |
-8.2 |
Lewy body disease |
75 |
-4.4 |
Life satisfaction |
984 |
-3.4 |
Lifespan |
2 |
-3.8 |
Life threatening arrhythmia |
16 |
-6.7 |
Lifetime average cigarettes per day in chronic obstructive pulmonary disease |
76 |
-2.9 |
Light vs. dark hair color |
60 |
-6.0 |
Limited cutaneous systemic scleroderma |
24 |
-2.6 |
Lipid metabolism phenotypes |
66 |
-4.5 |
Lipid traits |
46 |
-5.8 |
Lipid traits (pleiotropy) (HIPO component 1) |
34 |
-4.6 |
Lipid traits (pleiotropy) (HIPO component 2) |
2 |
-4.4 |
Lip morphology |
2 |
-2.9 |
Lipoprotein (a) - cholesterol levels |
15 |
-2.2 |
Lipoprotein (a) levels |
102 |
-5.1 |
Lipoprotein(a) levels adjusted for apolipoprotein(a) isoforms |
19 |
-3.2 |
Lipoprotein-associated phospholipase A2 activity and mass |
20 |
-8.9 |
Lipoprotein-associated phospholipase A2 activity change in response to statin therapy |
8 |
-3.1 |
Lipoprotein phospholipase A2 activity in cardiovascular disease |
66 |
-5.6 |
Liver disease severity in Alagille syndrome |
5 |
-3.5 |
Liver enzyme levels |
10 |
-2.6 |
Liver enzyme levels (alanine transaminase) |
90 |
-3.3 |
Liver enzyme levels (alkaline phosphatase) |
21 |
-4.0 |
Liver enzyme levels (aspartate transaminase) |
54 |
-2.9 |
Liver enzyme levels (gamma-glutamyl transferase) |
75 |
-4.0 |
Liver fibrosis in pediatric non-alcoholic fatty acid liver disease |
2 |
-5.0 |
Liver fibrosis severity in HIV/hepatitis C co-infection |
51 |
-2.7 |
Liver injury in anti-tuberculosis drug treatment |
15 |
-2.5 |
Liver injury in combined anti-retroviral and anti-tuberculosis drug-treated HIV with tuberculosis |
40 |
-4.3 |
Liver transplant-free survival in primary sclerosing cholangitis (time to event) |
83 |
-5.2 |
Lobe attachment |
7 |
-4.1 |
Lobe attachment (rater scored) |
25 |
-4.8 |
Lobe attachment (rater-scored or self-reported) |
862 |
-8.3 |
Lobe size |
17 |
-5.2 |
Lobular breast cancer (menopausal hormone therapy interaction) |
5 |
-4.0 |
Local histogram emphysema pattern |
29 |
-2.5 |
Logical memory (delayed recall) |
8 |
-2.2 |
Logical memory (delayed recall) in Alzheimer's disease dementia |
5 |
-9.7 |
Logical memory (delayed recall) in mild cognitive impairment |
9 |
-4.2 |
Logical memory (delayed recall) in normal cognition |
49 |
-3.0 |
Logical memory (immediate recall) |
8 |
-2.2 |
Logical memory (immediate recall) in Alzheimer's disease dementia |
19 |
-2.7 |
Logical memory (immediate recall) in mild cognitive impairment |
1 |
-1.7 |
Logical memory (immediate recall) in normal cognition |
18 |
-3.1 |
Loneliness |
197 |
-5.2 |
Loneliness (linear analysis) |
128 |
-7.3 |
Loneliness (MTAG) |
170 |
-5.5 |
Loneliness (multivariate analysis) |
193 |
-6.1 |
Longevity |
226 |
-3.6 |
Longevity (85 years and older) |
2 |
-1.8 |
Longevity (90 years and older) |
58 |
-3.3 |
Longitudinal alcohol consumption |
33 |
-3.3 |
Longitudinal change in brain amyloid plaque burden |
39 |
-4.1 |
Long-term memory (delayed word recall task) |
3 |
-3.1 |
Low density lipoprotein cholesterol levels |
458 |
-8.6 |
Lower body strength |
27 |
-3.2 |
Lower facial height |
46 |
-3.2 |
Low-grade serous and serous borderline ovarian cancer |
20 |
-4.5 |
Low-grade serous ovarian cancer |
1 |
-2.2 |
Low high density lipoprotein cholesterol levels |
79 |
-4.0 |
Low tan response |
121 |
-5.3 |
Low vWF levels |
19 |
-3.8 |
Low white blood cell count (conditioned on rs2814778) |
22 |
-3.8 |
Lp (a) levels |
31 |
-2.7 |
Lumbar spine bone mineral density |
306 |
-5.1 |
Lumbar spine bone mineral density (integral) |
105 |
-4.7 |
Lumbar spine bone mineral density (trabecular) |
57 |
-4.1 |
Lung adenocarcinoma |
257 |
-11.5 |
Lung cancer |
482 |
-6.3 |
Lung cancer (asbestos exposure interaction) |
1 |
-2.8 |
Lung Cancer (DNA repair capacity) |
3 |
-2.7 |
Lung cancer in ever smokers |
246 |
-5.2 |
Lung cancer in never smokers |
122 |
-4.8 |
Lung cancer (smoking interaction) |
24 |
-5.9 |
Lung cancer x radon exposure interaction (1df) |
41 |
-5.0 |
Lung disease severity in cystic fibrosis |
52 |
-5.3 |
Lung function (FEV1) |
361 |
-5.2 |
Lung function (FEV1/FVC) |
4139 |
-14.4 |
Lung function (FEV1/FVC) in asthma (dust mite allergen exposure interaction) |
2 |
-2.1 |
Lung function (FEV1) in asthma (dust mite allergen exposure interaction) |
60 |
-1.9 |
Lung function (forced expiratory flow during mid-portion (25 and 75) of forced vital capacity) |
17 |
-4.4 |
Lung function (forced expiratory volume in 1 second) |
26 |
-2.8 |
Lung function (forced vital capacity) |
19 |
-2.0 |
Lung function (FVC) |
3769 |
-7.2 |
Lung function (maximal voluntary ventilation) |
7 |
-2.8 |
Lupus nephritis in systemic lupus erythematosus |
77 |
-3.7 |
Luteinizing hormone levels in polycystic ovary syndrome |
11 |
-2.4 |
Lymphocyte counts |
524 |
-12.2 |
Lymphocyte percentage of white cells |
340 |
-6.4 |
Lymphoma |
24 |
-4.7 |
Macrophage colony stimulating factor levels |
128 |
-5.8 |
Macrophage inflammatory protein 1a levels |
67 |
-2.9 |
Macrophage inflammatory protein 1b levels |
111 |
-4.3 |
Macrophage Migration Inhibitory Factor levels |
41 |
-4.8 |
Macular telangiectasia type 2 |
3 |
-3.4 |
Macular thickness |
577 |
-6.1 |
Magnesium levels |
116 |
-4.3 |
Major coronary event in cardiovascular disease (time to event) (darapladib treatment interaction) |
5 |
-1.9 |
Major coronary event in darapladib-treated cardiovascular disease (time to event) |
3 |
-2.1 |
Major depression and alcohol dependence |
318 |
-5.6 |
Major depressive disorder |
1148 |
-4.8 |
Major depressive disorder (broad) |
82 |
-3.2 |
Major depressive disorder (ICD-10 coded) |
4 |
-2.9 |
Major depressive disorder (probable) |
56 |
-5.6 |
Major depressive disorder (stressful life events interaction) |
21 |
-2.1 |
Major depressive disorder (unexposed to adversity) |
16 |
-2.7 |
Malaria |
63 |
-3.0 |
Male fertility |
31 |
-2.7 |
Male infertility |
36 |
-4.0 |
Male-pattern baldness |
4028 |
-11.6 |
Male sexual orientation |
11 |
-4.1 |
Mammographic density |
26 |
-3.2 |
Mammographic density (dense area) |
72 |
-2.3 |
Mammographic density (non-dense area) |
33 |
-4.1 |
Marginal zone lymphoma |
2 |
-2.4 |
Maternal history of Alzheimer's disease |
7 |
-3.5 |
Mathematical ability |
53 |
-5.7 |
Matrix metalloproteinase levels |
53 |
-4.3 |
Maximal oxygen uptake response |
12 |
-2.4 |
Maximum cranial length |
29 |
-2.6 |
Maximum cranial width |
36 |
-5.1 |
Mean arterial pressure |
608 |
-4.8 |
Mean arterial pressure (alcohol consumption interaction) |
23 |
-5.2 |
Mean arterial pressure x alcohol consumption interaction (2df test) |
325 |
-6.7 |
Mean arterial pressure x alcohol consumption (light vs heavy) interaction (2df test) |
143 |
-8.2 |
Mean corpuscular hemoglobin |
2132 |
-49.2 |
Mean corpuscular hemoglobin concentration |
264 |
-18.3 |
Mean corpuscular volume |
762 |
-44.2 |
Mean diameter of HDL particles |
12 |
-6.2 |
Mean forced vital capacity from 2 exams |
15 |
-4.1 |
Mean platelet volume |
825 |
-18.4 |
Measles |
102 |
-3.5 |
Meconium ileus in cystic fibrosis |
25 |
-4.1 |
Medication adherence in chronic diseases |
24 |
-2.5 |
Medium HDL particle concentration |
12 |
-6.2 |
Medium LDL particle concentration |
5 |
-2.9 |
Melanoma |
122 |
-5.5 |
Memory dysfunction in frontotemporal lobe dementia |
1 |
0.0 |
Memory performance |
5 |
-7.3 |
Menarche (age at onset) |
2189 |
-4.3 |
Menarche and menopause (age at onset) |
15 |
-2.4 |
Meningococcal disease |
1 |
0.0 |
Menopause (age at onset) |
174 |
-3.5 |
Menstruation quality of life impact (acne) |
4 |
-2.2 |
Menstruation quality of life impact (aggressiveness) |
53 |
-3.5 |
Menstruation quality of life impact (bowel movement) |
25 |
-3.8 |
Menstruation quality of life impact (depression) |
22 |
-3.4 |
Menstruation quality of life impact (dysmenorrhea) |
42 |
-3.3 |
Menstruation quality of life impact (edema) |
4 |
-8.3 |
Menstruation quality of life impact (fever) |
21 |
-6.8 |
Menstruation quality of life impact (headache) |
14 |
-4.1 |
Menstruation quality of life impact (increased appetite) |
10 |
-3.6 |
Menstruation quality of life impact (joint pain) |
2 |
-2.7 |
Menstruation quality of life impact (loss of concentration) |
103 |
-3.1 |
Menstruation quality of life impact (nervousness) |
24 |
-3.8 |
Menstruation quality of life impact (pressure in breast) |
11 |
-2.1 |
Menstruation quality of life impact (sleepiness) |
5 |
-1.8 |
Menstruation quality of life impact (stiff neck) |
35 |
-2.3 |
Mental composite score |
24 |
-4.9 |
Mental development (prenatal lead exposure interaction) |
4 |
-1.9 |
Metabolic coherence (transcriptomic) |
10 |
-3.8 |
Metabolic syndrome |
158 |
-4.1 |
Metabolic syndrome (bivariate traits) |
43 |
-3.8 |
Metabolic syndrome (multivariate analysis) |
34 |
-3.3 |
Metabolic traits |
85 |
-3.7 |
Metabolite levels |
205 |
-3.5 |
Metabolite levels (5-HIAA/ MHPG Ratio) |
12 |
-4.9 |
Metabolite levels (5-HIAA) |
60 |
-9.1 |
Metabolite levels (Dihydroxy docosatrienoic acid) |
124 |
-4.3 |
Metabolite levels (HVA-5-HIAA Factor score) |
37 |
-3.0 |
Metabolite levels (HVA/5-HIAA ratio) |
71 |
-4.3 |
Metabolite levels (HVA/MHPG ratio) |
83 |
-3.0 |
Metabolite levels (HVA) |
15 |
-3.3 |
Metabolite levels (lipid measures) |
1 |
-1.9 |
Metabolite levels (lipoprotein measures) |
101 |
-6.6 |
Metabolite levels (MHPG) |
68 |
-3.3 |
Metabolite levels (Pyroglutamine) |
104 |
-2.6 |
Metabolite levels (small molecules and protein measures) |
19 |
-2.9 |
Metabolite levels (X-11787) |
206 |
-2.6 |
Metastasis at diagnosis in osteosarcoma |
6 |
-2.8 |
Metastasis in stage I-III microsatellite instability low/stable colorectal cancer (time to event) |
123 |
-4.4 |
Methadone dose in opioid dependence |
184 |
-2.8 |
Methotrexate-induced interstitial lung disease in rheumatoid arthritis |
23 |
-3.6 |
Methotrexate phramacokinetics (acute lymphoblastic leukemia) |
53 |
-6.9 |
Microalbuminuria |
49 |
-3.9 |
Middle childhood and early adolescence aggressive behavior |
38 |
-3.4 |
middle facial morphology traits (quantitative measurement) |
11 |
-4.5 |
Midgestational circulating levels of organochlorine pesticides |
1 |
-2.7 |
Midgestational circulating levels of PBDEs |
6 |
-1.3 |
Midgestational circulating levels of PBDEs (fetal genetic effect) |
26 |
-3.4 |
Midgestational circulating levels of PCBs |
153 |
-3.8 |
Midgestational circulating levels of PCBs (fetal genetic effect) |
9 |
-4.1 |
Midgestational cytokine/chemokine levels (fetal genetic effect) |
4 |
-2.4 |
Midgestational cytokine/chemokine levels (maternal genetic effect) |
25 |
-2.5 |
Migraine |
689 |
-2.6 |
Migraine - clinic-based |
214 |
-4.3 |
Migraine with aura |
136 |
-8.6 |
Migraine without aura |
247 |
-3.4 |
Mild influenza (H1N1) infection |
89 |
-4.2 |
Milk allergy |
14 |
-2.0 |
Mitochondrial DNA copy number |
17 |
-1.9 |
Mitochondrial DNA copy number (white blood cells) |
4 |
-2.6 |
Mitochondrial DNA levels |
101 |
-3.1 |
Mitral valve prolapse |
108 |
-3.8 |
Mixed cryoglobulinemia vasculitis in chronic hepatitis C infection |
12 |
-6.0 |
Moderate or severe diarrhoea in darapladib-treated cardiovascular disease (time to event) |
10 |
-3.4 |
Moderate to vigorous physical activity levels |
125 |
-10.4 |
Modic changes |
41 |
-2.7 |
Modified Stumvoll Insulin Sensitivity Index (BMI interaction) |
48 |
-2.3 |
Modified Stumvoll Insulin Sensitivity Index (model adjusted for BMI) |
4 |
-2.7 |
Molar-incisor hypomineralization |
29 |
-5.1 |
Monobrow |
202 |
-3.5 |
Monobrow thickness |
30 |
-3.8 |
Monocyte chemoattractant protein-1 levels |
77 |
-4.1 |
Monocyte chemoattractant protein-3 levels |
33 |
-3.0 |
Monocyte count |
636 |
-28.7 |
Monocyte early outgrowth colony forming units |
2 |
-2.2 |
Monocyte-lymphocyte ratio |
7 |
-5.6 |
Monocyte percentage of white cells |
634 |
-25.3 |
Monokine induced by gamma interferon levels |
100 |
-4.0 |
Mononucleosis |
80 |
-5.1 |
Mood disorder and prion disease |
23 |
-4.3 |
Mood disorder in prion disease |
16 |
-2.9 |
Mood instability |
329 |
-5.2 |
Morbidity-free survival |
51 |
-3.4 |
Morning person |
2156 |
-22.4 |
Morning vs. evening chronotype |
510 |
-14.0 |
Mortality in heart failure |
73 |
-3.2 |
Mortality in sepsis |
31 |
-4.4 |
Mosquito bite size |
468 |
-7.5 |
Motion sickness |
208 |
-3.2 |
Motor composite score |
52 |
-4.5 |
Mouth morphology (principal component model) |
1 |
-1.4 |
Moyamoya disease |
178 |
-5.5 |
Mucinous adenocarcinoma in colorectal cancer |
35 |
-3.8 |
Mucinous ovarian carcinoma |
5 |
-3.0 |
Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma) |
8 |
-3.9 |
Multiple keratinocyte cancers |
73 |
-41.4 |
Multiple myeloma |
122 |
-4.6 |
Multiple myeloma and monoclonal gammopathy |
14 |
-3.2 |
Multiple myeloma (hyperdiploidy) |
33 |
-2.9 |
Multiple myeloma (IgH translocation) |
107 |
-5.2 |
Multiple sclerosis |
1001 |
-25.7 |
Multiple sclerosis (age of onset) |
50 |
-2.9 |
Multiple sclerosis and C-reactive protein levels (pleiotropy) |
5 |
-2.8 |
Multiple sclerosis and HDL levels (pleiotropy) |
23 |
-3.3 |
Multiple sclerosis and LDL levels (pleiotropy) |
12 |
-2.7 |
Multiple sclerosis and systolic blood pressure (pleiotropy) |
10 |
-6.3 |
Multiple sclerosis and triglyceride levels (pleiotropy) |
32 |
-10.2 |
Multiple sclerosis and type 2 diabetes (pleiotropy) |
5 |
-3.1 |
Multiple sclerosis--Brain Glutamate Levels |
18 |
-3.4 |
Multiple sclerosis (OCB status) |
28 |
-10.0 |
Multiple sclerosis (severity) |
103 |
-5.9 |
Multiple system atrophy |
60 |
-2.5 |
Multiple system atrophy (pathologically confirmed) |
4 |
-4.2 |
Mumps |
98 |
-5.4 |
Musician's dystonia |
2 |
-2.5 |
Myasthenia gravis |
35 |
-5.4 |
Myeloid white cell count |
413 |
-12.8 |
Myeloproliferative neoplasms |
13 |
-3.2 |
Myocardial infarction |
135 |
-4.6 |
Myocardial infarction (early onset) |
45 |
-3.8 |
Myocardial infarction in cardiovascular disease (time to event) (darapladib treatment interaction) |
8 |
-2.9 |
Myocardial infarction in darapladib-treated cardiovascular disease (time to event) |
11 |
-2.7 |
Myocardial infarction in hypertension (calcium channel blocker interaction) |
5 |
-3.9 |
Myopia |
137 |
-3.8 |
Myopia (age of diagnosis) |
298 |
-5.5 |
Myopia (pathological) |
604 |
-11.8 |
Myopia (severe) |
22 |
-2.4 |
Myringotomy |
58 |
-4.4 |
Narcolepsy |
42 |
-5.7 |
Narcolepsy (age of onset) |
1 |
-2.6 |
Narcolepsy (onset before 2009 H1N1 influenza pandemic) |
4 |
-7.0 |
Narcolepsy with cataplexy |
40 |
-5.7 |
Narrowest width of the femoral neck |
5 |
-4.9 |
Nasal polyps |
32 |
-3.4 |
Nasopharyngeal carcinoma |
34 |
-4.1 |
Natriuretic peptide levels |
3 |
-2.0 |
Negative urgency |
7 |
-4.0 |
Neonatal cytokine/chemokine levels (fetal genetic effect) |
38 |
-4.4 |
Neonatal cytokine/chemokine levels (maternal genetic effect) |
17 |
-3.6 |
Neonatal lupus |
51 |
-2.3 |
Nephrolithiasis |
2 |
-3.0 |
Nephropathy |
18 |
-7.5 |
Nephrotic syndrome (acquired) |
28 |
-2.7 |
Neuranatomic and neurocognitive phenotypes |
30 |
-3.6 |
Neuritic plaques or cerebral amyloid angiopathy (pleiotropy) |
2 |
-2.1 |
Neuritic plaques or neurofibrillary tangles or cerebral amyloid angiopathy (pleiotropy) |
2 |
-2.1 |
Neuritic plaques or neurofibrillary tangles (pleiotropy) |
7 |
-2.8 |
Neuritic plaque |
18 |
-3.8 |
Neuroblastoma |
5 |
-2.1 |
Neurociticism |
639 |
-3.6 |
Neurocognitive impairment in HIV-1 infection (continuous) |
68 |
-5.2 |
Neurocognitive impairment in HIV-1 infection (dichotomous) |
12 |
-2.4 |
Neurofibrillary tangles |
46 |
-2.6 |
Neuromyelitis optica |
2 |
-2.4 |
Neuromyelitis optica (AQP4-IgG-positive) |
2 |
-2.4 |
Neuropathic pain in head and neck cancer |
6 |
-4.3 |
Neuropathic pain in type 2 diabetes |
65 |
-2.2 |
Neuroticism |
3620 |
-5.9 |
Neuroticism (age interaction) |
34 |
-3.7 |
Neuroticism (MTAG) |
300 |
-2.9 |
Neutralising antibody response to interferon beta therapy in multiple sclerosis (area under the curve for the first two years) |
1 |
-1.7 |
Neutralising antibody response to interferon beta therapy in multiple sclerosis (maximum antibody levels) |
1 |
-1.7 |
Neutralising antibody response to interferon beta therapy in multiple sclerosis (mean antibody levels) |
1 |
-1.7 |
Neutralising antibody response to interferon beta therapy in multiple sclerosis (presence of antibodies) |
12 |
-6.0 |
Neutrophil count |
527 |
-10.0 |
Neutrophil level response to clozapine in treatment-resistant schizophrenia |
1 |
-1.8 |
Neutrophil percentage of granulocytes |
426 |
-17.0 |
Neutrophil percentage of white cells |
296 |
-12.7 |
Nevirapine-induced rash |
5 |
-5.5 |
Nevus count |
27 |
-3.3 |
Nevus count or cutaneous melanoma |
77 |
-5.7 |
N-glycan levels |
136 |
-8.7 |
Nicotine dependence |
87 |
-6.4 |
Nicotine dependence and major depression (severity of comorbidity) |
199 |
-2.6 |
Nicotine dependence symptom count |
100 |
-6.2 |
nicotine metabolite ratio in current smokers |
16 |
-5.7 |
Nicotine use |
8 |
-1.5 |
Nicotine withdrawal |
28 |
-3.0 |
Nicotine withdrawal symptom count |
39 |
-4.6 |
Night sleep phenotypes |
617 |
-5.3 |
Nodular sclerosis Hodgkin lymphoma |
59 |
-10.3 |
Non-albumin protein levels |
180 |
-7.4 |
Nonalcoholic fatty liver disease |
65 |
-6.5 |
Non-alcoholic fatty liver disease histology (AST) |
47 |
-2.8 |
Non-alcoholic fatty liver disease histology (lobular) |
46 |
-3.9 |
Non-alcoholic fatty liver disease histology (other) |
87 |
-4.6 |
Nonalcoholic steatohepatitis-derived hepatocellular carcinoma |
1 |
-2.5 |
Non-cardia gastric cancer |
57 |
-4.6 |
Non-glioblastoma glioma |
38 |
-6.1 |
Non-melanoma skin cancer |
320 |
-6.1 |
Non-obstructive azoospermia |
48 |
-18.9 |
Non-response to antidepressants and depression |
2 |
-3.1 |
Non-response to bupropion and depression |
51 |
-5.3 |
Non-response to citalopram or escitalopram and depression |
4 |
-2.2 |
Non-response to selective serotonin reuptake inhibitors and depression |
2 |
-2.9 |
Non-Richardson's syndrome vs Richardson's syndrome in progressive supranuclear palsy |
2 |
-2.5 |
Non-small cell lung cancer |
45 |
-3.0 |
Non-small cell lung cancer (survival) |
28 |
-3.1 |
Non-substance related behavioral disinhibition |
57 |
-4.4 |
Nonsyndromic cleft lip with cleft palate |
218 |
-6.9 |
Nonsyndromic cleft lip with or without cleft palate |
59 |
-14.3 |
Nonsyndromic cleft lip with or without cleft palate x sex interaction (2df test) |
40 |
-3.4 |
Nontyphoidal Salmonella bacteraemia |
2 |
-2.4 |
Non-word reading |
154 |
-3.9 |
Non-word repetition |
13 |
-2.4 |
Normal body mass index vs. thin |
2 |
-2.3 |
Normal facial asymmetry (angle of deformation score) |
3 |
-1.6 |
Normal facial asymmetry (angle of surface orientation score) |
7 |
-2.6 |
Normal facial asymmetry (deformation magnitude) |
5 |
-4.4 |
Normalized brain volume |
3 |
-6.7 |
Nose length |
2 |
-1.0 |
Nose morphology |
264 |
-6.2 |
Nose size |
167 |
-7.4 |
N-terminal pro B-type natriuretic peptide levels |
6 |
-3.7 |
Nucleus accumbens volume in trauma-exposed individuals |
13 |
-3.9 |
Number of children |
34 |
-2.4 |
Number of children (6+ vs. 0 or 1) |
64 |
-2.5 |
Number of children ever born |
25 |
-3.4 |
Number of common colds |
54 |
-3.9 |
Number of pregnancies |
88 |
-2.4 |
Number of sexual partners |
734 |
-4.5 |
Number of stillbirths in continuous marriage |
4 |
-3.8 |
Number of twin births |
7 |
-3.1 |
Obese vs. thin |
57 |
-4.1 |
Obesity |
368 |
-3.6 |
Obesity (early onset extreme) |
166 |
-4.7 |
Obesity (extreme) |
235 |
-4.0 |
Obesity in adult survivors of childhood cancer exposed to cranial radiation |
7 |
-1.7 |
Obesity-related traits |
3295 |
-3.5 |
Obesity without metabolic disease |
130 |
-4.6 |
Objective response to lithium treatment |
1 |
-1.9 |
Objective response to lithium treatment in bipolar disorder |
3 |
-1.6 |
Obsessive-compulsive disorder |
160 |
-2.9 |
Obsessive-compulsive disorder or autism spectrum disorder |
51 |
-3.8 |
Obsessive-compulsive disorder x sex interaction |
6 |
-6.1 |
Obsessive-compulsive symptoms |
61 |
-3.4 |
Obstetric antiphospholipid syndrome |
23 |
-3.4 |
Obstructive sleep apnea |
23 |
-2.4 |
Obstructive sleep apnea (average oxygen saturation during sleep) |
4 |
-2.8 |
Obstructive sleep apnea during REM sleep (apnea hypopnea index) |
8 |
-4.1 |
Obstructive sleep apnea trait (apnea hypopnea index) |
112 |
-5.3 |
Obstructive sleep apnea trait (average respiratory event duration) |
36 |
-3.7 |
Offspring birth weight |
422 |
-5.6 |
Oleic acid (18:1n-9) levels |
12 |
-2.7 |
Oligoclonal band status in multiple sclerosis |
5 |
-6.1 |
Open-angle glaucoma and optic cup area |
3 |
-2.3 |
Open-angle glaucoma and vertical cup-disc ratio |
27 |
-6.7 |
Opioid dependence |
23 |
-3.8 |
Opioid requirements during laparoscopic-assisted colectomy |
2 |
-1.6 |
Opioid sensitivity |
14 |
-4.9 |
Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder |
48 |
-3.5 |
Optic cup area |
243 |
-5.2 |
Optic disc area |
188 |
-5.7 |
Optic disc parameters |
19 |
-3.1 |
Optic nerve measurement (cup area) |
100 |
-4.5 |
Optic nerve measurement (cup-to-disc ratio) |
90 |
-4.5 |
Optic nerve measurement (disc area) |
21 |
-4.9 |
Optic nerve measurement (rim area) |
38 |
-2.3 |
Oral cavity and pharyngeal cancer |
3 |
-3.2 |
Oral cavity cancer |
8 |
-2.2 |
Orofacial clefts |
170 |
-4.4 |
Orofacial clefts (maternal alcohol consumption interaction) |
2 |
-3.9 |
Oropharynx cancer |
62 |
-2.4 |
Orthostatic hypotension |
90 |
-3.4 |
Ossification of the posterior longitudinal ligament of the spine |
80 |
-5.1 |
Osteoarthritis |
145 |
-4.3 |
Osteoarthritis biomarkers |
13 |
-2.4 |
Osteoarthritis (hip) |
88 |
-6.5 |
Osteoarthritis (hospital diagnosed) |
3 |
-2.0 |
Osteoarthritis of the hip (hospital diagnosed) |
36 |
-3.5 |
Osteoarthritis of the hip or knee |
112 |
-4.5 |
Osteoarthritis of the hip or knee (hospital diagnosed) |
6 |
-2.4 |
Osteoarthritis of the hip (with total joint replacement) |
15 |
-3.4 |
Osteoarthritis of the knee (hospital diagnosed) |
8 |
-2.1 |
Osteoarthritis of the knee (with total joint replacement) |
18 |
-5.6 |
Osteoarthritis (self-reported) |
75 |
-2.9 |
Osteolysis in total hip arthroplasty |
23 |
-5.6 |
Osteolysis in total hip arthroplasty (time to prosthesis revision) |
25 |
-2.1 |
Osteoporosis |
14 |
-3.8 |
Osteoporosis-related phenotypes |
11 |
-5.9 |
Osteoprotegerin levels |
34 |
-3.3 |
Osteosarcoma |
6 |
-3.3 |
Other erythrocyte phenotypes |
10 |
-5.5 |
Otitis media |
2 |
-4.4 |
Otitis media (chronic) |
1 |
-2.3 |
Otitis media (chronic/recurrent) |
11 |
-3.6 |
Otitis media (recurrent) |
2 |
-2.7 |
Otosclerosis |
10 |
-1.7 |
Ovarian cancer |
105 |
-5.2 |
Ovarian cancer in BRCA1 mutation carriers |
15 |
-6.8 |
Ovarian cancer in BRCA2 mutation carriers |
5 |
-4.4 |
Ovarian disease with few adhesions |
12 |
-2.9 |
Ovarian reserve |
65 |
-5.5 |
Overall survival in osteosarcoma |
62 |
-2.4 |
Overall survival in serous epithelial ovarian cancer treated with paclitaxel and cisplatin |
52 |
-3.1 |
Overweight status |
28 |
-5.6 |
Paclitaxel disposition in epithelial ovarian cancer |
157 |
-3.7 |
Paclitaxel-induced cytotoxicity |
34 |
-3.7 |
Paclitaxel-induced neuropathy |
52 |
-4.4 |
Paget's disease |
26 |
-5.6 |
Pain |
28 |
-3.5 |
Pain medicine use during menstruation |
26 |
-5.1 |
Pallidum volume in trauma-exposed individuals |
4 |
-1.4 |
Palmitic acid (16:0) levels |
82 |
-3.5 |
Palmitoleic acid (16:1n-7) levels |
57 |
-2.7 |
Pancreatic cancer |
207 |
-4.8 |
Pancreatic ductal adenocarcinoma |
24 |
-4.9 |
Pancreatitis |
23 |
-4.1 |
Paneth cell defects in Crohn's disease |
37 |
-3.9 |
Panic disorder |
83 |
-3.9 |
Papillary thyroid cancer |
45 |
-4.3 |
Parasitemia in Tripanosoma cruzi seropositivity |
123 |
-2.6 |
Parental extreme longevity (95 years and older) |
163 |
-4.3 |
Parental lifespan |
18 |
-4.9 |
Parental longevity (at least one long-lived parent) |
6 |
-3.7 |
Parental longevity (both parents in top 10) |
11 |
-4.5 |
Parental longevity (combined parental age at death) |
110 |
-4.5 |
Parental longevity (combined parental attained age, Martingale residuals) |
112 |
-4.6 |
Parental longevity (father's attained age) |
25 |
-3.4 |
Parental longevity (mother's age at death) |
111 |
-3.5 |
Parent of origin effect on language impairment (paternal) |
22 |
-3.2 |
Parkinson disease and lewy body pathology |
65 |
-9.8 |
Parkinsonism in frontotemporal lobe dementia |
11 |
-3.4 |
Parkinson's disease |
432 |
-4.9 |
Parkinson's disease (age of onset) |
7 |
-2.9 |
Parkinson's disease (familial, age at onset) |
6 |
-4.1 |
Parkinson's disease (motor and cognition) |
14 |
-6.7 |
Parkinson's disease (pesticide exposure interaction) |
1 |
-1.4 |
Partial epilepsies |
23 |
-2.8 |
Paternal history of Alzheimer's disease |
7 |
-3.5 |
Pathological gambling |
5 |
-6.4 |
PCA3 expression level |
11 |
-3.4 |
Peak cortisol response to low dose short synacthen test in corticosteroid treated asthma |
4 |
-3.6 |
Peak creatinine levels in vancomycin therapy |
6 |
-2.4 |
Peak expiratory flow |
721 |
-8.3 |
Peak insulin response |
102 |
-4.5 |
Peak velocity of the mitral A-wave |
4 |
-5.0 |
Peanut allergy |
33 |
-4.4 |
Peanut allergy (maternal genetic effects) |
1 |
-4.4 |
Peanut allergy (parent-of-origin effect) |
10 |
-5.2 |
Pediatric areal bone mineral density (concordant skeletal phenotype) |
1 |
-3.9 |
Pediatric areal bone mineral density (radius) |
85 |
-4.6 |
Pediatric areal bone mineral density (radius vs spine & hip discordant skeletal phenotype) |
28 |
-5.2 |
Pediatric autoimmune diseases |
81 |
-6.0 |
Pediatric bone mineral content (femoral neck) |
48 |
-4.3 |
Pediatric bone mineral content (hip) |
83 |
-4.3 |
Pediatric bone mineral content (radius) |
66 |
-7.0 |
Pediatric bone mineral content (spine) |
72 |
-3.2 |
Pediatric bone mineral density (femoral neck) |
42 |
-4.1 |
Pediatric bone mineral density (hip) |
46 |
-3.2 |
Pediatric bone mineral density (spine) |
63 |
-4.8 |
Pediatric non-alcoholic fatty liver disease activity score |
30 |
-2.1 |
Pediatric nonalcoholic steatohepatitis |
2 |
-2.1 |
PEG-asparaginase hypersensitivity without enzyme activity in childhood acute lymphoblastic leukaemia |
8 |
-2.6 |
Pelvic organ prolapse |
73 |
-4.0 |
Pelvic organ prolapse (moderate/severe) |
96 |
-4.4 |
Pemphigus foliaceus |
7 |
-3.5 |
Pemphigus vulgaris |
24 |
-2.7 |
Perceived unattractiveness to mosquitoes |
155 |
-5.6 |
Percentage gas trapping |
97 |
-5.3 |
Percent glycated albumin |
2 |
-1.7 |
Percent mammographic density |
37 |
-8.0 |
Perceptual rivalry (voluntary modulation strength) |
3 |
-4.8 |
Pericardial adipose tissue adjusted for height and weight |
45 |
-2.7 |
Pericardial fat |
42 |
-2.8 |
Periodontal microbiota |
60 |
-3.5 |
Periodontitis |
75 |
-4.7 |
Periodontitis (CDC/AAP) |
43 |
-3.0 |
Periodontitis (DPAL) |
74 |
-3.3 |
Periodontitis (Mean PAL) |
79 |
-3.5 |
Periodontitis (PAL4Q3) |
47 |
-3.0 |
Peripheral arterial disease (traffic-related air pollution interaction) |
619 |
-3.0 |
Peripheral artery disease |
81 |
-2.5 |
Permanent tooth development |
6 |
-2.7 |
Personality dimensions |
71 |
-3.9 |
Personality traits in bipolar disorder |
14 |
-3.1 |
Pharmacokinetics of antiepileptic drugs in severe mental disorder (concentration drug ratio) |
16 |
-3.0 |
Pharmacokinetics of antipsychotic drugs in severe mental disorder (concentration drug ratio) |
18 |
-6.4 |
Pharmacokinetics of olanzapine in severe mental disorder (concentration dose ratio) |
11 |
-2.3 |
Philtrum width |
86 |
-7.4 |
Phoneme awareness |
82 |
-4.1 |
Phospholipid levels in large HDL |
14 |
-5.8 |
Phospholipid levels in medium HDL |
14 |
-5.8 |
Phospholipid levels (plasma) |
27 |
-4.4 |
Phosphorus levels |
41 |
-4.5 |
Photic sneeze reflex |
444 |
-4.5 |
Physical activity (moderate intensity activity duration) |
23 |
-4.2 |
Physical activity (overall physical activity time) |
121 |
-8.2 |
Phytosterol levels |
2 |
-4.3 |
Pit-and-Fissure caries |
72 |
-2.7 |
Placebo response in major depressive disorder ( change in symptom score) |
45 |
-3.1 |
Placental abruption |
17 |
-2.3 |
Plantar warts |
82 |
-4.3 |
Plasma amyloid beta peptide concentrations (ABx-40) |
32 |
-5.6 |
Plasma amyloid beta peptide concentrations (ABx-42) |
38 |
-3.4 |
Plasma anastrozole concentration in anastrozole-treated estrogen receptor positive breast cancer |
37 |
-7.3 |
Plasma androstenedione levels in resected early stage-receptor positive breast cancer |
3 |
-3.7 |
Plasma clozapine levels in treatment-resistant schizophrenia |
1 |
-2.7 |
Plasma clozapine-norclozapine ratio in treatment-resistant schizophrenia |
1 |
0.0 |
Plasma clusterin levels |
178 |
-3.1 |
Plasma cystastin c levels in acute coronary syndrome |
12 |
-4.4 |
Plasma factor VII activating protease levels |
165 |
-60.7 |
Plasma free amino acid levels |
81 |
-3.7 |
Plasma free amino acid levels (adjusted for one other PFAA) |
16 |
-2.5 |
Plasma free amino acid levels (adjusted for twenty other PFAAs) |
58 |
-4.0 |
Plasma homocysteine levels |
11 |
-3.1 |
Plasma homocysteine levels (post-methionine load test) |
3 |
-2.8 |
Plasma kynurenine levels in major depressive disorder |
8 |
-1.9 |
Plasma kynurenine to tryptophan ratio in major depressive disorder |
6 |
-1.2 |
Plasma neurofilament light levels |
8 |
-2.2 |
Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid) |
36 |
-5.6 |
Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid) |
38 |
-4.0 |
Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid) |
86 |
-2.9 |
Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid) |
24 |
-13.9 |
Plasma omega-6 polyunsaturated fatty acid levels (adrenic acid) |
4 |
-4.0 |
Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid) |
107 |
-3.5 |
Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid) |
67 |
-3.9 |
Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid) |
92 |
-4.5 |
Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid) |
40 |
-3.0 |
Plasma parathyroid hormone levels |
86 |
-2.7 |
Plasma plasminogen levels |
5 |
-4.1 |
Plasma proprotein convertase subtilisin/kexin type 9 levels in stable coronary artery disease |
45 |
-3.5 |
Plasma pyridoxic acid to pyridoxal phosphate ratio |
5 |
-5.6 |
Plasma renin activity levels |
39 |
-7.6 |
Plasma thyroid-stimulating hormone levels |
113 |
-2.7 |
Plasma trimethylamine N-oxide levels |
12 |
-2.9 |
Plasma trimethyllysine levels |
22 |
-5.0 |
Plasma t-tau levels |
17 |
-2.7 |
Plasminogen activator inhibitor type 1 levels (PAI-1) |
7 |
-5.5 |
Platelet aggregation |
50 |
-5.6 |
Platelet count |
829 |
-13.5 |
Plateletcrit |
638 |
-16.1 |
Platelet-derived growth factor BB levels |
175 |
-3.8 |
Platelet distribution width |
465 |
-17.6 |
Platelet thrombus formation |
19 |
-9.1 |
Platinum-induced myelosuppression in non-small cell lung cancer |
10 |
-2.5 |
Pneumococcal bacteremia |
21 |
-6.4 |
Pneumoconiosis in silica exposure |
4 |
-2.5 |
Pneumonia |
156 |
-4.3 |
Political ideology |
58 |
-8.2 |
Polychlorinated biphenyl levels |
141 |
-4.8 |
Polycystic ovary syndrome |
170 |
-3.9 |
Polymyositis |
13 |
-4.3 |
Poor prognosis in Crohn's disease |
3 |
-2.8 |
Positive affect |
1113 |
-6.6 |
Positive urgency |
82 |
-4.3 |
Possible neuropathic pain in post total joint replacement surgery for osteoarthritis |
42 |
-5.4 |
Post bronchodilator FEV1 |
828 |
-6.2 |
Post bronchodilator FEV1/FVC ratio |
1157 |
-3.2 |
Post bronchodilator FEV1/FVC ratio in COPD |
326 |
-3.1 |
Post bronchodilator FEV1/FVC ratio in smoking |
6 |
-2.8 |
Post bronchodilator FEV1 in COPD |
200 |
-4.1 |
Post bronchodilator percent predicted FEV1 in smoking |
21 |
-6.8 |
Postburn hypertrophic scarring severity |
3 |
0.0 |
Postburn scar height |
1 |
0.0 |
Postburn scar pliability |
47 |
-4.3 |
Posterior cortical atrophy and Alzheimer's disease |
95 |
-3.4 |
Postoperative atrial fibrillation in coronary artery bypass grafting surgery |
2 |
0.0 |
Postoperative survival time in hepatocellular carcinoma |
27 |
-4.1 |
Postprandial triglyceride response to high fat diet meal |
21 |
-3.5 |
Post-traumatic stress disorder |
164 |
-4.5 |
Post-traumatic stress disorder (asjusted for relatedness) |
32 |
-3.2 |
Potassium levels |
26 |
-5.5 |
Pre bronchodilator FEV1/FVC ratio |
39 |
-3.3 |
Pre bronchodilator FEV1/FVC ratio in never-smokers |
41 |
-3.7 |
Preeclampsia |
53 |
-5.4 |
Premature menopause in childhood cancer survivors |
39 |
-4.1 |
Premature ovarian failure |
9 |
-2.8 |
Preschool internalizing problems |
32 |
-3.3 |
Presence of antiphospholipid antibodies |
143 |
-3.2 |
Preterm birth (maternal effect) |
29 |
-4.0 |
Pre-treatment pain in head and neck squamous cell carcinoma |
35 |
-3.5 |
Prevalent atrial fibrillation |
70 |
-5.6 |
Prevalent type 2 diabetes |
50 |
-4.8 |
Primary biliary cholangitis |
207 |
-11.4 |
Primary biliary cirrhosis |
70 |
-9.7 |
Primary sclerosing cholangitis |
125 |
-7.9 |
Primary tooth development (number of teeth) |
38 |
-3.6 |
Primary tooth development (time to first tooth eruption) |
27 |
-6.6 |
Primary vesicoureteric reflux |
4 |
-3.5 |
PR interval |
232 |
-4.9 |
PR interval in Tripanosoma cruzi seropositivity |
288 |
-2.6 |
Prion diseases |
116 |
-4.3 |
Problematic alcohol use in trauma-exposed individuals |
14 |
-4.4 |
Progression free survival in metastatic colorectal cancer (CAPOX-B vs CAPOX-B plus cetuximab) |
9 |
-3.4 |
Progression free survival in metastatic colorectal cancer (chemotherapy interaction) |
1 |
-2.1 |
Progression free survival in serous epithelial ovarian cancer treated with carboplatin and paclitaxel |
1 |
-1.8 |
Progressive supranuclear palsy |
19 |
-3.9 |
Proinsulin levels |
71 |
-2.7 |
Proliferative diabetic retinopathy in type 2 diabetes |
3 |
-4.5 |
Proliferative diabetic retinopathy (vs no DR) |
100 |
-4.8 |
Proliferative diabetic retinopathy (vs NPDR and no DR) |
92 |
-4.3 |
Prostate cancer |
668 |
-7.4 |
Prostate cancer (advanced) |
91 |
-9.1 |
Prostate cancer aggressiveness |
3 |
-3.4 |
Prostate cancer (early onset) |
64 |
-7.0 |
Prostate cancer (survival) |
14 |
-3.6 |
Prostate-specific antigen levels |
120 |
-5.7 |
Prostate-specific antigen levels (conditioned on lead SNPs) |
51 |
-5.1 |
Protein C levels |
5 |
-1.5 |
Protein quantitative trait loci |
113 |
-3.4 |
Proteinuria and chronic kidney disease |
7 |
-2.6 |
Proteinuria in chronic kidney disease |
6 |
-2.4 |
Prothrombin fragments F1+2 levels in ischemic stroke |
9 |
-4.8 |
Prothrombin time |
41 |
-3.2 |
PR segment |
21 |
-3.8 |
Prudent dietary pattern |
89 |
-3.3 |
Psoriasis |
398 |
-9.0 |
Psoriasis vulgaris |
191 |
-4.4 |
Psoriatic arthritis |
23 |
-3.7 |
Psychiatric diseases (pleiotropy) (HIPO component 1) |
9 |
-3.0 |
Psychological distress |
41 |
-2.5 |
Psychosis and Alzheimer's disease |
84 |
-3.6 |
Psychosis (atypical) |
27 |
-6.2 |
Psychosis in Alzheimer's disease |
45 |
-5.5 |
Psychosis proneness (hypomanic personality scale) |
6 |
-2.4 |
Psychosis proneness (hypomanic personality scale and perceptual aberration scale) |
3 |
-2.7 |
Psychosis proneness (hypomanic personality scale and revised physical anhedonia scale) |
11 |
-2.8 |
Psychosis proneness (hypomanic personality scale and revised social anhedonia scale) |
21 |
-3.8 |
Psychosis proneness (perceptual aberration scale and revised social anhedonia scale) |
10 |
-2.8 |
Psychosis proneness (revised physical anhedonia scale) |
3 |
-2.1 |
Psychosis proneness (revised physical anhedonia scale and revised social anhedonia scale) |
9 |
-2.8 |
Psychosis proneness (revised social anhedonia scale) |
9 |
-2.8 |
Psychotic symptoms in prion disease |
26 |
-4.0 |
Pubertal anthropometrics |
136 |
-5.1 |
Pulmonary arterial hypertension |
7 |
-2.8 |
Pulmonary arterial hypertension (without BMPR2 mutations) |
1 |
-1.9 |
Pulmonary emphysema |
4 |
-1.5 |
Pulmonary function |
213 |
-4.8 |
Pulmonary function decline |
91 |
-3.8 |
Pulmonary function in asthmatics |
40 |
-5.2 |
Pulmonary function (smoking interaction) |
205 |
-3.2 |
Pulse pressure |
2667 |
-11.5 |
Pulse pressure (alcohol consumption interaction) |
7 |
-2.3 |
Pulse pressure in young-onset hypertension |
16 |
-3.6 |
Pulse pressure x alcohol consumption interaction (2df test) |
158 |
-6.1 |
Pulse pressure x alcohol consumption (light vs heavy) interaction (2df test) |
20 |
-4.6 |
Pursuit maintenance gain |
306 |
-2.8 |
Pursuit maintenance gain in psychotic disorders |
17 |
-2.5 |
Putamen volume |
70 |
-3.3 |
P wave duration |
43 |
-5.0 |
P wave terminal force |
35 |
-4.7 |
Pyoderma gangrenosum in inflammatory bowel disease |
13 |
-2.8 |
QRS complex (12-leadsum) |
116 |
-5.3 |
QRS complex (Cornell) |
105 |
-3.8 |
QRS complex (Sokolow-Lyon) |
55 |
-3.5 |
QRS duration |
430 |
-3.7 |
QRS duration in Tripanosoma cruzi seropositivity |
83 |
-3.4 |
QRS interval (sulfonylurea treatment interaction) |
108 |
-3.8 |
QT interval |
693 |
-5.5 |
QT interval (ambient particulate matter interaction) |
87 |
-5.2 |
QT interval (drug interaction) |
62 |
-3.7 |
QT interval in Tripanosoma cruzi seropositivity |
53 |
-3.3 |
QT interval (sulfonylurea treatment interaction) |
57 |
-2.4 |
Quantitative traits |
144 |
-3.7 |
Radiation response |
24 |
-3.0 |
RANTES levels |
101 |
-4.0 |
Rapid automised naming of digits |
89 |
-4.0 |
Rapid automised naming of letters |
152 |
-4.4 |
Rapid automised naming of pictures |
66 |
-2.7 |
Rate of cognitive decline in mild cognitive impairment (time interaction) |
1 |
-2.9 |
Reaction time |
2133 |
-23.9 |
Reading ability (multivariate) |
123 |
-3.4 |
Reading and spelling |
39 |
-2.4 |
Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy) |
10 |
-4.8 |
Reading disability or specific language impairment (pleiotropy) |
79 |
-3.9 |
Reasoning |
3 |
-3.0 |
Recalcitrant atopic dermatitis |
65 |
-6.7 |
Recombination measurement |
10 |
-1.4 |
Recurrent major depressive disorder |
82 |
-3.4 |
Red blood cell count |
3165 |
-17.6 |
Red blood cell density in sickle cell anemia |
29 |
-3.7 |
Red blood cell fatty acid levels |
1 |
-1.9 |
Red blood cell traits |
164 |
-10.3 |
Red cell distribution width |
1588 |
-45.5 |
Reduced foot dorsiflexion strength in Charcot-Marie-Tooth disease type 1A |
2 |
-1.6 |
Red vs. brown/black hair color |
87 |
-7.0 |
Red wine liking |
12 |
-4.0 |
Reflection (response to stress) |
45 |
-3.7 |
Refractive astigmatism |
257 |
-4.7 |
Refractive error |
116 |
-4.8 |
Refractory celiac disease type II |
6 |
-2.7 |
Regular attendance at a gym or sports club |
14 |
-2.2 |
Regular attendance at a pub or social club |
92 |
-2.8 |
Regular attendance at a religious group |
96 |
-2.7 |
Relapse in multiple sclerosis |
3 |
-1.9 |
Relative amplitude of rest-activity cycles |
20 |
-2.5 |
Relative hand skill |
26 |
-6.4 |
Relative hand skill in reading disability |
30 |
-4.6 |
Relative wall thickness |
13 |
-5.6 |
Remission after SSRI treatment in major depression |
5 |
-2.9 |
Remission after SSRI treatment in MDD or neuroticism |
11 |
-2.9 |
Remission after SSRI treatment in MDD or openness |
2 |
-3.1 |
Renal cell carcinoma |
123 |
-6.6 |
Renal function and chronic kidney disease |
24 |
-4.3 |
Renal function-related traits (BUN) |
67 |
-4.2 |
Renal function-related traits (eGRFcrea) |
85 |
-5.2 |
Renal function-related traits (sCR) |
47 |
-3.1 |
Renal function-related traits (urea) |
8 |
-3.0 |
Renal sinus fat |
22 |
-2.2 |
Renal transplant outcome |
7 |
-3.0 |
Residual cognition |
41 |
-4.8 |
Resistance to antihypertensive treatment in hypertension |
105 |
-5.9 |
Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous) |
3 |
-3.6 |
Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (dichotomous) |
18 |
-3.9 |
Resistant hypertension |
13 |
-7.2 |
Resistin levels |
18 |
-2.8 |
Respiratory diseases |
406 |
-9.8 |
Response to abacavir-containing treatment in HIV-1 infection (virologic failure) |
68 |
-4.5 |
Response to acetaminophen (hepatotoxicity) |
35 |
-13.6 |
Response to alcohol consumption (flushing response) |
5 |
-3.0 |
Response to amphetamines |
347 |
-3.2 |
Response to angiotensin II receptor blocker therapy |
104 |
-3.6 |
Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) |
16 |
-4.8 |
Response to antidepressants |
53 |
-4.1 |
Response to antidepressants and depression |
2 |
-2.6 |
Response to antidepressants in depression |
7 |
-2.9 |
Response to antidepressants (symptom improvement) |
153 |
-2.7 |
Response to antidepressants (symptom remission) |
35 |
-2.9 |
Response to antidepressant treatment (citalopram) |
23 |
-7.0 |
Response to anti-depressant treatment in major depressive disorder |
52 |
-4.4 |
Response to antineoplastic agents |
48 |
-5.4 |
Response to antipsychotic therapy (extrapyramidal side effects) |
105 |
-2.2 |
Response to antipsychotic treatment |
389 |
-3.5 |
Response to antipsychotic treatment in schizophrenia |
35 |
-4.8 |
Response to antipsychotic treatment in schizophrenia (reasoning) |
36 |
-3.5 |
Response to antipsychotic treatment in schizophrenia (working memory) |
48 |
-2.6 |
Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy) |
33 |
-3.7 |
Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy) |
94 |
-2.6 |
Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy) |
32 |
-4.1 |
Response to anti-TNF alpha therapy in inflammatory bowel disease |
8 |
-2.3 |
Response to anti-TNF therapy in rheumatoid arthritis |
22 |
-4.0 |
Response to aripiprazole in schizophrenia |
14 |
-3.9 |
Response to bleomycin (chromatid breaks) |
4 |
-5.1 |
Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1) |
65 |
-4.4 |
Response to bupropion and depression |
9 |
-3.4 |
Response to bupropion in depression |
12 |
-3.6 |
Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50) |
20 |
-5.2 |
Response to carboplatin and paclitaxel in ovarian cancer (MTT IC50) |
4 |
-5.0 |
Response to carboplatin in ovarian cancer (MTT IC50) |
66 |
-3.0 |
Response to chemotherapy in breast cancer (hypertension) (bevacizumab) |
12 |
-3.3 |
Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab) |
38 |
-2.8 |
Response to cholinesterase inhibitors in Alzheimer's disease |
15 |
-3.2 |
Response to citalopram or escitalopram and depression |
1 |
-2.2 |
Response to citalopram or escitalopram in depression |
15 |
-2.9 |
Response to citalopram treatment |
70 |
-4.2 |
Response to cognitive-behavioural therapy in anxiety disorder |
123 |
-4.1 |
Response to cyclophosphamide in systemic lupus erythematosus with lupus nephritis |
29 |
-3.2 |
Response to cytadine analogues (cytosine arabinoside) |
44 |
-3.7 |
Response to cytidine analogues (gemcitabine) |
22 |
-4.7 |
Response to Dalcetrapib treatment in acute coronary syndrome |
4 |
-3.0 |
Response to efavirenz-containing treatment in HIV 1 infection (virologic failure) |
194 |
-5.0 |
Response to exercise (triglyceride level interaction) |
20 |
-3.3 |
Response to fenofibrate |
10 |
-5.2 |
Response to fenofibrate (adiponectin levels) |
39 |
-4.2 |
Response to fenofibrate (HDL cholesterol levels) |
5 |
-2.1 |
Response to fenofibrate (total cholesterol levels) |
2 |
-2.5 |
Response to fenofibrate (triglyceride levels) |
12 |
-2.8 |
Response to gemcitabine in pancreatic cancer |
12 |
-1.8 |
Response to haloperidol in schizophrenia |
32 |
-2.3 |
Response to hepatitis B vaccine |
40 |
-4.5 |
Response to hepatitis C treatment |
19 |
-4.2 |
Response to Homoharringtonine (cytotoxicity) |
32 |
-3.8 |
Response to iloperidone treatment (QT prolongation) |
12 |
-1.4 |
Response to inhaled corticosteroid treatment in asthma (change in FEV1) |
60 |
-5.2 |
Response to inhaled glucocorticoid treatment in asthma (change in FEV1) |
11 |
-2.8 |
Response to interferon beta in multiple sclerosis |
26 |
-2.5 |
Response to interferon beta therapy |
5 |
-4.0 |
Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer |
14 |
-2.7 |
Response to irinotecan in non-small-cell lung cancer |
1 |
0.0 |
Response to ketamine in bipolar disorder or major depression (antidepressant effects) |
12 |
-2.4 |
Response to ketamine in bipolar disorder or major depression (dissociation effects) |
36 |
-7.0 |
Response to ketogenic dietary therapies in epilepsy |
7 |
-3.4 |
Response to lithium treatment in bipolar disorder |
22 |
-3.6 |
Response to long-chain n-3 polyunsaturated fatty acid supplementation (change in triglyceride levels) |
49 |
-4.6 |
Response to long-term oxygen therapy in chronic obstructive pulmonary disease |
44 |
-3.0 |
Response to lurasidone in schizophrenia |
43 |
-3.8 |
Response to mepolizumab in severe asthma |
53 |
-5.2 |
Response to metformin (IC50) |
50 |
-3.4 |
Response to methotrexate in juvenile idiopathic arthritis |
106 |
-5.1 |
Response to methotrexate in rheumatoid arthritis |
5 |
-2.8 |
Response to methylphenidate treatment in attention-deficit/hyperactivity disorder (blood pressure) |
6 |
-3.8 |
Response to montelukast in asthma (change in FEV1) |
11 |
-2.6 |
Response to mTOR inhibitor (everolimus) |
45 |
-3.8 |
Response to mTOR inhibitor (rapamycin) |
36 |
-6.1 |
Response to olanzapine in schizophrenia |
32 |
-6.0 |
Response to opioid analgesics in cancer (pain decrease) |
5 |
-4.2 |
Response to paliperidone in schizophrenia (CGI-S score) |
94 |
-5.4 |
Response to paliperidone in schizophrenia (Multivariate) |
62 |
-2.7 |
Response to paliperidone in schizophrenia (negative Marder score) |
191 |
-2.8 |
Response to paliperidone in schizophrenia (PANSS score) |
108 |
-3.6 |
Response to paliperidone in schizophrenia (positive Marder score) |
162 |
-3.7 |
Response to perphenazine in schizophrenia |
24 |
-4.8 |
Response to platinum-based agents |
77 |
-5.3 |
Response to platinum-based chemotherapy (carboplatin) |
102 |
-3.1 |
Response to platinum-based chemotherapy (cisplatin) |
91 |
-5.8 |
Response to platinum-based chemotherapy in non-small-cell lung cancer |
8 |
-3.7 |
Response to platinum-based neoadjuvant chemotherapy in cervical cancer |
7 |
-2.4 |
Response to protease inhibitor treatment in hepatitis c (peak serum total bilirubin levels) |
14 |
-2.6 |
Response to quetiapine in schizophrenia |
16 |
-5.4 |
Response to radiotherapy in cancer (late toxicity) |
96 |
-4.8 |
Response to radiotherapy in prostate cancer (overall toxicity) |
25 |
-2.4 |
Response to radiotherapy in prostate cancer (toxicity, rectal bleeding) |
3 |
-3.4 |
Response to radiotherapy in prostate cancer (toxicity, urinary frequency) |
20 |
-2.5 |
Response to ranibizumab in age-related macular degeneration (exudative) |
3 |
-4.1 |
Response to risperidone in schizophrenia |
4 |
-5.8 |
Response to selective serotonin reuptake inhibitors and depression |
55 |
-5.2 |
Response to selective serotonin reuptake inhibitors in depression |
20 |
-4.8 |
Response to serotonin reuptake inhibitors in major depressive disorder |
85 |
-2.5 |
Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels) |
33 |
-4.7 |
Response to serotonin reuptake inhibitors in non-psychotic unipolar depression |
53 |
-4.0 |
Response to simvastatin treatment (PCSK9 protein level change) |
22 |
-2.7 |
Response to SSRI in MDD or openness |
11 |
-3.5 |
Response to SSRI (symptom remission) |
17 |
-3.1 |
Response to statins (HDL cholesterol change) |
4 |
-2.2 |
Response to statins (LDL cholesterol change) |
47 |
-5.6 |
Response to statin therapy |
199 |
-3.3 |
Response to tamoxifen in breast cancer |
8 |
-4.4 |
Response to tamoxifen in oestrogen receptor positive/HER2 negative breast cancer |
1 |
0.0 |
Response to taxane treatment (docetaxel) |
78 |
-6.5 |
Response to taxane treatment (placlitaxel) |
25 |
-2.9 |
Response to temozolomide |
27 |
-4.1 |
Response to thiopurine immunosuppressants in inflammatory bowel disease (pancreatitis) (azathioprine and mercaptopurine) |
2 |
-2.2 |
Response to TNF-alpha inhibitors in rheumatoid arthritis |
62 |
-3.5 |
Response to TNF antagonist treatment |
84 |
-3.9 |
Response to TNF inhibitor in rheumatoid arthritis (change in disease activity score) |
3 |
-3.8 |
Response to TNF inhibitor in rheumatoid arthritis (change in patient global heath assessment score) |
2 |
-5.6 |
Response to TNF inhibitor in rheumatoid arthritis (change in swollen 28-joint count) |
122 |
-16.7 |
Response to TNF inhibitor in rheumatoid arthritis (change in tender 28-joint count) |
61 |
-4.4 |
Response to tocilizumab in rheumatoid arthritis |
148 |
-4.7 |
Response to treatment for acute lymphoblastic leukemia |
103 |
-4.7 |
Response to Vitamin E supplementation |
2 |
-2.2 |
Response to zileuton treatment in asthma (FEV1 change interaction) |
64 |
-2.8 |
Response to ziprazidone in schizophrenia |
12 |
-2.8 |
Resting heart rate |
478 |
-24.4 |
Resting metabolic rate |
13 |
-4.0 |
Resting oxygen saturation in chronic osbtructive pulmonary disease (pulse oxymetry) |
2 |
-1.4 |
Resting-state electroencephalogram vigilance |
99 |
-3.0 |
Restless legs syndrome |
135 |
-2.9 |
Reticulocyte count |
544 |
-13.0 |
Reticulocyte fraction of red cells |
553 |
-22.0 |
Retinal arteriolar caliber |
14 |
-3.3 |
Retinal vascular caliber |
8 |
-5.3 |
Retinopathy in non-diabetics |
12 |
-5.2 |
Rheumatic fever |
61 |
-4.5 |
Rheumatic heart disease |
14 |
-7.5 |
Rheumatoid arthritis |
787 |
-21.1 |
Rheumatoid arthritis (ACPA-negative) |
31 |
-3.4 |
Rheumatoid arthritis (ACPA-positive) |
193 |
-8.9 |
Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive) |
31 |
-3.7 |
Rheumatoid factor seropositivity in rheumatoid arthritis |
7 |
-3.1 |
Right lateral prefrontal cortical growth |
111 |
-5.6 |
Risk-taking tendency (4-domain principal component model) |
505 |
-4.3 |
Risky sexual behaviors (alcohol dependence interaction) |
38 |
-3.0 |
Risky sexual behaviors in alcohol dependence |
35 |
-4.6 |
Rosacea symptom severity |
205 |
-4.3 |
Rotator cuff tears |
5 |
-2.6 |
RR interval (heart rate) |
151 |
-4.2 |
Rubella |
94 |
-3.6 |
Rumination (response to stress) |
45 |
-2.6 |
Sagittal craniosynostosis |
10 |
-3.4 |
Sarcoidosis |
5 |
-3.8 |
Sarcoidosis (Lofgren's syndrome vs non-Lofgren's syndrome) |
3 |
-4.0 |
Sarcoidosis (non-Lofgren's syndrome without extrapulmonary manifestations) |
7 |
-2.5 |
Sasang constitutional medicine type (So-Eum) |
30 |
-7.9 |
Scalp hair shape |
26 |
-2.0 |
Scarlet fever |
154 |
-4.4 |
Schizophrenia |
4258 |
-7.8 |
Schizophrenia (age at onset) |
95 |
-4.4 |
Schizophrenia, bipolar disorder and depression (combined) |
12 |
-4.8 |
Schizophrenia (cytomegalovirus infection interaction) |
20 |
-5.4 |
Schizophrenia (inflammation and infection response interaction) |
14 |
-3.8 |
Schizophrenia (negative symptoms) |
3 |
-2.1 |
Schizophrenia or bipolar disorder |
6 |
-2.9 |
Schizophrenia, schizoaffective disorder or bipolar disorder |
2 |
-2.2 |
Schizophrenia (treatment resistant) |
38 |
-5.4 |
Schizophrenia vs type 2 diabetes |
35 |
-2.6 |
Sciatica caused by lumbar disc herniation (treated with microdiscectomy) |
4 |
-9.8 |
Sclerosing cholangitis and ulcerative colitis (combined) |
1 |
-1.7 |
Seasonality |
42 |
-3.2 |
Seasonality and depression |
66 |
-3.8 |
Seborrheic dermatitis |
43 |
-3.5 |
Sedentary behaviour duration |
25 |
-5.2 |
Select biomarker traits |
143 |
-4.3 |
Selective IgA deficiency |
193 |
-7.6 |
Self-employment |
3 |
-4.6 |
Self-rated health |
60 |
-3.3 |
Self-reported allergy |
229 |
-9.8 |
Self-reported childhood asthma in adult smokers |
14 |
-3.9 |
Self-reported math ability |
2544 |
-5.2 |
Self-reported math ability (MTAG) |
3790 |
-6.6 |
Self-reported risk-taking behaviour |
218 |
-4.9 |
Self-reported tiredness |
4 |
-4.6 |
Sensation seeking |
15 |
-3.2 |
Sense of smell |
55 |
-8.8 |
Sensory disturbances after bilateral sagittal split ramus osteotomy |
6 |
-2.9 |
Sepsis from pneumonia (survival) |
4 |
-3.3 |
Sepsis in extremely premature infants |
9 |
-3.2 |
Sero-negative rheumatoid arthritis |
7 |
-4.3 |
Serous borderline ovarian cancer |
2 |
-2.4 |
Serous invasive ovarian cancer |
17 |
-3.3 |
Serum 25-Hydroxyvitamin D levels |
60 |
-4.3 |
Serum albumin level |
76 |
-3.8 |
Serum alkaline phosphatase levels |
135 |
-8.1 |
Serum bilirubin levels in metabolic syndrome |
25 |
-3.9 |
Serum bilirubin levels x Mediterranean diet adherence interaction in metabolic syndrome |
99 |
-2.5 |
Serum bilirubin levels x sex interaction in metabolic syndrome |
82 |
-3.0 |
Serum creatinine levels |
10 |
-4.0 |
Serum dimethylarginine levels (asymmetric/symetric ratio) |
64 |
-3.1 |
Serum folate levels |
52 |
-4.8 |
Serum galactose-deficient IgA1 levels |
10 |
-2.7 |
Serum lycopene concentrations |
11 |
-3.1 |
Serum metabolite concentrations in chronic kidney disease |
73 |
-3.5 |
Serum metabolite levels |
188 |
-4.3 |
Serum metabolite ratios in chronic kidney disease |
23 |
-4.2 |
Serum parathyroid hormone levels |
9 |
-8.3 |
Serum prostate-specific antigen levels |
8 |
-4.1 |
Serum protein levels (sST2) |
7 |
-2.1 |
Serum selenium levels |
7 |
-4.0 |
Serum sulfate level |
65 |
-4.9 |
Serum tamsulosin hydrochloride concentration |
28 |
-1.5 |
Serum thyroid-stimulating hormone levels |
147 |
-3.8 |
Serum total cholesterol levels |
20 |
-2.4 |
Serum total protein level |
130 |
-5.6 |
Serum urate levels in chronic kidney disease |
4 |
-2.0 |
Serum urea levels |
20 |
-6.3 |
Serum uric acid levels |
287 |
-7.3 |
Serum uric acid levels in response to allopurinol in gout |
51 |
-2.5 |
Serum VEGFR2 concentration |
1 |
0.0 |
Serum vitamin D-binding protein levels |
10 |
-2.9 |
Severe aortic features in Marfan syndrome |
19 |
-5.6 |
Severe depressive disorders in coronary artery disease |
5 |
-1.1 |
Severe diabetic retinopathy in type 2 diabetes |
6 |
-2.6 |
Severe gingival inflammation |
14 |
-2.0 |
Severe influenza A (H1N1) infection |
173 |
-5.0 |
Severe malaria |
85 |
-3.6 |
Severe malaria (adjusted for sickle cell variant rs334) |
44 |
-2.0 |
Severe progression in rheumatoid arthritis |
3 |
-3.0 |
Severe skin toxicity response to cetuximab in colorectal cancer |
50 |
-4.3 |
Severity of facial solar lentigines |
15 |
-3.4 |
Severity of nausea and vomiting of pregnancy |
36 |
-16.3 |
Sex hormone-binding globulin levels |
69 |
-4.0 |
Sex hormone levels |
28 |
-2.8 |
Sexual dimorphism in anthropometric traits |
92 |
-2.7 |
Sexual dysfunction (female) |
31 |
-5.3 |
Sexual dysfunction (SSRI/SNRI-related) |
66 |
-5.5 |
Shingles |
161 |
-4.2 |
Short-term memory (digit-span task) |
26 |
-3.4 |
Short-term memory (visuospatial task) |
17 |
-1.8 |
Sickle cell anemia (haemolysis) |
13 |
-2.9 |
Sight-threatening diabetic retinopathy in type 2 diabetes |
5 |
-4.3 |
Sitting height ratio |
168 |
-4.8 |
Sjogren's syndrome |
71 |
-3.8 |
Skin aging (microtopography measurement) |
23 |
-4.5 |
Skin and soft tissue Staphylococcus aureus infection |
1 |
-1.8 |
Skin colour saturation |
2 |
-2.0 |
Skin fluorescence in type 1 diabetes |
3 |
-2.2 |
Skin, hair and eye pigmentation (multivariate analysis) |
38 |
-4.0 |
Skin pigmentation |
67 |
-2.9 |
Skin pigmentation traits |
2 |
-2.0 |
Sleep depth |
15 |
-4.0 |
Sleep duration |
898 |
-4.6 |
Sleep duration (long sleep) |
39 |
-6.3 |
Sleep duration (oversleepers vs undersleepers) |
27 |
-5.8 |
Sleep duration (short sleep) |
118 |
-3.1 |
Sleep latency |
1 |
-2.2 |
Sleep quality |
7 |
-2.7 |
Sleep-related phenotypes |
28 |
-2.9 |
Sleep time |
10 |
-4.3 |
Sleep traits (multi-trait analysis) |
37 |
-5.1 |
Small-cell lung cancer (survival) |
2 |
-1.8 |
Small cell lung carcinoma |
128 |
-2.4 |
Small intestine neuroendocrine tumor |
28 |
-6.2 |
Small LDL particle concentration |
8 |
-3.1 |
Small vessel stroke |
18 |
-3.1 |
Smoking behavior |
254 |
-3.3 |
Smoking behaviour (cigarettes smoked per day) |
185 |
-3.4 |
Smoking behaviour (maximum cigarettes in a 24 hour period) |
93 |
-3.7 |
Smoking cessation |
132 |
-5.6 |
Smoking cessation in chronic obstructive pulmonary disease |
23 |
-3.9 |
Smoking cessation (MTAG) |
489 |
-10.7 |
Smoking initiation |
358 |
-3.9 |
Smoking initiation (ever regular vs never regular) (MTAG) |
4040 |
-9.6 |
Smoking initiation (ever regular vs never regular) |
2647 |
-7.9 |
Smoking quantity |
28 |
-5.0 |
Smoking status |
1143 |
-3.9 |
Smoking status (current vs former) |
1 |
-2.8 |
Smoking status (ever vs never smokers) |
1739 |
-5.4 |
Smoking status (heavy vs light) |
31 |
-2.4 |
Smooth-surface caries |
186 |
-4.3 |
Snoring |
200 |
-7.8 |
Social autistic-like traits |
22 |
-5.5 |
Social communication problems |
73 |
-4.6 |
Social science traits (pleiotropy) (HIPO component 1) |
51 |
-2.9 |
Sodium levels |
40 |
-3.8 |
Soluble E-selectin levels |
7 |
-3.8 |
Soluble ICAM-1 |
4 |
-3.2 |
Soluble interleukin-2 receptor subunit alpha |
45 |
-10.3 |
Soluble levels of adhesion molecules |
4 |
-3.1 |
Speech perception in dyslexia |
5 |
-5.0 |
Sperm motility |
2 |
-2.9 |
S-phenylmercapturic acid levels in smokers |
8 |
-4.9 |
Spherical equivalent |
161 |
-3.8 |
Spherical equivalent (joint analysis main effects and education interaction) |
72 |
-3.3 |
Spherical equivalent or myopia (age of diagnosis) |
713 |
-3.3 |
Sphingolipid levels |
25 |
-3.5 |
Spine bone size |
8 |
-4.0 |
Spontaneous dizygotic twinning |
21 |
-6.2 |
Spontaneous preterm birth (maternal effect) |
12 |
-3.1 |
Spontaneous preterm birth (preterm birth) |
53 |
-4.1 |
Spontaneous preterm birth (preterm delivery) |
3 |
-1.6 |
Sporadic neuroblastoma |
21 |
-3.8 |
Sporadic pituitary adenoma |
11 |
-4.6 |
Squamous cell carcinoma |
34 |
-2.9 |
Squamous cell lung carcinoma |
143 |
-4.3 |
Staphylococcus aureus infection |
21 |
-9.5 |
Staphylococcus aureus nasal carriage (intermittent) |
64 |
-4.4 |
Staphylococcus aureus nasal carriage (persistent) |
35 |
-4.6 |
Stearic acid (18:0) levels |
27 |
-3.6 |
Stem cell factor levels |
93 |
-5.4 |
Stem cell growth factor beta levels |
109 |
-3.2 |
Stimulated C-peptide levels in type I diabetes |
5 |
-2.8 |
Strenuous sports or other exercises |
29 |
-6.5 |
Strep throat |
98 |
-15.5 |
Stroke |
286 |
-5.1 |
Stroke (ischemic) |
71 |
-6.1 |
Stroke (pediatric) |
23 |
-4.5 |
Stromal-cell-derived factor 1 alpha levels |
74 |
-4.2 |
Subclinical atherosclerosis traits (other) |
23 |
-4.2 |
Subclinical trait of interstitial lung disease (basilar peel-core ratio of high attentuation areas on CT scan) |
6 |
-3.0 |
Subclinical trait of interstitial lung disease (basilar percentage of high attenuation areas on CT scan) |
4 |
-3.7 |
Subclinical trait of interstitial lung disease (percentage of high attenuation areas on CT scan) |
1 |
-3.6 |
Subcortical brain region volumes |
129 |
-3.9 |
Subcutaneous adipose tissue |
246 |
-5.3 |
Subcutaneous adipose tissue attenuation (Hounsfield unit scale) |
7 |
-3.6 |
Subcutaneous adipose tissue (sex interaction) |
2 |
-2.5 |
Subiculum volume |
7 |
-3.1 |
Subiculum volume (corrected for total hippocampal volume) |
15 |
-2.3 |
Subjective response to lithium treatment |
8 |
-3.7 |
Subjective response to lithium treatment in bipolar disorder |
16 |
-6.1 |
Subjective well-being |
412 |
-4.6 |
Subjective well-being (MTAG) |
246 |
-4.9 |
Substance dependence |
8 |
-2.0 |
Substance use disorder |
16 |
-2.9 |
Sudden cardiac arrest |
175 |
-4.7 |
Suffering from nerves |
29 |
-5.2 |
Suicidal ideation |
135 |
-5.2 |
Suicidality |
24 |
-2.3 |
Suicidality (suicidal ideation/attempts) |
2 |
-2.4 |
Suicide |
10 |
-2.1 |
Suicide attempts |
181 |
-2.5 |
Suicide attempt severity |
5 |
-1.6 |
Suicide attempts in bipolar disorder |
50 |
-3.4 |
Suicide attempts in depression or bipolar disorder |
3 |
-4.1 |
Suicide attempts in major depressive disorder |
18 |
-3.7 |
Suicide ideation score in major depressive disorder |
11 |
-2.8 |
Suicide in bipolar disorder |
47 |
-2.4 |
Suicide risk |
9 |
-3.7 |
Sulfasalazine-induced agranulocytosis |
64 |
-5.3 |
Sum basophil neutrophil counts |
379 |
-12.6 |
Sum eosinophil basophil counts |
595 |
-18.8 |
Sum neutrophil eosinophil counts |
386 |
-13.9 |
Sunburns |
306 |
-3.9 |
Superior crus of antihelix expression |
16 |
-4.3 |
Superior frontal gyrus grey matter volume |
74 |
-3.2 |
Supraventricular ectopy |
29 |
-2.4 |
Surgical necrotising enterocolitis in extremely premature birth |
69 |
-2.6 |
Survival in breast cancer (estrogen-receptor positive) |
17 |
-3.2 |
Survival in colon cancer |
30 |
-5.8 |
Survival in colorectal cancer (non-distant metastatic) |
6 |
-3.7 |
Survival in colorectal cancer |
7 |
-2.0 |
Survival in endocrine treated breast cancer (estrogen-receptor positive) |
10 |
-2.2 |
Survival in head and neck cancer |
19 |
-2.2 |
Survival in microsatellite instability low/stable colorectal cancer |
115 |
-5.4 |
Survival in pancreatic cancer |
117 |
-2.0 |
Survival in rectal cancer |
132 |
-3.9 |
Survival in sporadic amyotrophic lateral sclerosis |
40 |
-5.0 |
Susceptibility to persistent hepatitis B virus infection |
10 |
-3.2 |
Symmetrical dimethylarginine levels |
94 |
-2.9 |
Systemic juvenile idiopathic arthritis |
136 |
-4.5 |
Systemic lupus erythematosus |
1607 |
-28.8 |
Systemic lupus erythematosus and Systemic sclerosis |
99 |
-6.5 |
Systemic lupus erythematosus or rheumatoid arthritis |
28 |
-6.6 |
Systemic sclerosis |
98 |
-4.2 |
Systemic sclerosis (anti-centromere-positive) |
8 |
-3.0 |
Systemic sclerosis (anti-topoisomerase-positive) |
4 |
-2.9 |
Systemic seropositive rheumatic diseases (Systemic sclerosis or systemic lupus erythematosus or rheumatoid arthritis or idiopathic inflammatory myopathies) |
52 |
-4.3 |
Systolic blood pressure |
5756 |
-11.8 |
Systolic blood pressure (alcohol consumption interaction) |
9 |
-2.8 |
Systolic blood pressure change trajectories |
2 |
-5.5 |
Systolic blood pressure (cigarette smoking interaction) |
265 |
-3.2 |
Systolic blood pressure (dietary potassium intake interaction) |
13 |
-3.3 |
Systolic blood pressure in sickle cell anemia |
14 |
-3.3 |
Systolic blood pressure night-to-day ratio in hypertension |
3 |
-1.5 |
Systolic blood pressure response to hydrochlorothiazide in hypertension |
119 |
-6.3 |
Systolic blood pressure x alcohol consumption interaction (2df test) |
380 |
-6.5 |
Systolic blood pressure x alcohol consumption (light vs heavy) interaction (2df test) |
122 |
-8.5 |
Systolic blood pressure x smoking status (current vs non-current) interaction (1df test) |
10 |
-3.1 |
Systolic blood pressure x smoking status (current vs non-current) interaction (2df test) |
196 |
-3.8 |
Systolic blood pressure x smoking status (ever vs never) interaction (2df test) |
176 |
-4.3 |
Systolic blood pressure x sodium interaction (1df test) |
8 |
-4.3 |
Takayasu arteritis |
126 |
-7.6 |
Takotsubo syndrome |
36 |
-5.7 |
Tandem gait |
4 |
-2.8 |
Tanning |
43 |
-2.5 |
Tardive dyskinesia |
3 |
-1.7 |
Taxane-induced peripheral neuropathy in breast cancer |
19 |
-2.7 |
TB-LM or TBLH-BMD (pleiotropy) |
55 |
-4.2 |
Telomere length |
264 |
-6.5 |
Temperament (bipolar disorder) |
67 |
-8.0 |
Temperament |
116 |
-5.5 |
Temporomandibular joint disorder |
10 |
-2.7 |
Tenofovir clearance in HIV infection |
148 |
-4.5 |
Testicular cancer |
2 |
-5.5 |
Testicular germ cell cancer |
3 |
-5.1 |
Testicular germ cell tumor |
114 |
-6.6 |
Testosterone levels |
14 |
-2.9 |
Testosterone levels in polycystic ovary syndrome |
49 |
-5.4 |
Tetralogy of Fallot |
15 |
-3.2 |
Theory of mind score in adolescence (Emotional Triangles Task) |
1 |
-3.4 |
Thiazide-induced adverse metabolic effects in hypertensive patients |
321 |
-3.3 |
Thionamide-induced agranulocytosis in Graves' disease |
16 |
-6.0 |
Thiopurine-induced alopecia in inflammatory bowel disease |
3 |
0.0 |
Thiopurine-induced digestive symptoms in inflammatory bowel disease |
1 |
-2.0 |
Thiopurine-induced leukopenia in inflammatory bowel disease (conditioned on rs116855232) |
2 |
-3.4 |
Thiopurine-induced pancreatitis in inflammatory bowel disease |
4 |
-2.2 |
Thiopurine S-methyltransferase activity |
10 |
-4.4 |
Thoracic-to-hip circumference ratio |
2 |
-3.1 |
Thrombin-activatable fibrinolysis inhibitor activation peptide |
10 |
-3.4 |
Thrombin-activatable fibrinolysis inhibitor levels |
1 |
-2.8 |
Thrombin-antithrombin complex levels in ischemic stroke |
44 |
-2.9 |
Thrombin generation potential phenotypes |
5 |
-3.7 |
Thrombocytopenia in coronary artery bypass surgery |
16 |
-2.6 |
Thrombomodulin levels in ischemic stroke |
20 |
-4.6 |
Thrombosis |
15 |
-4.3 |
Thyroid cancer |
25 |
-5.5 |
Thyroid cancer (Papillary, radiation-related) |
17 |
-3.4 |
Thyroid function |
42 |
-2.9 |
Thyroid hormone levels |
198 |
-6.8 |
Thyroid nodules |
5 |
-2.2 |
Thyroid peroxidase antibody levels |
12 |
-5.5 |
Thyroid peroxidase antibody positivity |
70 |
-14.7 |
Thyroid stimulating hormone levels |
167 |
-10.3 |
Thyroid volume |
14 |
-3.0 |
Thyrotoxic hypokalemic periodic paralysis |
55 |
-5.9 |
Thyroxine levels |
2 |
-2.4 |
Ticagrelor levels in individuals with acute coronary syndromes treated with ticagrelor |
2 |
-3.4 |
Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction) |
241 |
-5.5 |
Toenail selenium levels |
90 |
-2.9 |
Tonometry |
28 |
-4.6 |
Tonsillectomy |
423 |
-4.7 |
Tooth agenesis |
1 |
-1.8 |
Tooth agenesis (mandibular second premolars) |
2 |
-2.9 |
Tooth agenesis (mandibular third molar) |
23 |
-3.9 |
Tooth agenesis (maxillary lateral incisors) |
27 |
-4.3 |
Total bilirubin levels |
17 |
-9.4 |
Total bilirubin levels in HIV-1 infection |
5 |
-3.8 |
Total body bone mineral density |
700 |
-5.0 |
Total body bone mineral density (age 0-15) |
29 |
-5.6 |
Total body bone mineral density (age 30-45) |
59 |
-5.7 |
Total body bone mineral density (age 45-60) |
74 |
-5.4 |
Total body bone mineral density (age over 60) |
121 |
-4.8 |
Total cholesterol change in response to fenofibrate in statin-treated type 2 diabetes |
37 |
-2.3 |
Total cholesterol levels |
747 |
-10.4 |
Total cholesterol levels in HDL |
9 |
-5.2 |
Total cholesterol levels in large HDL |
1 |
-2.9 |
Total cholesterol levels in large LDL |
4 |
-3.0 |
Total cholesterol levels in LDL |
6 |
-3.6 |
Total cholesterol levels in medium LDL |
5 |
-2.9 |
Total cholesterol levels in small LDL |
8 |
-3.1 |
Total glycated albumin levels |
24 |
-4.0 |
Total hippocampal volume |
12 |
-4.3 |
Total mean fractional anisotropy measurement in first episode schizophrenia |
7 |
-3.8 |
Total triglycerides levels |
1 |
-2.8 |
Total ventricular volume |
36 |
-4.2 |
Total ventricular volume (Alzheimer's disease interaction) |
32 |
-4.0 |
Tourette's syndrome or obsessive-compulsive disorder |
14 |
-1.8 |
Tourette syndrome |
86 |
-4.1 |
Tragus size |
5 |
-4.0 |
TRAIL levels |
124 |
-3.6 |
Trans-epidermal water loss |
2 |
-2.5 |
Trans fatty acid levels |
230 |
-4.8 |
Treatment resistant depression |
7 |
-3.0 |
Treatment response for severe sepsis |
23 |
-4.2 |
Trichloroethylene-induced hypersensitivity syndrome |
2 |
-2.5 |
Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes |
33 |
-2.4 |
Triglyceride levels |
388 |
-6.9 |
Triglyceride levels in small VLDL |
1 |
-2.8 |
Triglycerides |
959 |
-9.2 |
Triglycerides-Blood Pressure (TG-BP) |
28 |
-5.6 |
Triglycerides x physical activity interaction (2df test) |
35 |
-5.7 |
Triglyceride to HDL cholesterol ratio |
3 |
-2.6 |
Triiodothyronine levels |
8 |
-6.6 |
Triiodothyronine levels and thyroxine levels |
15 |
-3.7 |
Triiodothyronine/thyroxine ratio |
6 |
-2.3 |
Triptolide cytotoxicity |
68 |
-5.2 |
Tuberculosis |
289 |
-3.2 |
Tumor biomarkers |
3 |
-4.2 |
Tumor necrosis factor alpha levels |
66 |
-4.9 |
Tumor necrosis factor beta levels |
17 |
-2.1 |
Tumor necrosis factor receptor II (red blood cell fatty acid level interaction) |
2 |
-1.3 |
Two-hour glucose challenge |
38 |
-4.7 |
Two-hour glucose in pregnancy (gestational week 30-32) |
19 |
-4.8 |
Type 1 diabetes |
240 |
-13.0 |
Type 1 diabetes and autoimmune thyroid diseases |
21 |
-4.9 |
Type 1 diabetes autoantibodies in high risk HLA genotype individuals (time to event) |
6 |
-2.0 |
Type 1 diabetes in high risk HLA genotype individuals (time to event) |
22 |
-2.8 |
Type 1 diabetes nephropathy |
18 |
-4.8 |
Type 2 diabetes |
2082 |
-4.4 |
Type 2 diabetes (age of onset) |
123 |
-2.6 |
Type 2 diabetes (dietary heme iron intake interaction) |
4 |
-2.4 |
Type 2 diabetes nephropathy |
32 |
-6.2 |
Type 2 diabetes nephropathy including microalbuminuria |
41 |
-7.7 |
Type 2 diabetes (young onset) and obesity |
3 |
-5.5 |
Ulcerative colitis |
821 |
-12.1 |
Ulcerative colitis or Crohn's disease |
18 |
-3.6 |
Ulna and radius bone mineral density |
15 |
-5.5 |
Uncontrolled blood pressure in combination therapy (beta blocker and thiazide diuretic) |
1 |
-1.8 |
Underweight status |
5 |
-2.3 |
Upper eyelid morphology |
52 |
-3.3 |
Upper eyelid sagging severity |
117 |
-7.3 |
Urate levels |
199 |
-6.0 |
Urate levels (BMI interaction) |
225 |
-7.1 |
Urate levels in lean individuals |
45 |
-2.5 |
Urate levels in obese individuals |
143 |
-3.5 |
Urate levels in overweight individuals |
135 |
-4.3 |
Urea levels |
45 |
-4.7 |
Urgency urinary incontinence |
8 |
-1.6 |
Uric acid levels |
278 |
-3.3 |
Urinary 1,3-butadiene metabolite levels in smokers |
2 |
-3.0 |
Urinary albumin excretion |
116 |
-3.8 |
Urinary albumin excretion (no hypertensive medication) |
45 |
-3.8 |
Urinary albumin excretion rate in type 1 diabetes |
6 |
-3.0 |
Urinary albumin-to-creatinine ratio |
33 |
-3.7 |
Urinary albumin-to-creatinine ratio in diabetes |
7 |
-5.7 |
Urinary albumin-to-creatinine ratio in non-diabetics |
6 |
-3.0 |
Urinary bladder cancer |
10 |
-3.6 |
Urinary electrolytes (magnesium/calcium ratio) |
17 |
-3.6 |
Urinary magnesium-to-creatinine ratio |
8 |
-4.0 |
Urinary metabolite concentrations in chronic kidney disease |
14 |
-2.8 |
Urinary metabolites |
13 |
-4.1 |
Urinary metabolites (H-NMR features) |
9 |
-4.5 |
Urinary tract infection frequency |
108 |
-6.3 |
Urinary uric acid to urinary creatinine ratio |
29 |
-3.9 |
Urinary uromodulin levels |
5 |
-1.9 |
Uterine fibroid number (single vs multiple) |
43 |
-3.6 |
Uterine fibroids |
144 |
-3.4 |
Uterine fibroid size (maximum dimension) |
2 |
-1.5 |
Uterine fibroid size (maximum volume) |
11 |
-3.3 |
Uveal melanoma |
2 |
-2.4 |
Vaccenic acid (18:1n-7) levels |
1 |
-3.6 |
Vaccine-related adverse events |
2 |
0.0 |
Vaginal discharge (itching) |
7 |
-2.7 |
Vaginal discharge (metrorrhagia) |
2 |
-2.7 |
Vaginal discharge (smell) |
48 |
-5.9 |
Varicose veins |
102 |
-5.7 |
Vascular brain injury |
19 |
-3.1 |
Vascular endothelial growth factor levels |
103 |
-4.6 |
Vasculitis associated with antineutrophil cytoplasmic antibody reactive to myeloperoxidase |
1 |
-2.5 |
Vaspin levels |
5 |
-2.9 |
Vein graft stenosis in coronary artery bypass grafting |
20 |
-4.4 |
Velopharyngeal dysfunction |
317 |
-6.0 |
Venlafaxine response in generalised anxiety disorder (HAMA-A score reduction after 24 weeks) |
19 |
-4.8 |
Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 12 weeks) |
8 |
-4.1 |
Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 24 weeks) |
5 |
-2.3 |
Venlafaxine response in generalised anxiety disorder (responders vs non-responders after 12 weeks) |
1 |
-2.0 |
Venlafaxine response in generalised anxiety disorder (responders vs non-responders after 24 weeks) |
39 |
-4.1 |
Venous thromboembolism |
43 |
-5.2 |
Venous thromboembolism adjusted for sickle cell variant rs77121243-T |
252 |
-2.6 |
Ventricular ectopy |
4 |
-2.4 |
Ventricular ectopy or supraventricular ectopy (pleiotropy) |
16 |
-2.7 |
Verbal declarative memory |
142 |
-5.9 |
Verbal intelligence quotient (cesarean section interaction) |
15 |
-7.4 |
Verbal memory |
5 |
-1.6 |
Verbal memory performance (delayed recall level) |
1 |
-1.7 |
Verbal memory performance (immediate recall change) |
20 |
-4.0 |
Verbal memory performance (immediate recall level) |
72 |
-6.0 |
Verbal memory performance (residualized delayed recall change) |
13 |
-3.1 |
Verbal memory performance (residualized delayed recall level) |
12 |
-4.7 |
Verbal-numerical reasoning |
36 |
-2.4 |
Vertical cup-disc ratio |
241 |
-4.6 |
Very long-chain saturated fatty acid levels (fatty acid 20:0) |
53 |
-3.4 |
Very long-chain saturated fatty acid levels (fatty acid 22:0) |
59 |
-3.1 |
Very long-chain saturated fatty acid levels (fatty acid 24:0) |
13 |
-4.5 |
Very low density lipoprotein cholesterol levels |
2 |
-2.6 |
Vestibular neuritis |
3 |
-0.9 |
Vigorous physical activity |
7 |
-3.2 |
Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia |
19 |
-2.3 |
Viral capsid antigen IgG seropositivity |
7 |
-2.2 |
Virologic severity in Herpes simplex virus type 2 infection |
22 |
-3.5 |
Visceral adipose tissue |
32 |
-3.5 |
Visceral adipose tissue adjusted for BMI |
207 |
-5.2 |
Visceral adipose tissue attenuation (Hounslow unit scale) |
7 |
-3.6 |
Visceral adipose tissue/subcutaneous adipose tissue ratio |
155 |
-3.7 |
Visceral adipose tissue/subcutaneous adipose tissue ratio adjusted for BMI |
15 |
-5.1 |
visceral adipose tissue/total adipose tissue ratio |
16 |
-2.5 |
Visceral fat |
298 |
-3.9 |
Visual memory |
3 |
-4.2 |
Vitamin B12 levels |
63 |
-3.5 |
Vitamin B levels in ischemic stroke |
11 |
-3.2 |
Vitamin D levels |
94 |
-4.0 |
Vitamin D levels (dietary vitamin D intake interaction) |
2 |
-6.0 |
Vitamin E levels |
16 |
-9.6 |
Vitiligo |
85 |
-5.4 |
Vitiligo (early onset) |
4 |
-7.7 |
Vitiligo (late onset) |
3 |
-5.1 |
Vogt-Koyanagi-Harada syndrome |
42 |
-5.0 |
Volumetric brain MRI |
53 |
-3.8 |
Voxel-wise structural brain imaging measurements |
5 |
-2.8 |
vWF and FVIII levels |
69 |
-4.6 |
vWF levels |
39 |
-5.6 |
vWF levels in ischaemic stroke and hyperhomocysteinaemia |
3 |
-3.3 |
Waist circumference |
744 |
-4.6 |
Waist circumference adjusted for BMI (adjusted for smoking behaviour) |
415 |
-5.5 |
Waist circumference adjusted for BMI in active individuals |
416 |
-6.3 |
Waist circumference adjusted for BMI in inactive individuals |
69 |
-5.4 |
Waist circumference adjusted for BMI in non-smokers |
321 |
-6.0 |
Waist circumference adjusted for BMI in smokers |
11 |
-4.1 |
Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction) |
445 |
-6.1 |
Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction) |
414 |
-5.5 |
Waist circumference adjusted for BMI (smoking interaction) |
3 |
-2.7 |
Waist circumference adjusted for body mass index |
956 |
-6.5 |
Waist circumference and related phenotypes |
32 |
-5.0 |
Waist-hip ratio |
2643 |
-11.3 |
Waist-to-hip circumference ratio (alcohol intake interaction) |
30 |
-6.1 |
Waist-to-hip circumference ratio (dietary energy interaction) |
3 |
-2.2 |
Waist-to-hip circumference ratio (ever vs never smoking interaction) |
40 |
-2.5 |
Waist-to-hip circumference ratio (recreational physical activity interaction) |
17 |
-4.3 |
Waist-to-hip circumference ratio (smoking years interaction) |
29 |
-2.3 |
Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour) |
406 |
-8.2 |
Waist-to-hip ratio adjusted for BMI (age <50) |
103 |
-5.8 |
|
126 |
-7.0 |
Waist-to-hip ratio adjusted for BMI in active individuals |
328 |
-7.0 |
Waist-to-hip ratio adjusted for BMI in inactive individuals |
83 |
-5.7 |
Waist-to-hip ratio adjusted for BMI in non-smokers |
168 |
-8.1 |
Waist-to-hip ratio adjusted for BMI in smokers |
22 |
-4.2 |
Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction) |
371 |
-6.6 |
Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction) |
166 |
-8.2 |
Waist-to-hip ratio adjusted for BMI |
1069 |
-6.8 |
Waist-to-hip ratio adjusted for BMI x sex interaction |
178 |
-4.4 |
Waist-to-hip ratio adjusted for BMI x sex x age interaction (4df test) |
444 |
-7.9 |
Waist-to-hip ratio adjusted for body mass index |
567 |
-7.0 |
Waldenstrom macroglobulinemia / lymphoplasmacytic lymphoma |
3 |
-1.3 |
Warfarin maintenance dose |
61 |
-3.6 |
Wegener's granulomatosis |
38 |
-4.7 |
Weight |
556 |
-5.1 |
Weight loss (gastric bypass surgery) |
15 |
-1.9 |
Well-being spectrum (multivariate analysis) |
1424 |
-5.6 |
Western dietary pattern |
54 |
-3.0 |
White blood cell count |
2763 |
-29.9 |
White blood cell count (basophil) |
177 |
-18.4 |
White blood cell count (eosinophil) |
17 |
-3.8 |
White blood cell count (lymphocyte) |
1 |
-2.6 |
White blood cell count (monocyte) |
8 |
-6.2 |
White blood cell count (neutrophil) |
2 |
-3.1 |
White blood cell types |
41 |
-3.9 |
White matter growth |
12 |
-3.0 |
White matter hyperintensities in ischemic stroke |
8 |
-2.1 |
White matter hyperintensity burden |
105 |
-3.1 |
White matter hyperintensity volume |
24 |
-3.7 |
White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy |
19 |
-3.6 |
White matter integrity |
76 |
-4.2 |
White matter integrity (bipolar disorder risk interaction) |
23 |
-2.5 |
White matter lesion progression |
11 |
-2.2 |
White matter lesion progression (adjusted for white matter lesion burden at baseline) |
26 |
-4.3 |
White matter microstructure (global fractional anisotropy) |
64 |
-2.8 |
White matter microstructure in first episode schizophrenia (left posterior cingulate cortex) |
3 |
-5.2 |
White matter microstructure in first episode schizophrenia (right anterior cingulate cortex) |
3 |
-4.6 |
White wine liking |
3 |
-4.6 |
Whole-brain volume |
101 |
-3.4 |
Whole-brain volume (Alzheimer's disease interaction) |
22 |
-4.6 |
Wilms tumor |
27 |
-8.7 |
Word reading |
113 |
-3.3 |
Word spelling |
93 |
-7.8 |
Working memory |
32 |
-3.8 |
World class endurance athleticism |
35 |
-4.1 |
Worry |
657 |
-4.0 |
Worry too long after an embarrassing experience |
41 |
-2.3 |
Worry/vulnerability (special factor of neuroticism) |
46 |
-4.0 |
Yang-deficiency constitution |
8 |
-3.7 |
Yeast infection |
105 |
-4.1 |
Yu-Zhi constitution type in type 2 diabetes |
44 |
-4.3 |
Albuminuria |
11 |
-4.7 |
Alzheimer's disease or fasting glucose levels (pleiotropy) |
38 |
-2.5 |
Alzheimer's disease or HDL levels (pleiotropy) |
32 |
-6.6 |
Anti-thyroglobulin (TgAb) levels in Hashimoto's thyroiditis |
39 |
-3.5 |
Anti-thyroid peroxidase (TPOAb) and anti-thyroglobulin (TgAb) levels in Hashimoto's thyroiditis |
44 |
-2.9 |
Anti-thyroid peroxidase (TPOAb) levels in Hashimoto's thyroiditis |
17 |
-3.3 |
Anti-Toxoplasma gondii IgG seropositivity |
15 |
-5.5 |
Asthma (adult onset) |
216 |
-7.7 |
Asthma onset (childhood vs adult) |
251 |
-7.2 |
Carbamazepine-induced hyponatremia in epilepsy |
24 |
-2.8 |
Carbamazepine metabolism (carbamazepine-10,11-diol to carbamazepine ratio) in epilepsy |
9 |
-1.8 |
Carbamazepine- or oxcarbazepine-induced hyponatremia in epilepsy |
15 |
-2.7 |
Colorectal cancer or advanced adenoma |
499 |
-6.5 |
Emotional lability in attention deficit hyperactivity disorder |
10 |
-2.2 |
Facial attractiveness (female raters) |
15 |
-3.2 |
Facial attractiveness (male raters) |
16 |
-4.7 |
Frontal fibrosing alopecia |
115 |
-4.8 |
Homeostasis model assessment of insulin resistance in less-fat diet |
3 |
-2.6 |
Homeostasis model assessment of insulin resistance in more-fat diet |
4 |
-3.4 |
Homeostasis model assessment of insulin resistance x saturated fatty acids interaction |
3 |
-2.6 |
Hyperglycemia in higher physical activity |
4 |
-3.0 |
Hyperinsulinemia in lower physical activity |
6 |
-1.7 |
Hyperinsulinemia in obesity |
28 |
-3.3 |
Hyperinsulinemia x BMI interaction |
1 |
0.0 |
Hyperinsulinemia x physical activity interaction |
6 |
-1.7 |
Incident chronic kidney disease |
12 |
-2.5 |
Latent naming speed |
12 |
-4.4 |
Medication use (adrenergics, inhalants) |
252 |
-8.3 |
Medication use (agents acting on the renin-angiotensin system) |
1076 |
-4.8 |
Medication use (anilides) |
4 |
-2.3 |
Medication use (antidepressants) |
1 |
-1.9 |
Medication use (antiglaucoma preparations and miotics) |
36 |
-3.3 |
Medication use (antihistamines for systemic use) |
85 |
-7.0 |
Medication use (antihypertensives) |
5 |
-5.1 |
Medication use (anti-inflammatory and antirheumatic products, non-steroids) |
31 |
-4.5 |
Medication use (antimigraine preparations) |
135 |
-3.6 |
Medication use (antithrombotic agents) |
2 |
-1.2 |
Medication use (beta blocking agents) |
320 |
-4.1 |
Medication use (calcium channel blockers) |
577 |
-5.6 |
Medication use (diuretics) |
568 |
-4.6 |
Medication use (drugs affecting bone structure and mineralization) |
84 |
-5.3 |
Medication use (drugs for peptic ulcer and gastro-oesophageal reflux disease) |
8 |
-2.4 |
Medication use (drugs used in diabetes) |
282 |
-4.0 |
Medication use (glucocorticoids) |
87 |
-8.3 |
Medication use (HMG CoA reductase inhibitors) |
283 |
-9.4 |
Medication use (salicylic acid and derivatives) |
4 |
-2.6 |
Medication use (thyroid preparations) |
444 |
-11.7 |
Medication use (vasodilators used in cardiac diseases) |
1 |
-3.5 |
Monoclonal gammopathy of undetermined significance |
5 |
-2.7 |
Mouth ulcers |
204 |
-14.7 |
Oxcarbazepine-induced hyponatremia in epilepsy |
2 |
-1.4 |
Primary central nervous system lymphoma |
6 |
-6.4 |
Psychological resilience (outcome-based) |
25 |
-3.6 |
Psychological resilience (outcome-based) in high deployment stress exposure |
22 |
-7.9 |
Psychological resilience (self-assessed) |
19 |
-2.4 |
Rapid alternating stimulus test for letters/numbers |
15 |
-2.7 |
Rapid automised naming and rapid alternating stimulus test performance |
15 |
-2.7 |
Right-sided colonic diverticulosis |
12 |
-2.9 |
Severe carbamazepine- or oxcarbazepine-induced hyponatremia in epilepsy |
28 |
-3.4 |
Skin reflectance (Melanin index) |
191 |
-2.7 |
Sleep (number of episodes) |
12 |
-1.9 |
Sodium levels in epilepsy |
4 |
-2.8 |
Tinnitus in cisplatin-treated testicular cancer |
18 |
-3.3 |
Trunk fat mass adjusted for trunk lean mass |
13 |
-3.9 |
Type 2 diabetes and end-stage kidney disease |
24 |
-2.3 |
Type 2 diabetes and end-stage kidney disease in APOL1 risk genotype negative individuals |
10 |
-3.7 |
Urolithiasis |
25 |
-6.3 |
Accommodative esotropia |
56 |
-1.9 |
Airway obstruction (FEV1/FVC<70) in never smokers |
9 |
-2.2 |
Alanine aminotransferase levels in non-alcoholic fatty liver disease |
90 |
-3.2 |
Alcohol dependence or heroin dependence or methamphetamine dependence |
11 |
-8.2 |
Alcohol dependence (time spent drinking) |
2 |
-1.9 |
Alcohol use disorder |
186 |
-4.5 |
Alcohol withdrawal symptoms |
4 |
-3.7 |
Allergic rhinitis x sex interaction |
12 |
-6.5 |
Alzheimer's disease in hypertension |
22 |
-2.5 |
Alzheimer's disease in hypertension-negative individuals |
13 |
-2.0 |
Amblyopia |
45 |
-5.9 |
Annualised percent change of cerebrospinal fluid AB1-42 levels |
12 |
-5.3 |
Anti-adalimumab antibody production in response to treatment in Crohn's disease |
25 |
-4.7 |
Anxiety and stress-related disorders |
15 |
-3.5 |
Arterial stiffness index |
89 |
-7.9 |
Artificially sweetened beverage consumption |
13 |
-3.3 |
Aspartate aminotransferase levels in non-alcoholic fatty liver disease |
71 |
-5.7 |
Asthma (age of onset) |
62 |
-3.8 |
Atorvastatin-induced myopathy |
16 |
-3.1 |
Atypical femoral fracture in phosphonate treatment |
61 |
-5.5 |
Balance difficulty in Charcot-Marie-Tooth disease type 1A |
16 |
-2.5 |
Benign prostatic hyperplasia |
35 |
-2.9 |
Bipolar II disorder |
27 |
-6.4 |
Bisphosphonate-associated atypical femoral fracture |
53 |
-3.3 |
Bitter alcoholic beverage consumption |
309 |
-2.8 |
Bitter beverage consumption |
82 |
-3.6 |
Bitter non-alcoholic beverage consumption |
67 |
-3.8 |
Bitter taste perception (6-n-propylthiouracil) in obesity with metabolic syndrome |
86 |
-3.0 |
Bitter taste perception (phenylthiocarbamide) in obesity with metabolic syndrome |
12 |
-3.2 |
Blood cell traits (multivariate analysis) |
14 |
-3.8 |
Breakfast cereal skipping frequency |
37 |
-3.5 |
Breakfast skipping |
37 |
-3.5 |
Candidemia |
31 |
-4.8 |
Cannabis use disorder |
14 |
-2.6 |
Cardiac troponin-I levels |
10 |
-4.1 |
Celiac disease and Rheumatoid arthritis |
121 |
-7.1 |
Cerebral microbleed progression |
2 |
-2.9 |
Cerebral microbleeds |
8 |
-4.0 |
Cerebrospinal fluid sTREM-2 levels |
4 |
-5.6 |
Change in neurofilament light levels |
17 |
-4.2 |
Chronic lymphocytic leukemia or multiple sclerosis |
33 |
-6.5 |
Chronic lymphocytic leukemia or systemic lupus erythematosus |
48 |
-4.5 |
Chronic mountain sickness |
12 |
-2.9 |
Cognitive ability in schizophrenia |
8 |
-2.0 |
Cognitive ability, years of educational attainment or schizophrenia (pleiotropy) |
1292 |
-4.0 |
Cognitive impairment |
37 |
-3.9 |
Composite immunoglobulin trait (IgA/IgM) |
11 |
-4.6 |
Composite immunoglobulin trait (IgA x IgG) |
4 |
-2.9 |
Composite immunoglobulin trait (IgA x IgG/IgM) |
16 |
-3.3 |
Composite immunoglobulin trait (IgA x IgG x IgM) |
2 |
-1.4 |
Composite immunoglobulin trait (IgG/IgM) |
15 |
-5.2 |
Corneal endothelial cell density |
41 |
-5.1 |
Corneal endothelial cell shape (percentage of hexagonally shaped cells) |
14 |
-3.0 |
Corneal endothelial cell size variation coefficient |
63 |
-4.7 |
Corneal hysteresis |
37 |
-9.5 |
Corneal resistance factor |
18 |
-3.9 |
Decreased sensory function in Charcot-Marie-Tooth disease type 1A |
13 |
-3.2 |
Dentures |
101 |
-4.2 |
Diabetic maculopathy in type 2 diabetes |
29 |
-2.5 |
Diabetic maculopathy with decreased visual acuity in type 2 diabetes |
5 |
-2.1 |
Diabetic peripheral neuropathy in type 2 diabetes |
8 |
-3.5 |
Diffuse large B-cell lymphoma or multiple sclerosis |
22 |
-7.2 |
Diffuse large B-cell lymphoma or systemic lupus erythematosus |
2 |
-1.1 |
Diverticulitis |
97 |
-6.7 |
Early spontaneous preterm birth |
34 |
-5.2 |
Emphysema annual change measurement in smokers (adjusted lung density) |
162 |
-3.6 |
Emphysema annual change measurement in smokers (percent low attenuation area) |
156 |
-4.4 |
End-stage kidney disease |
33 |
-2.8 |
Epigenetic age acceleration in alcohol use disorder |
31 |
-7.2 |
Esotropia |
2 |
-6.4 |
Estimated glomerular filtration rate in diabetes |
103 |
-3.7 |
Estimated glomerular filtration rate in non-diabetics |
255 |
-4.2 |
Facial morphology traits (63 three-dimensional facial segments) |
55 |
-3.2 |
Fagerstr?m test for nicotine dependence |
9 |
-3.2 |
Fasting blood proinsulin levels |
12 |
-3.2 |
Fasting glucose change |
29 |
-4.8 |
Fasting glucose change (long-term) |
49 |
-6.3 |
Fasting glucose change (short-term) |
34 |
-7.2 |
Fish intake frequency |
17 |
-7.1 |
Follicular lymphoma or multiple sclerosis |
3 |
-3.1 |
Foot deformity in Charcot-Marie-Tooth disease 1A |
9 |
-5.6 |
Foot plantar flexion strength in Charcot-Marie-Tooth disease 1A |
1 |
0.0 |
Geographic atrophy lesion growth rate in age-related macular degeneration |
35 |
-9.4 |
Glucosuria |
35 |
-2.6 |
Glucosuria (mild) |
35 |
-2.6 |
Glucosuria (moderate to severe) |
35 |
-2.6 |
Glycemic traits (pleiotropy) |
32 |
-2.7 |
Grapefruit juice consumption |
4 |
-4.2 |
group IIA secretory phospholipase A2 levels in individuals with elevated hsCRP |
72 |
-4.1 |
HDL cholesterol levels in current drinkers |
200 |
-7.9 |
HDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df) |
254 |
-6.8 |
HDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df) |
244 |
-6.5 |
Health literacy |
59 |
-3.1 |
Hearing loss in Charcot-Marie-Tooth disease 1A |
6 |
-2.1 |
Heart rate in heart failure with reduced ejection fraction |
314 |
-3.3 |
Heel bone mineral density (MTAG) |
41 |
-5.7 |
Hematuria |
1 |
-2.7 |
Hematuria (moderate to severe) |
1 |
-2.7 |
|
18 |
-6.7 |
Intake of sweets |
44 |
-6.4 |
Intake of total sugars |
224 |
-4.1 |
Intertrochanteric region size |
63 |
-4.8 |
Intraocular pressure (Goldman correlated) |
1 |
-2.7 |
Knee pain |
16 |
-2.2 |
LDL cholesterol levels in current drinkers |
143 |
-6.5 |
LDL cholesterol levels in current smokers |
4 |
-7.6 |
LDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df) |
160 |
-6.6 |
LDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df) |
155 |
-6.3 |
LDL cholesterol levels x smoking (current vs non smokers) interaction (1df test) |
4 |
-7.6 |
LDL cholesterol levels x smoking (current vs non smokers) interaction (2df test) |
4 |
-7.6 |
Leukocyte telomere length |
10 |
-4.0 |
Liver fibrosis in non-alcoholic fatty acid liver disease |
95 |
-4.1 |
|
62 |
-5.1 |
|
1 |
-2.1 |
Low susceptibility to hepatitis C infection |
28 |
-2.5 |
Low urine pH |
14 |
-3.1 |
Lung function in heavy smokers (low FEV1 vs high FEV1) |
1 |
0.0 |
Lung function in never smokers (high FEV1 vs average FEV1) |
9 |
-2.0 |
Lung function in never smokers (low FEV1 vs average FEV1) |
15 |
-2.1 |
Lung function in never smokers (low FEV1 vs high FEV1) |
141 |
-4.2 |
Lung function (low FEV1 vs high FEV1) |
108 |
-4.9 |
Lung function (low FEV1 vs high FEV1) x smoking interaction |
8 |
-4.2 |
Lymphangioleiomyomatosis (sporadic) |
24 |
-3.4 |
Marginal zone lymphoma or multiple sclerosis |
9 |
-3.5 |
Marginal zone lymphoma or rheumatoid arthritis |
13 |
-2.6 |
Marginal zone lymphoma or systemic lupus erythematosus |
72 |
-3.9 |
Maximum habitual alcohol consumption |
141 |
-7.6 |
Meningococcal C functional antibody titers post childhood immunization |
12 |
-2.4 |
Mental health study participation (completed survey) |
43 |
-4.4 |
Mental health study participation (provided email address) |
46 |
-3.6 |
Mild to moderate chronic kidney disease |
17 |
-2.2 |
Moderate-to-late spontaneous preterm birth |
56 |
-4.9 |
Morningness |
1537 |
-4.8 |
Multisite chronic pain |
86 |
-3.3 |
Neurological blood protein biomarker levels |
104 |
-4.4 |
Neuropathy in Charcot-Marie-Tooth disease type 1A |
3 |
-3.5 |
Non-accommodative esotropia |
12 |
-4.5 |
Non-alcoholic fatty liver disease activity score |
34 |
-2.6 |
Non-muscle-invasive bladder cancer tumour size |
14 |
-3.6 |
Nonobstructive coronary artery disease |
7 |
-3.1 |
Number of alcoholic drinks required to feel an effect (first five times drinking) |
1 |
-3.1 |
Number of alcoholic drinks required to feel an effect (long-term average) |
2 |
-1.8 |
Number of decayed, missing and filled tooth surfaces or use of dentures |
101 |
-4.2 |
Occipital lobe volume |
70 |
-6.9 |
Opioid overdose severity score |
114 |
-2.5 |
Peginterferon alfa-2a treatment response in chronic hepatitis B infection |
57 |
-7.1 |
Pemphigus |
2 |
-5.1 |
Pepsinogen I/II ratio |
65 |
-2.9 |
Perceived intensity of aspartame |
47 |
-2.6 |
Perceived intensity of fructose |
2 |
0.0 |
Perceived intensity of glucose |
26 |
-3.7 |
Perceived intensity of neohesperidin dihydrochalcone |
34 |
-2.8 |
Perceived intensity of sucrose |
63 |
-5.0 |
Perceived intensity of sweet substances |
12 |
-1.9 |
Perceived sweetness of sucrose |
56 |
-2.8 |
Periodontal disease related phenotype (PCT3) |
5 |
-4.1 |
Periodontal disease related phenotype (PCT4) |
5 |
-2.1 |
Periodontal disease related phenotype (PCT5) |
15 |
-2.1 |
Periodontal disease-related phenotype (Socransky) |
111 |
-2.4 |
Phenylephrine infusion rate during anesthesia |
45 |
-3.6 |
Plasma anti-thyroglobulin and anti-thyroid peroxidase levels (bivariate analysis) |
37 |
-4.2 |
Plasma anti-thyroglobulin levels |
83 |
-5.6 |
Plasma anti-thyroid peroxidase levels |
118 |
-3.1 |
Plasma factor V levels in venous thrombosis |
41 |
-3.2 |
Plasma factor V levels in venous thrombosis (conditioned on rs6027) |
66 |
-3.0 |
Platelet reactivity measurement (collagen-epinephrine) |
4 |
-3.1 |
Post-bronchodilator FEV1 x air pollution (CO) interaction in childhood asthma |
15 |
-6.1 |
Post-bronchodilator FEV1 x air pollution (NO2) interaction in childhood asthma |
50 |
-7.2 |
Postoperative acute renal failure after cardiac surgery |
4 |
-2.6 |
Postoperative atrial fibrillation after cardiac surgery |
10 |
-4.8 |
Postoperative complication after cardiac surgery |
5 |
-3.6 |
Postoperative delirium after cardiac surgery |
19 |
-4.6 |
Postoperative myocardial infarction after cardiac surgery |
6 |
-2.4 |
Postoperative stroke after cardiac surgery |
68 |
-3.4 |
Post-traumatic stress disorder (re-experiencing symptoms) |
55 |
-4.6 |
Post-traumatic stress disorder symptoms in trauma-exposed soldiers |
34 |
-3.0 |
Predicted visceral adipose tissue |
1151 |
-4.0 |
Pre-treatment viral load in HIV-1 infection |
235 |
-2.8 |
Proliferative diabetic retinopathy |
5 |
-3.6 |
Psychological wellbeing index 12 (lack of enjoying daily life) |
7 |
-2.5 |
Pulmonary function (FVC) x omega-3 PUFA (docosahexaenoic acid) interaction (2df) |
5 |
-4.7 |
Pure non-grapefruit juice consumption |
31 |
-7.8 |
Response to allopurinol in gout (change in serum uric acid levels) |
8 |
-4.5 |
Response to cognitive-behavioural therapy in anxiety and major depressive disorders |
24 |
-5.1 |
Response to cognitive-behavioural therapy in major depressive disorder |
25 |
-3.7 |
Response to direct-acting antiviral treatment in hepatitis C virus genotype 3 |
69 |
-4.0 |
Response to fluticasone propionate/salmeterol in chronic obstructive pulmonary disease |
1 |
-3.2 |
Response to interferon treatment in hepatitis C virus genotype 3 |
31 |
-4.1 |
Salty taste perception in obesity with metabolic syndrome |
12 |
-4.3 |
same-sex sexual behaviour |
13 |
-2.6 |
Schizoaffective disorder-bipolar type |
14 |
-4.4 |
Scoliosis in Charcot-Marie-Tooth disease 1A |
5 |
-3.1 |
Serum platinum levels after completion of cisplatin chemotherapy |
93 |
-3.8 |
Simvastatin-induced myopathy |
60 |
-2.9 |
Skin pigmentation (conditioned on rs1426654 and rs35397) |
20 |
-2.8 |
Smoking status (heavy vs never) |
54 |
-3.2 |
Sour taste perception in obesity with metabolic syndrome |
11 |
-4.9 |
Spontaneous preterm birth without premature rupture of membranes |
64 |
-3.0 |
Spontaneous preterm birth with premature rupture of membranes |
25 |
-3.7 |
Statin-induced myopathy |
5 |
-2.7 |
Statin-induced myopathy (severe) |
7 |
-2.9 |
Stress sensitivity (neuroticism score x major depressive disorder status interaction) |
116 |
-17.2 |
Sucrose liking |
35 |
-2.6 |
Sugar-sweetened beverage consumption |
23 |
-7.2 |
Suicide attempts in bipolar disorder or schizophrenia |
72 |
-2.9 |
Suicide attempts in major depressive disorder or bipolar disorder or schizophrenia |
14 |
-2.5 |
Suicide attempts in schizophrenia |
77 |
-2.6 |
Sweet beverage consumption |
34 |
-7.0 |
Sweet taste perception in obesity with metabolic syndrome |
10 |
-3.5 |
Taste perception (total score including phenylthiocarbamide) in obesity with metabolic syndrome |
34 |
-3.0 |
Tea consumption |
251 |
-2.0 |
Thyroglobulin plasma levels |
17 |
-3.6 |
Thyrotoxic hypokalemic periodic paralysis and Graves disease |
138 |
-8.6 |
Thyrotoxic hypokalemic periodic paralysis in Graves disease |
88 |
-7.3 |
Time to smoke first cigarette in the morning |
19 |
-5.5 |
Total body bone mineral density (MTAG) |
70 |
-4.8 |
Toxicity response to radiotherapy in prostate cancer (decreased urine stream) (time to event) |
74 |
-6.3 |
Toxicity response to radiotherapy in prostate cancer (hematuria) (time to event) |
33 |
-3.4 |
Toxicity response to radiotherapy in prostate cancer (increased urinary frequency) (time to event) |
7 |
-2.6 |
Toxicity response to radiotherapy in prostate cancer (rectal bleeding) (time to event) |
45 |
-2.8 |
Triglyceride levels in current drinkers |
162 |
-4.6 |
Triglyceride levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df) |
169 |
-4.4 |
Triglyceride levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df) |
168 |
-4.5 |
Trochanter size |
3 |
-2.4 |
Trunk fat mass |
132 |
-4.7 |
Umami taste perception in obesity with metabolic syndrome |
4 |
-3.7 |
Urinary potassium excretion |
118 |
-13.8 |
Urinary sodium excretion |
478 |
-5.0 |
Urine pH measurement |
14 |
-3.1 |
Walking difficulty in Charcot-Marie-Tooth disease 1A |
3 |
-3.4 |